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A B S T R A C T
Background
Pancreatic cancer (PC) is a highly lethal disease with few effective treatment options. Over the past few decades, many anti-cancer
therapies have been tested in the locally advanced and metastatic setting, with mixed results. This review attempts to synthesise all the
randomised data available to help better inform patient and clinician decision-making when dealing with this difficult disease.
Objectives
To assess the effect of chemotherapy, radiotherapy or both for first-line treatment of advanced pancreatic cancer. Our primary outcome
was overall survival, while secondary outcomes include progression-free survival, grade 3/4 adverse events, therapy response and quality
of life.
Search methods
We searched for published andunpublished studies inCENTRAL (searched14 June 2017), Embase (1980 to 14 June 2017),MEDLINE
(1946 to 14 June 2017) and CANCERLIT (1999 to 2002) databases. We also handsearched all relevant conference abstracts published
up until 14 June 2017.
Selection criteria
All randomised studies assessing overall survival outcomes in patients with advanced pancreatic ductal adenocarcinoma. Chemotherapy
and radiotherapy, alone or in combination, were the eligible treatments.
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Data collection and analysis
Two review authors independently analysed studies, and a third settled any disputes. We extracted data on overall survival (OS),
progression-free survival (PFS), response rates, adverse events (AEs) and quality of life (QoL), and we assessed risk of bias for each study.
Main results
We included 42 studies addressing chemotherapy in 9463 patients with advanced pancreatic cancer. We did not identify any eligible
studies on radiotherapy.
We did not find any benefit for chemotherapy over best supportive care. However, two identified studies did not have sufficient data
to be included in the analysis, and many of the chemotherapy regimens studied were outdated.
Compared to gemcitabine alone, participants receiving 5FU hadworse OS (HR 1.69, 95%CI 1.26 to 2.27, moderate-quality evidence),
PFS (HR 1.47, 95% CI 1.12 to 1.92) and QoL. On the other hand, two studies showed FOLFIRINOX was better than gemcitabine
for OS (HR 0.51 95% CI 0.43 to 0.60, moderate-quality evidence), PFS (HR 0.46, 95% CI 0.38 to 0.57) and response rates (RR
3.38, 95% CI 2.01 to 5.65), but it increased the rate of side effects. The studies evaluating CO-101, ZD9331 and exatecan did not
show benefit or harm when compared with gemcitabine alone.
Giving gemcitabine at a fixed dose rate improved OS (HR 0.79, 95% CI 0.66 to 0.94, high-quality evidence) but increased the rate of
side effects when compared with bolus dosing.
When comparing gemcitabine combinations to gemcitabine alone, gemcitabine plus platinum improved PFS (HR 0.80, 95% CI 0.68
to 0.95) and response rates (RR 1.48, 95% CI 1.11 to 1.98) but not OS (HR 0.94, 95% CI 0.81 to 1.08, low-quality evidence).
The rate of side effects increased. Gemcitabine plus fluoropyrimidine improved OS (HR 0.88, 95% CI 0.81 to 0.95), PFS (HR 0.79,
95% CI 0.72 to 0.87) and response rates (RR 1.78, 95% CI 1.29 to 2.47, high-quality evidence), but it also increased side effects.
Gemcitabine plus topoisomerase inhibitor did not improve survival outcomes but did increase toxicity. One study demonstrated that
gemcitabine plus nab-paclitaxel improved OS (HR 0.72, 95% CI 0.62 to 0.84, high-quality evidence), PFS (HR 0.69, 95% CI 0.58 to
0.82) and response rates (RR 3.29, 95% CI 2.24 to 4.84) but increased side effects. Gemcitabine-containing multi-drug combinations
(GEMOXEL or cisplatin/epirubicin/5FU/gemcitabine) improved OS (HR 0.55, 95% CI 0.39 to 0.79, low-quality evidence), PFS
(HR 0.43, 95% CI 0.30 to 0.62) and QOL.
We did not find any survival advantages when comparing 5FU combinations to 5FU alone.
Authors’ conclusions
Combination chemotherapy has recently overtaken the long-standing gemcitabine as the standard of care. FOLFIRINOX and gemc-
itabine plus nab-paclitaxel are highly efficacious, but our analysis shows that other combination regimens also offer a benefit. Selection
of the most appropriate chemotherapy for individual patients still remains difficult, with clinicopathological stratification remaining
elusive. Biomarker development is essential to help rationalise treatment selection for patients.
P L A I N L A N G U A G E S U M M A R Y
The effects of anti-cancer therapies on advanced pancreatic cancer
Review question
This review aimed to answer the question, which therapies are the most effective for advanced pancreatic cancer?
Background
Pancreatic cancer (PC) is a serious, often fatal disease, and many people are not diagnosed until they have advanced tumours that
cannot be removed with surgery. Symptoms include abdominal pain, weight loss, and yellowing of the skin and eyes. Up until recently,
gemcitabine was the standard drug for treating advanced pancreatic cancer, but this gave people only a modest benefit.
Study characteristics
We looked for all studies in people with pancreatic cancer that could not be operated on (locally advanced) or that had already spread
beyond the pancreas (metastatic). We found 42 clinical studies involving 9463 participants who were receiving their first therapy for
PC. Our search is current to June 2017.
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The studies compared one therapy against either best supportive care (symptom management only) or another type of therapy. Studies
had to evaluate overall survival (or time to death). The study could be testing either chemotherapy (drugs that kill or slow the growth
of cancer cells) or radiotherapy (X-ray treatment). We collected data on survival, tumour response rate, side effects and quality of life.
The results of clinical studies addressing targeted/biological therapies, immunotherapies, second-line therapies and local treatments for
locally advanced disease will be reported in a separate Cochrane Review.
Key results
This review has shown that in advanced disease, combination chemotherapy with FOLFIRINOX (5-fluorouracil, irinotecan, oxaliplatin
combination); GEMOXEL (gemcitabine, oxaliplatin and capecitabine); cisplatin/epirubicin/5FU/gemcitabine; gemcitabine plus nab-
paclitaxel; and gemcitabine plus a fluoropyrimidine agent, provide a survival advantage over gemcitabine alone. These combinations
do increase side effects. Gemcitabine given slowly using a fixed rate of infusion may be more effective than giving it in the standard
way, which is quickly over 30 minutes.
Quality of the evidence
The quality of the evidence varied greatly amongst comparisons. The highest quality evidence was for gemcitabine versus fixed dose
rate gemcitabine and some of the gemcitabine combinations (fluoropyrimidine, topoisomerase, and taxane). We judged the studies for
quality using factors like how well they were conducted, how well they reported results and whether they used a placebo.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Anti- cancer therapy versus best supportive care for advanced pancreatic cancer
Person or population: advanced pancreat ic cancer
Setting: f irst-line therapy
Intervention: ant i-cancer therapy
Comparison: best support ive care
Outcomes Anticipated risk of death* (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evi-
dence
(GRADE)
Comments Toxicity and QoL
Risk with best sup-
portive care
Risk with anti- can-
cer therapy
Overall survival Study populat ion HR 1.08
(0.88 to 1.33)
298
(4 RCTs)
⊕⊕⊕©
Moderatea
- The analysis showed that tox-
icity data were inconsistent ly
reported. Most studies re-
port ing this outcome noted
that gastrointest inal adverse
events were the most f re-
quent, occurring in between
15% to 31%. 1 study noted
haematological toxicity was
present in 81.5%of people. 2
out of the 3 studies that anal-
ysed QoL demonstrated a
benef it with ant i-cancer ther-
apy. 1 study showed no dif -
ference between the 2 groups
707 per 1000 734 per 1000
(660 to 804)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; HR: hazard rat io; RCT : randomised controlled trial.
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GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aConf idence interval include both benef it and harm; opt imal information size not met.
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B A C K G R O U N D
Recently published global cancer statistics show that pancreatic
cancer (PC) accounted for 184,400 deaths worldwide in 2012,
with the highest incidence in men in high-income countries at
8.6 cases per 100,000 (Torre 2015). In Australia, although PC is
relatively uncommon (incidence of 11 per 100,000), it is highly
lethal, representing the fourth leading cause of death from can-
cer (Tracey 2010). The US National Cancer Institute has re-
ported a five-year survival of 21.5% for those with localised dis-
ease (www.cancer.gov); however, a review of the Finnish Cancer
Registry showed five-year survival of only 4.3% for those with lo-
calised disease and an overall five-year survival of 0.2% (Carpelan
2005).
PC is a notoriously insidious cancer, commonly presenting with
vague, non-specific symptoms that classically consist of the triad
of epigastric abdominal pain, weight loss and jaundice (Howard
1977; Warshaw 1992), which gradually worsen over time. Physi-
cal examination is often normal, with the commonest sign of an
enlarged liver present in fewer than half of patients (Von Hoff
2005). Thus, most patients have advanced disease when they are
diagnosed.
Approximately 10% of early stage pancreatic carcinomas are
amenable to curative surgery (Siegel 2013). However, the risk of
relapse after surgical resection is still quite high, with only 10% of
patients surviving for five years (Conlon 1996; Shahrudin 1997).
Although studies have reported a benefit for chemotherapy in ad-
vanced disease (Burris 1997; Heinemann 2008; Conroy 2011;
Von Hoff 2013), the role of second and subsequent lines of che-
motherapy remains controversial (Nagrial 2015). The benefits of
radiotherapy, either alone or in combination, as a palliative treat-
ment for advanced or relapsed disease, is uncertain (Sultana 2007).
Hammel 2013 tested contemporary chemotherapy and radiother-
apy techniques but did not demonstrate a survival benefit in lo-
cally advanced disease. Biological therapies are emerging in the
treatment of pancreatic cancer and but have yet to find their place
in routine clinical practice (Castellanos 2011).
There are other published meta-analyses that look at various as-
pects covered by this review. Li 2014 analysed eight studies that
assessed randomised data using gemcitabine and fluoropyrimi-
dine agents, finding a benefit using gemcitabine plus fluoropy-
rimidine. Petrelli 2014 analysed 29 studies that assessed gemc-
itabine monotherapy versus chemotherapy combinations, find-
ing improved outcomes with the chemotherapy combinations.
Two studies have used a Bayesian network meta-analysis to per-
form direct and indirect comparisons of chemotherapy combina-
tions (Chan 2014; Gresham 2014). Chan 2014 concluded that
FOLFIRINOX was likely to be the most efficacious regimen in
the advanced stage. Two meta-analyses have assessed chemother-
apy plus radiotherapy (Bernstein 2014; Chen 2013), both find-
ing a small benefit to adding chemotherapy to radiation; however,
neither included the recent study conducted by Hammel 2013.
Anti-cancer therapies in the metastatic setting ideally aim to im-
prove people’s quality and length of life, with tolerable side effects.
This review will analyse both the anti-cancer effects and the ad-
verse effects of treatments in patients with pancreatic cancer.
Description of the condition
Pancreatic ductal adenocarcinoma (PDAC) is a cancer arising from
the ducts in the pancreas gland. It can be localised to the pancreas
(local disease), locally advanced (still confined to the area around
the pancreas but possibly involving lymph glands or other imme-
diately adjacent structures) or metastatic (with cancer spread to
distant areas).
This review includes studies in patients with locally advanced (not
amenable to local therapies) or metastatic PC, formally defined as
follows (Callery 2009).
1. Locally advanced or unresectable, defined by:
i) greater than 180° of superior mesenteric vein
encasement, any coeliac abutment;
ii) unreconstructable superior mesenteric vein or portal
occlusion;
iii) aortic invasion or encasement;
iv) nodal involvement beyond the field of resection.
2. Metastatic, defined by distant sites of disease.
Description of the intervention
Chemotherapy
Chemotherapy encompasses all cytotoxic or antineoplastic drug
treatments, intravenous or oral, which work by killing or slowing
the growth of cancer cells. Although the schedules differ between
therapies, most are given on a four-weekly basis (one cycle) for up
to six cycles.
Radiotherapy
Radiation therapy uses X-rays to destroy or injure cancer cells so
they cannot multiply (Queensland Cancer Fund 2012). It is given
in a number of different ways.
1. External beam radiotherapy: delivered over a number of
sessions (fractions) utilising an external radiotherapy source
emitting X-rays, gamma rays, electrons or heavy particles.
2. Stereotactic body radiation therapy: a highly conformal
(targeted) technique for delivering external beam radiotherapy in
a single fraction (stereotactic radiosurgery) or a number of
fractions (stereotactic radiotherapy).
3. Brachytherapy: internal radiotherapy utilising a radioactive
source placed into or adjacent to the pancreas and administered
in a single fraction or number of fractions, given alone or in
combination with external beam radiotherapy.
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4. Intraoperative radiotherapy: administration of external
source radiotherapy or brachytherapy at the time of surgery,
given alone or in combination with external beam radiotherapy.
Best supportive care
Best supportive care in advanced disease is defined as anything
other than chemotherapy. It may include symptom control by
radiotherapy (not to the primary site), palliative surgery, biliary
stent insertion, analgesia, blood transfusion, and psychological or
social support.
How the intervention might work
The primary goal for all treatments for locally advanced or
metastatic pancreatic cancer is to palliate symptoms and improve
overall survival (see Appendix 1, ’Glossary of terms’). In general,
chemotherapy and radiotherapy can potentially kill cancer cells in
the body and reduce the severity of the disease. This can in turn,
reduce symptoms and increase survival times. In the advanced set-
ting, chemotherapy and radiotherapy do not offer a cure. Best sup-
portive care is usually administered alongside chemotherapy and
radiotherapy, but it can be the sole treatment given to some pa-
tients. All anti-cancer therapies can cause side effects, which com-
monly include fatigue, nausea, vomiting, low blood counts (hae-
moglobin, white cells and platelets) and diarrhoea. Radiotherapy
can cause local pain, skin rash, fatigue, nausea and vomiting.
Why it is important to do this review
Given the poor prognosis of PC, evidence-based clinical decision-
making is paramount in guiding patients through treatments. Per-
forming a meta-analysis of studies will ensure that clinicians and
patients have a reference to inform their clinical choices.
The meta-analysis published previously in Yip 2009 has been crit-
icised for not using hazard ratios to assess survival (Sultana 2007).
This update will use hazard ratios and also assess quality of life.
PC is a notoriously difficult cancer in which to perform clinical
studies, and much controversy exists. Although there is evidence
in the first line setting that supports the use of FOLFIRINOX
(Conroy 2011), gemcitabine plus erlotinib (Moore 2007), gemc-
itabine plus fluoropyrimidine (Cunningham 2009), or nab-pacli-
taxel (Von Hoff 2013), questions remain with regard to toxicity,
cost and survival benefits. There is conflicting evidence on the
place for and schedule of chemoradiation as well as debate about
the optimum drug and dose (Kim 2007; Philip 2011).
Previous meta-analyses have had narrow search criteria (Chan
2014; Li 2014; Petrelli 2014), or they have used only phase III
randomised data (Gresham 2014). Here, we have attempted to
synthesise and organise all available randomised data concerning
patients having treatment for advanced pancreas cancer in order
to help inform clinical decision-making and guide further research
in this area.
O B J E C T I V E S
To assess the effect of chemotherapy, radiotherapy or both for first-
line treatment of advanced pancreatic cancer. Our primary out-
come was overall survival, while secondary outcomes include pro-
gression-free survival, grade 3/4 adverse events, therapy response
and quality of life.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled studies, both published and unpublished,
comparing one of the intervention types versus placebo, another
intervention type or best supportive care.
Types of participants
People with a diagnosis of pancreatic adenocarcinoma established
by either histological or cytological findings (investigations on
body tissue or cells). Studies enrolling people with advanced, un-
resectable or recurrent disease were eligible for inclusion.
Types of interventions
Any type of chemotherapy, radiotherapy or combination of che-
motherapy plus radiotherapy versus placebo, no treatment, best
supportive care or another chemotherapy and/or radiotherapy
treatment regimen.
Best supportive care in advanced disease may include symptom
control by radiotherapy (not to the primary site), palliative surgery,
biliary stent insertion, analgesia, blood transfusion and psycho-
logical or social support.
We looked for interventions falling into the following compar-
isons.
1. Any chemotherapy treatment versus placebo, no treatment
or best supportive care.
2. Any chemotherapy treatment versus any other
chemotherapy treatment.
3. Any radiotherapy treatment versus placebo, no treatment or
best supportive care.
4. Any radiotherapy treatment versus any other radiotherapy
treatment.
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5. Any combination of radiotherapy and chemotherapy versus
placebo, no treatment or best supportive care.
6. Any combination of radiotherapy and chemotherapy versus
any other combination of radiotherapy and chemotherapy.
After searching was complete, the studies were organised into four
specific comparisons.
1. Anti-cancer therapy versus best supportive care
2. Various types of chemotherapy versus gemcitabine
3. Gemcitabine combinations versus gemcitabine alone
4. Fluoropyrimidine combinations versus fluoropyrimidines
alone
Types of outcome measures
Primary outcomes
Overall survival (OS) - survival until death from any cause
Secondary outcomes
1. Progression-free survival (PFS) - time to progression of
disease on a given therapy. This is usually detected by an increase
of the size or number of cancer lesions seen on a computer
tomography scan (CT) using the Response Evaluation Criteria in
Solid Tumours (RECIST) criteria (Nishino 2010).
2. Quality of life (QoL), measured with a validated
instrument, such as the European Organisation for Research and
Treatment of Cancer (EORTC) quality of life questionnaire for
cancer patients (QLQ-C30) (eortc.be/qol/).
3. Response rates - this relates to the shrinkage of a cancer in
response to therapy and is usually measured on CT scans, with
cancer shrinkage defined according to the RECIST criteria
(Nishino 2010).
4. Grade 3/4 adverse events - adverse events are defined by the
National Cancer Institute (cancer.gov) as an unfavourable and
unintended sign or symptom associated with a medical
treatment. Severity is graded. Grade 3 is classed as a severe or
medically significant event but not immediately life threatening.
Hospitalisation is indicated, and the effects limit the patients’
ability to self care. Grade 4 is classed as a life-threatening event
requiring urgent attention.
Search methods for identification of studies
The authors completed searches to identify all relevant published
and unpublished randomised controlled studies. Articles pub-
lished in any language were eligible for inclusion.
We searched the following electronic databases.
1. Cochrane Central Register of Controlled Trials
(CENTRAL; 2017; Issue 6), which includes the Cochrane Upper
Gastrointestinal and Pancreatic Diseases Group Trials Register,
in the Cochrane Library (searched 14 June 2017); Appendix 2.
2. MEDLINE (1946 to 14 June 2017); Appendix 3.
3. EMBASE (1980 to 14 June 2017); Appendix 4.
4. CANCERLIT (1999 to 2002). We did not undertake
subsequent searches in CANCERLIT, as the database merged
with MEDLINE in 2002.
To identify randomised controlled studies, we applied phases one,
two and three of the Cochrane highly sensitive search strategy, as
described in the Cochrane Handbook for Reviews of Interventions
(Higgins 2011).
Electronic searches
We handsearched reference lists from studies and review articles
from the electronic searching to identify further relevant studies.
We also handsearched published abstracts from the following con-
ference proceedings.
1. American Gastroenterological Association (AGA) (1994 to
2014).
2. American Society of Clinical Oncology (ASCO) (1996 to
2016).
3. American Association of Cancer Research (AACR) (1957 to
2014).
4. American Pancreatic Association (APA) (2001 to 2014).
5. Digestive Disease Week (DDW) (1994 to 2014).
6. European Cancer Conference (ECCO) (1997, 1999, 2001,
2003, 2005, 2007, 2009, 2011, 2013).
7. European Society of Medical Oncology (ESMO) (1998,
2000, 2002, 2004, 2006, 2008, 2010, 2012, 2014).
8. Joint ECCO/ESMO meeting (2009, 2010, 2011, 2013).
9. European Pancreatic Club (EPC) (2000 to 2014).
10. Gastrointestinal Cancers Symposium (2007 to 2015).
11. United European Gastroenterology Week (UEGF) (1960 to
2014).
We searched the following information resources.
1. National Cancer Institute Physician Data Query.
2. UK Co-ordinating Committee on Cancer Research.
We also searched the following study registers.
1. Australian and New Zealand Clinical Trials Registry.
2. National Research Register.
3. Medical Research Council.
4. Clinicaltrials.gov.
5. Current Controlled Trials.
6. Trialscentral.
7. Center Watch.
Searching other resources
We searched the Internet using the Google search engine. In ad-
dition, we contacted members of the Cochrane Upper Gastroin-
testinal and Pancreatic Diseases Group and other experts in the
field and ask them to provide details of outstanding clinical studies
and any relevant unpublished materials that were known to them.
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Data collection and analysis
Selection of studies
We scanned titles of studies from the electronic search, removing
duplicates. Two independent review authors (VC and AN) then
considered the titles and abstracts to exclude clearly ineligible stud-
ies. We retrieved the full text of all remaining records, and two
review authors (VC and AN) independently assessed them against
inclusion criteria for the review, resolving disagreements with ad-
judication by a third review author (DY) according to the process
outlined in Chapter 7.2.3 of theCochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011). We documented reasons
for excluding studies according to Higgins 2011.
Data extraction and management
Two independent review authors (VC and AN) extracted data,
recording the inclusion/exclusion criteria, number of participants
and treatment arms for each study. For survival outcomes, we
recorded hazard ratios (HRs) for OS and PFS from the published
data where possible. If not reported, then we extracted time-to-
event data and derived the HRs using the methods described in
Tierney 2007. We also extracted median survival times. For re-
sponse rates and adverse events (AEs), we recorded the number
of people who had experienced an event of interest and the total
number of people evaluated for that event to determine the risk
ratio (RR). We extracted details on QoL in a descriptive fashion
as published.
Assessment of risk of bias in included studies
Two review authors used the Cochrane ’Risk of bias’ tool to inde-
pendently assess risk of bias in the studies, with a a third indepen-
dent review author settling disputes (Higgins 2011).
We summarised the results in a ’Risk of bias summary’ graph. We
interpreted the results of meta-analyses in light of the findings of
the risk of bias assessments.
Measures of treatment effect
For survival data, we used the HR with 95% confidence intervals
(CI) and median survival times. For dichotomous data (response
rates and grade 3/4 AEs), we used the risk ratio (RR) with a 95%
CI. We report quality of life in a descriptive, tabulated fashion.
Unit of analysis issues
For studies that compared more than one treatment arm with a
control arm in the same meta-analysis, we divided the number
of participants in the control group by the number of treatment
arms. There were no other unit of analysis issues.
Dealing with missing data
When we could not extract data from the text, or when statistics
were missing, we attempted to contact the authors of the original
article to obtain the necessary information.
Assessment of heterogeneity
We assessed heterogeneity by visual inspection of the forest plots
and statistically with the Chi² test for homogeneity and the I²
statistic for inconsistency.
Assessment of reporting biases
Hadwe included comparisonswithmore than10 included studies,
we would have constructed funnel plots to assess reporting bias.
Data synthesis
We used the generic inverse variance method for all meta-analyses
according to the guidance in theCochraneHandbook for Systematic
Reviews of Interventions (Higgins 2011). Due to the heterogeneity
of the interventions and comparators, we used a random-effects
model in all instances. We performed all analyses using Review
Manager 5 (RevMan 5) software (RevMan 2014), following an
intention-to-treat principle when data permitted.
Subgroup analysis and investigation of heterogeneity
We did not perform any subgroup analyses.
Sensitivity analysis
We planned to perform sensitivity analyses by excluding studies
at high risk of bias from the meta-analysis, but due to the small
number of studies in the various comparisons, we were unable to
do so.
Summary of findings table
We created four summary of findings tables describing the primary
outcome measure of OS for participants. We included a narrative
summary of the toxicity and QoL data in the comments section
of the table. We calculated the median 12-month survival rate for
the control arm to calculate the assumed risk for each comparison.
We used the percentage of people alive at 12 months if it was
available, otherwise we extracted the data from the Kaplan-Meier
curves. We then applied the summary HR to this rate to give an
anticipated effect on the rate of death with the intervention versus
the comparator, expressed as number of events per 1000 people.
We used the 6-month survival rate if all control arm participants
had died by 12 months.
We used the GRADE approach to assess the quality of the body
of evidence for the outcome OS as described by the GRADE
Working Group and in the GRADE Handbook (Guyatt 2011;
Schünemann 2013).
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R E S U L T S
Description of studies
Results of the search
Figure 1 presents the study flow chart. We identified 1304 studies
through electronic searches and an additional 80 studies through
handsearching. After removing duplicates and studies that were
clearly not eligible for inclusion, we assessed 215 full-text articles.
Of these, we excluded 155, including 49 that did not meet the
inclusion criteria for the review, and 106 that will be reported in
a separate Cochrane Review.
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Figure 1. 1 Study flow diagram.
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Included studies
The original published protocol had wide inclusion criteria. Due
to the large number of studies identified, we decided to split the re-
view.Therefore, wewill report studies addressing biological agents,
immunotherapy, second-line therapies and local therapies for lo-
cally advanced disease separately. This report focuses on studies of
either chemotherapy or radiotherapy in the advanced setting only.
We included sixty studies assessing the effects on chemotherapy
in advanced PC (Characteristics of included studies). We did not
identify any studies that addressed radiotherapy in the advanced
setting. Of the included studies, we were able to include 42 with
data on 9463 participants in a meta-analysis.
We categorised these studies into five main categories.
1. Any anti-cancer treatment versus best supportive care (6
studies: Andren-Sandberg 1983; Frey 1981; Glimelius 1996;
Huguier 2001,Takada 1998; Xinopoulos 2008).
2. Various types of chemotherapy versus gemcitabine (8
studies: Burris 1997; Cheverton 2004; Conroy 2011; Poplin
2009; Poplin 2013; Singhal 2014; Smith 2003; Tempero 2003).
3. Gemcitabine combination versus gemcitabine alone (7
studies addressing platinum plus gemcitabine: Colucci 2002;
Colucci 2010; Heinemann 2006; Li 2004; Louvet 2005; Viret
2004; Wang 2002; 10 studies addressing fluoropyrimidine plus
gemcitabine: Berlin 2002; Cunningham 2009; Di Costanzo
2005; Herrmann 2007; Lee 2017; Ohkawa 2004; Ozaka 2012;
Riess 2005; Scheithauer 2003; Ueno 2013; 3 studies addressing
topoisomerase inhibitors plus gemcitabine: Abou-Alfa 2006;
Rocha Lima 2004; Stathopoulos 2006; 1 study addressing taxane
plus gemcitabine: Von Hoff 2013; 2 studies addressing multi-
drug combinations including gemcitabine: Petrioli 2015; Reni
2005; and 4 studies of other agents combined with gemcitabine:
Gansauge 2002; Meng 2012; Oettle 2005; Ueno 2013 - EPA
study).
4. Fluoropyrimidine-based studies (4 studies: Ducreux 2004;
Kovach 1974; Maisey 2002; Moertel 1979).
5. Single studies addressing unique treatment comparisons (13
studies: Afchain 2009; Boeck 2008; Bukowski 1983; Corrie
2017; Hirao 2011; Kelsen 1991; Kulke 2009; Levi 2004; Lohr
2012; Lutz 2005; Moertel 1977; Reni 2012; Topham 1991).
1 Anti-cancer therapy versus best supportive care
Six studies compared a type of anticancer therapy with best sup-
portive care (BSC). Andren-Sandberg 1983 (N = 47) compared
5FU/CCNU plus vincristine (n = 25) versus BSC (n = 22). Frey
1981 included 152 participants with unresectable PC and as-
sessed 5-fluorouracil (5FU) plus chloroethylcyclohexylnitrosurea
(CCNU). Glimelius 1996 studied people with advanced PC or
biliary tract cancer; of the 53 participants with PC, 29 were given
5FU/LV,with orwithout etoposide, and24 receivedBSC.Huguier
2001 included45participantswith unresectable PC; the treatment
arm was cisplatin plus 5FU plus leucovorin (LV). Takada 1998
included 83 people with unresectable PC; the treatment arm was
5FU plus doxorubicin plus mitomycin C (MMC). Xinopoulos
2008 included 49 people with locally advanced PC; the treatment
arm was gemcitabine.
2 Various types of chemotherapy versus gemcitabine
Eight studies compared various types of chemotherapy versus gem-
citabine.
2.1 5FU versus gemcitabine
Therewas one study in this group involving 126 peoplewith symp-
tomatic advanced PC; 63 were given 5FU and 63 gemcitabine
chemotherapy (Burris 1997).
2.2 FOLFIRINOX versus gemcitabine
Conroy 2011 tested FOLFIRINOX in 342 people, and Singhal
2014 in 310 people, with metastatic PC.
2.3 CO-101 versus gemcitabine
One study in 367 participants with metastatic PC compared CO-
101 (lipid conjugate form of gemcitabine) versus gemcitabine (
Poplin 2013).
2.4 ZD9331 versus gemcitabine
One study addressed this comparison (Smith 2003), including 55
participants with locally advanced (LA) or metastatic PC. The
treatment arm was ZD9331 (thymidylate synthase inhibitor).
2.5 Fixed-dose rate gemcitabine versus standard infusional
gemcitabine
Two studies were available for analysis: Poplin 2009 and Tempero
2003. Both had slightly different schedules: Poplin 2009 involved
824 participants with LA or metastatic PC and compared gem-
citabine at 1000 mg/m² given over 30 min weekly for 7 out of
8 weeks then 3 out of 4 weeks versus gemcitabine given at 1500
mg/m² over 150 min 3 out of 4 weeks. Tempero 2003 involved
92 people with LA or metastatic PC and compared a dose-dense
regimen of gemcitabine 2200 mg/m² weekly, 3 out of 4 weeks
versus gemcitabine 1500 mg/m² given at 10 mg/m²/min, weekly,
3 out of 4 weeks.
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2.6 Exatecan (DX-8951f) versus gemcitabine
One study addressed this comparison (Cheverton 2004), includ-
ing 339 chemotherapy-naive participants with LA or metastatic
PC. The treatment arm was exatecan (a hexacyclic, water-soluble,
topoisomerase-1 inhibitor).
3 Gemcitabine combination studies
3.1 Gemcitabine plus a platinum agent versus gemcitabine
alone
Seven studies compared gemcitabine plus a platinum agent versus
gemcitabine alone (Colucci 2002; Colucci 2010; Heinemann
2006; Li 2004; Louvet 2005; Viret 2004; Wang 2002). Louvet
2005 used oxaliplatin, while the rest used cisplatin. All studies
had gemcitabine alone as the control arm and gemcitabine plus a
platinum agent in the treatment arm. Colucci 2002 (N = 107),
Colucci 2010 (N = 400), Heinemann 2006 (N = 195). Li 2004
(N = 46) and Louvet 2005 (N = 326) all included people with LA
or metastatic PC, while Viret 2004 (N = 83) and Wang 2002 (N
= 42) included participants with stage III/IV PC.
3.2 Gemcitabine plus fluoropyrimidine versus gemcitabine
alone
Ten studies compared gemcitabine plus fluoropyrimidine versus
gemcitabine alone (Berlin 2002; Cunningham 2009; Di Costanzo
2005; Herrmann 2007; Lee 2017; Ohkawa 2004; Ozaka 2012;
Riess 2005; Scheithauer 2003; Ueno 2013).
• Two studies assessed infusional 5FU in 567 participants
with with LA/metastatic PC (Di Costanzo 2005; Riess 2005),
and one study tested bolus 5FU in 322 participants with
unresectable PC (Berlin 2002).
• Four studies used capecitabine in: 533 people with LA/
metastatic PC (Cunningham 2009), 319 people with inoperable/
metastatic PC (Herrmann 2007), 214 people with LA/metastatic
PC (Lee 2017), and 83 people with metastatic PC (Scheithauer
2003).
• Two studies used oral tegafur (S1) in LA/metastatic PC:
Ozaka 2012 included 112 participants and Ueno 2013 832.
Ueno 2013 was a multi-armed study that compared gemcitabine
versus S1 versus gemcitabine plus S1.
• One study assessed tegafur-uracil (UFT) in 19 participants
(Ohkawa 2004).
3.3 Gemcitabine plus toposiomerase inhibitor versus
gemcitabine alone
Three studies compared gemcitabine plus a toposiomerase in-
hibitor versus gemcitabine alone in participants with LA or
metastatic PC (Abou-Alfa 2006; Rocha Lima 2004; Stathopoulos
2006). Rocha Lima 2004 (N = 360) and Stathopoulos 2006 (N
= 130) tested irinotecan, and Abou-Alfa 2006 (N = 349) used ex-
atecan.
3.4 Gemcitabine plus taxane versus gemcitabine alone
Only one study, in 861 participants with metastatic PC, was suit-
able for analysis (Von Hoff 2013).
3.5 Gemcitabine plus other combinations of chemotherapy
versus gemcitabine alone
Two studies assessed gemcitabine plus other combinations of che-
motherapy: Petrioli 2015 included 67 people with metastatic
PC and combined oxaliplatin plus capecitabine plus gemc-
itabine (GEMOXEL). Reni 2005 assessed 99 people with LA/
metastatic PC and used a combination cisplatin-epirubicin-5FU-
gemcitabine.
3.6 Gemcitabine in combination with other agents versus
gemcitabine alone
Four studies examined different agents in combination with gem-
citabine: Gansauge 2002 looked at 90 participants with unre-
sectable PC and used Ukrain (herbal medicine), Meng 2012 as-
sessed 76 people with unresectable PC and used huachansu (Chi-
nese herbal medicine), Oettle 2005 included 565 people with LA/
metastatic PC and used pemetrexed, and Ueno 2013 - EPA study
included 66 people with advanced PC and used eicosapentaenoic
acid supplement (EPA).
4 Fluoropyrimidine combinations versus
fluoropyrimidine alone
Four studies compared fluoropyrimidine combinations versus flu-
oropyrimidine alone (Ducreux 2004; Kovach 1974; Maisey 2002;
Moertel 1979). Ducreux 2004 was a three-armed study in 63 par-
ticipants with LA or metastatic PC, and Kovach 1974 included
82 participants with unresectable PC and compared 5FU versus
bis-chloroethylnitrosurea (BCNU) alone versus 5FU plus BCNU.
Maisey 2002 analysed 209 participants with LA or metastatic
PC and compared 5FU versus 5FU plus mitomycin C (MMC).
Moertel 1979 involved 176 people with metastatic PC and used
streptozocin in the treatment arm. We were unable to include
Cullinan 1985 and Cullinan 1990 in the meta-analysis, as they
were multi-armed studies in which the control arm could not be
split.
5 Single studies addressing unique treatment
comparisons
Many studies addressed unique comparisons, so we could not
group them with other studies.
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• Boeck 2008 studied capecitabine plus oxaliplatin (n = 61)
versus capecitabine plus gemcitabine (n = 64) versus modified
gemcitabine plus oxaliplatin (n = 63).
• Kulke 2009 was a multi-armed study comparing fixed dose
rate gemcitabine (n = 64) versus infusional gemcitabine plus
cisplatin (n = 66) versus infusional gemcitabine plus docetaxel (n
= 65) versus infusional gemcitabine plus irinotecan (n = 60).
• Afchain 2009 compared standard gemcitabine plus
oxaliplatin (n = 20) versus a simplified gemcitabine plus
oxaliplatin protocol (n = 37).
• Bukowski 1983 compared mitomycin C plus 5FU (MF) (n
= 73) versus streptozocin plus MMC plus 5FU (SMF) (n = 72).
• Hirao 2011 looked at gemcitabine given on a three-week
schedule (n = 45) versus gemcitabine given on a four-week
schedule (n = 45).
• Kelsen 1991 compared streptozocin plus MMC plus 5FU
(SMF) (n = 42) versus cisplatin plus ara-C plus caffeine (CAC)
(n = 40).
• Levi 2004 studied 5FU given either as a constant or
chronomodulated infusion, with (n = 52) versus without (n =
55) cisplatin.
• Lutz 2005 compared gemcitabine plus docetaxel (n = 49)
versus cisplatin plus docetaxel (n = 47).
• Moertel 1977 looked at streptozocin plus 5FU (n = 40)
versus streptozocin plus cyclophosphamide (n = 48).
• Reni 2012 compared capecitabine plus cisplatin plus
gemcitabine plus docetaxel (PDXG) (n = 53) versus capecitabine
plus cisplatin plus gemcitabine plus epirubicin (PEXG) (n = 48).
• Finally, Topham 1991 looked at epirubicin (n = 32) versus
5FU plus epirubicin plus MMC (n = 30).
Excluded studies
We excluded 155 studies. Other Cochrane Reviews will cover
the 53 studies addressing biological agents, the 11 assessing im-
munotherapies, the 25 looking at local therapies in locally ad-
vanced disease and the 17 focusing on second-line therapies. We
excluded the remaining 49 studies for the following reasons.
• Five studies did not mandate histological confirmation in
the study protocol (Abdel Wahab 1999; Johnson 2001;
Mallinson 1980; Nakai 2012; Palmer 1994).
• Two studies included some participants who did not have
advanced stage PC (Andersen 1981; Lygidakis 1995).
• Fifteen studies did not provide sufficient data (Baker 1976;
Cohen 2010; GITSG 1985; Kim 2011; Oberic 2011; Queisser
1979; Ramanathan 2011; Sakata 1992; Senzer 2006; Shapiro
2005; Sultana 2009; Sun 2011; Tagliaferri 2013; Trouilloud
2012; Van Cutsem 2013).
• Nine studies included people with non-PDAC histologies
(Ducreux 2002; GITSG 1988; Lokich 1979; Mizuno 2013;
Moertel 1981; Oster 1986; Schein 1978; Sudo 2014; Takada
1994).
• Five were cross-over studies (Berglund 2010; Dahan 2010;
Heinemann 2013 (GUT); Horton 1981; Javle 2011).
• Two were retrospective studies (Nio 2010; Reni 2009).
• Five had a non-randomised study design (Bukowski 1993;
Gong 2007; Mitry 2006; Yongxiang 2001; Zemskov 2000).
• Three studies published only interim results (GITSG 1979;
Topham 1993; Tuinmann 2008).
• Survival was not an endpoint in three studies (Ardalan
1988; Meyer 2008; Schmitz-Winnenthal 2013).
Risk of bias in included studies
Figure 2 and Figure 3 summarise the risk of bias of all included
studies. Many studies did not publish sufficient details to make
a judgement on selection bias. Of those that did, all were judged
to be at a low risk of bias because they used centralised randomi-
sation techniques. Only one study was double-blind and placebo
controlled (Meng 2012), and we judged it to be at low risk for
performance bias. We assessed the remainder of the studies to
be at a high risk of bias. We considered studies that used OS
as the primary endpoint to be at a low risk for detection bias
(Abou-Alfa 2006; Berlin 2002; Cheverton 2004; Colucci 2010;
Conroy 2011; Cullinan 1985; Cullinan 1990; Cunningham 2009;
Frey 1981; Gansauge 2002; Glimelius 1996; Heinemann 2006;
Herrmann 2007; Huguier 2001; Kulke 2009; Lee 2017; Levi
2004; Li 2004; Lohr 2012; Louvet 2005; Oettle 2005; Poplin
2009; Poplin 2013; Riess 2005; Rocha Lima 2004; Singhal 2014;
Smith 2003; Stathopoulos 2006; Takada 1998; Tempero 2003;
Ueno 2013; Von Hoff 2013; Xinopoulos 2008). If tumour as-
sessments were needed to assess the primary outcome (e.g. RR or
PFS), we assigned a low risk of bias only if an independent reviewer
or by a blinded radiologist conducted the assessments (Ducreux
2004; Reni 2005; Reni 2012; Scheithauer 2003). We judged all
other studies to be at a high risk of bias. We deemed studies that
reported the intention-to-treat population (all participants ran-
domised on the study regardless if they received any treatment or
not) to be at a low risk of attrition bias, while we considered stud-
ies that did not report all randomised patients to be at a high risk
of bias (Bukowski 1983; Cullinan 1985; Ducreux 2004; Kelsen
1991; Louvet 2005; Moertel 1977; Ozaka 2012). We detected se-
lective reporting bias in only two studies (Bukowski 1983;Moertel
1979), the former because only the participants with measurable
disease were reported in detail and the latter because the toxicity
data were not comprehensively reported.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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We describe details of the risk of bias of the included studies in
the Effects of interventions section.
Effects of interventions
See: Summary of findings for the main comparisonAnti-cancer
therapy versus best supportive care for advanced pancreatic
cancer; Summary of findings 2 Various types of chemotherapy
versus gemcitabine for advanced pancreatic cancer; Summary
of findings 3 Gemcitabine combinations versus gemcitabine
alone for advanced pancreatic cancer; Summary of findings 4
Fluoropyrimidine combinations versus fluoropyrimidine alone for
advanced pancreatic cancer
1 Anti-cancer therapy versus best supportive care
(BSC)
Six studies addressed any anti-cancer therapy versus best sup-
portive care (Andren-Sandberg 1983; Frey 1981; Glimelius 1996;
Huguier 2001, Takada 1998; Xinopoulos 2008). The main po-
tential source of bias in these studies came from their non-blinded
design; however, we did not feel this significantly affected the
results for overall survival (Figure 2; Figure 3). In three studies
the risk of selection bias was unclear due to insufficient reporting
(Andren-Sandberg 1983; Glimelius 1996; Xinopoulos 2008).
Four of the six studies provided data in sufficient detail to derive
hazard ratios (HR) for OS, with 298 people analysed. Pooled data
of four studies in 298 people showed an HR of 1.08 (95% CI
0.88 to 1.33; Analysis 1.1). There was no statistical heterogeneity
between studies (I² = 0%).Median survival ranged from 3.0 to 8.6
months in the anti-cancer therapy group and 2.5 to 7.0 months
in the BSC group. The difference in median survival times ranged
from 0.9 months in favour of BSC to 3.5 months in favour of
anticancer therapy (Table 1).
Three studies reported quality of life (Table 1). Andren-Sandberg
1983 did not find a difference in Karnofsky performance status
(KPS) score. In Glimelius 1996, the EORTC QLQ-C30 results
favoured the treatment group; however, there was a high rate of
dropouts in the later time points. The third study (Xinopoulos
2008) demonstrated a superior QoL (EORTC QLQ-C30) in the
gemcitabine group during the first month (P = 0.028), but there
was no difference in months two to four, and the BSC group had
a superior QoL in months five (P = 0.010) and six (P = 0.0003).
Trials either did not study or did not adequately report PFS and
response rates, with the exception of Takada 1998. This study
reported complete or partial response in one person in the anti-
cancer therapy group versus none in the BSC group.
With respect to adverse effects or toxicity in the anti-cancer therapy
group, Frey 1981 reported that 31% of participants experienced at
least one toxicity, with the most common being gastrointestinal.
Huguier 2001 reported that the most common toxicities were
haematological and gastrointestinal (each seen in 15% of people).
Takada 1998 showed that the commonest grade 3/4 adverse events
(AEs) were anorexia, which occurred in in 15/28 participants and
nausea/vomiting, in 5/24 participants. Haematological toxicities
were the most common in Xinopoulos 2008, with leucopenia
occurring in 81.5% of participants.
2 Various types of chemotherapy versus gemcitabine
Eight studies compared various types of chemotherapy versus gem-
citabine (Burris 1997; Cheverton 2004; Conroy 2011; Poplin
2009; Poplin 2013; Singhal 2014; Smith 2003; Tempero 2003),
analysing a total of 1844 participants in six treatment subgroups.
Due to the heterogeneity of the investigational agents, we did
not pool the results. Five studies provided PFS data (Burris 1997;
Conroy 2011; Poplin 2009; Singhal 2014; Smith 2003). Themain
potential source of bias in these studies came from the non-blinded
study design. We were unable to comprehensively assess selection
bias in some studies (Cheverton 2004; Singhal 2014; Smith 2003;
Tempero 2003), and there was a high risk of detection bias noted
in Burris 1997, Poplin 2013 and Smith 2003; however, we did not
consider that it significantly affected results for overall survival.
2.1 5FU versus gemcitabine
Burris 1997 (N = 126) was the only study to compare 5FU with
gemcitabine, showing an HR for OS of 1.69 (95% CI 1.26 to
2.27, P < 0.001; Analysis 2.1). The difference in median survival
was 1.3 months in favour of gemcitabine (Table 2). The analysis
of PFS showed an HR of 1.47 (95% CI 1.12 to 1.92, P = 0.005;
Analysis 2.2). There were better outcomes for both OS and PFS
with gemcitabine, and this group also showed more treatment
response (0 in the 5FU arm versus 3 in the gemcitabine arm; risk
ratio (RR) 0.14, 95% CI 0.01 to 2.71, P = 0.19). On the other
hand, the gemcitabine arm showed a higher risk of most types of
grade 3/4 toxicity: anaemia (0 in the 5FUarm versus 6 events in the
gemcitabine arm: RR 0.08, 95%CI 0.0 to 1.34, P = 0.08; Analysis
2.5); neutropenia (3 events versus 16 events: RR 0.19, 95% CI
0.06 to 0.61, P = 0.006; Analysis 2.6); thrombocytopenia (1 event
versus 6 events: RR 0.17, 95% CI 0.02 to 1.34, P = 0.09; Analysis
2.7); and nausea (3 events versus 8 events: RR 0.38, 95% CI 0.10
to 1.35, P = 0.13; Analysis 2.8). Diarrhoea was the exception (3
events in the 5FU arm versus 1 event in the gemcitabine arm:
RR 3.00, 95% CI 0.32 to 28.07, P = 0.34; Analysis 2.9). Clinical
benefit was superior in the gemcitabine arm compared with the
5FU arm, with a higher clinical benefit response (23.8% versus
4.8%), shorter median time to clinical benefit response (3 weeks
versus 7 weeks) and longer duration of clinical benefit response
(18 weeks versus 13 weeks) (Table 2).
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2.2 FOLFIRINOX versus gemcitabine
Two studies in 652 people assessed the effects of FOLFIRINOX
versus gemcitabine (Conroy 2011; Singhal 2014). The FOLFIRI-
NOX group generally outperformed gemcitabine, showing im-
proved OS (HR 0.51, 95% CI 0.43 to 0.60, P < 0.001; I² =
29%; Analysis 2.1), longer median survival (4.3months versus 3.4
months; Table 2), longer PFS (HR 0.46, 95% CI 0.38 to 0.57,
N = 652, P < 0.001; I² = 0%; Analysis 2.2), longer time to degra-
dation of QoL (HR 0.46, 95% CI 0.35 to 0.61, P < 0.001; I²
= 0%; Analysis 2.3; Table 2), and more treatment responses (54
responses versus 16 responses: RR 3.38, 95% CI 2.01 to 5.65, P
< 0.001; Analysis 2.4). On the other hand, FOLFIRINOX also
showed more grade 3/4 haematological toxicity for: anaemia (13
events versus 10 events: RR 1.30, 95% CI 0.59 to 2.88, P = 0.52;
Analysis 2.5), neutropenia (75 events versus 35 events: RR 2.14,
95% CI 1.52 to 3.01, P < 0.001: Analysis 2.6), and thrombocy-
topenia (15 events versus 6 events: RR 2.50, 95% CI 0.99 to 6.29,
P = 0.05; Analysis 2.7).
2.3 CO-101 versus gemcitabine
Poplin 2013 tested CO-101 in 367 people. Outcomes were not
different for participants in either arm. The HR for OS was 1.07
(95%CI 0.86 to 1.34, P = 0.68; Analysis 2.1).Median survival was
similar in both groups, 5.2 months for CO-101 and 6.0 months
for gemcitabine (Table 2). The trial did not report PFS. The RR
for response was 0.67 (95% CI 0.43 to 1.04, P = 0.08; Analysis
2.4). We could neither prove nor rule out differences in various
types of grade 3/4 toxicity (Analysis 2.5; Analysis 2.6; Analysis
2.7).
2.4 ZD9331 versus gemcitabine
Smith 2003 compared ZD9331 versus gemcitabine in 55 people.
There was no difference in survival for participants in either arm.
TheHR forOSwas 0.86 (95%CI 0.42 to 1.76, P = 0.68; Analysis
2.1) and for PFS, it was 0.78 (95% CI 0.46 to 1.32, P = 0.36;
Analysis 2.2). Median survival was 5.0 months and 3.6 months,
respectively (Table 2). The RR for response was 0.42 (95% CI
0.04 to 4.33, P = 0.46, Analysis 2.4). We could neither prove nor
rule out differences in various types of grade 3/4 toxicity (Analysis
2.5; Analysis 2.6; Analysis 2.7; Analysis 2.8; Analysis 2.9).
2.5 Fixed dose rate gemcitabine (FDR-gem) versus standard
infusional gemcitabine
Two studies assessed the effects of FDR-gem in 644 people (Poplin
2009; Tempero 2003). OS was improved in the FDR-gem group
(HR 0.79, 95% CI 0.66 to 0.94, P = 0.009, I² = 0%; Analysis
2.1). In the two studies, median survival was 1.3 months and 3.0
months longer in the FDR-gem group (Table 2). Only Poplin
2009 (N = 552) reported PFS, finding no significant difference be-
tween groups (HR 0.88, 95% CI 0.77 to 1.01, P = 0.06, Analysis
2.2). There were more responses seen in the FDR-gem group (30
responses versus 19 responses), but this was not significant (RR
1.59, 95% CI 0.91 to 2.79, P = 0.10; Analysis 2.4). Analyses also
showed more grade 3/4 toxicity in the FDR-gem group: anaemia
(62 events versus 35 events: RR 1.79, 95% CI 1.22 to 2.63, P =
0.003; Analysis 2.5), neutropenia (183 events versus 100 events:
RR 1.85, 95% CI 1.53 to 2.23, P < 0.001; Analysis 2.6), throm-
bocytopenia (107 events versus 39 events: RR 2.77, 95% CI 1.99
to 3.86, P < 0.001; Analysis 2.7), and nausea (37 events versus 25
events: RR 1.52, 95% CI 0.94 to 2.46, P = 0.09; Analysis 2.8).
Diarrhoea was the exception (5 events versus 12 events: RR 0.44,
95% CI 0.16 to 1.23, P = 0.12; Analysis 2.9).
2.6 Exatecan (DX-8951f) versus gemcitabine
Cheverton 2004 demonstrated that exatecan had an inferior effect
on OS compared with gemcitabine (HR 1.27, 95% CI 0.96 to
1.68, P = 0.093). Median survival in the two respective groups was
5 months versus 6.6 months; 6-month survival rates were 44.1%
versus 51.1%; and 12-month survival rates, 17.9% versus 22.1%.
There were insufficient data to include this study in the PFS anal-
ysis; however, median PFS was 2.8 months versus 4.4 months.
Response rates were available in 276 people (1 response versus 10
responses: RR 0.10, 95% CI 0.01 to 0.78, P = 0.03; Analysis 2.4).
Toxicity data were available in 330 people and showed that both
agents performed similarly for grade 3/4 anaemia (10 events versus
10 events: RR 1.00, 95% CI 0.43 to 2.34, P = 1.00; Analysis 2.5),
neutropenia (32 events versus 32 events: RR 1.00, 95%CI 0.64 to
1.55, P = 1.00; Analysis 2.6), thrombocytopenia (12 events versus
16 events: RR 0.75, 95% CI 0.37 to 1.54, P = 0.43; Analysis 2.7)
and nausea (7 events versus 4 events: RR 1.75, 95% CI 0.52 to
5.86, P = 0.36; Analysis 2.8). QoL analysis showed that time to
worsening of clinical benefit was longer in the gemcitabine arm,
with 3.7 months to worsening of pain in the exatecan group ver-
sus 7.9 months in the gemcitabine group (P = 0.049). The gem-
citabine group also showed a longer time to worsening KPS (3.4
months versus 4.6 months; P = 0.011) and to weight loss (2.3
months versus 3.8 months; P = 0.020). Global and pancreas-spe-
cific QoL questionnaires failed to elicit significant differences be-
tween the two groups. (Table 2).
3 Gemcitabine combination studies
We identified six subgroups in this comparison, and we pooled
results in the subgroups only and not overall.
3.1 Gemcitabine plus a platinum agent versus gemcitabine
alone
The HR for OS based on six studies in 1140 participants showed
no difference between the treatment groups, 0.94 (95% CI 0.81
to 1.08, P = 0.38; Analysis 3.1). There was some statistical het-
erogeneity (I² = 15%). Four studies in 1015 participants reported
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PFS and showed some improvement in the gemcitabine + plat-
inum group, giving an HR of 0.80 (95% CI 0.68 to 0.95, P =
0.01; Analysis 3.2). There was high statistical heterogeneity (I² =
46%). The median survival times are listed in Table 3.
All studies (N = 1186) reported response rates favouring the com-
bined treatment arm (100 responses versus 67 responses: RR 1.48,
95%CI 1.11 to 1.98, P = 0.007, I² = 0%; Analysis 3.3). Data from
all studies (N = 1156) contributed to meta-analyses for grade 3/4
anaemia (62 events in the gemcitabine plus platinum group versus
45 events in the gemcitabine alone group: RR 1.41, 95% CI 0.87
to 2.31, P = 0.17; Analysis 3.4) and neutropenia (122 events versus
97 events: RR 1.34, 95% CI 0.90 to 1.97, P = 0.14; Analysis 3.5),
with similar rates between groups. For other adverse events, data
in 1110 participants from six studies showed more grade 3/4 AEs
in the combination group: thrombocytopenia (78 events versus
35 events: RR 1.96, 95% CI 1.00 to 3.84, P = 0.05; Analysis 3.6)
and nausea (52 events versus 22 events: RR 2.28, 95% CI 1.40 to
3.71, P = 0.001; Analysis 3.7), although for diarrhoea, we could
not rule out the possibility that these results were due to chance
(23 events versus 14 events: RR 1.48, 95% CI 0.62 to 3.53, P =
0.38; Analysis 3.8).
Four studies reported QoL data. Colucci 2010 measured QoL
using the EORTC QLQ C30 questionnaires in multiple areas.
Scores were from a scale of 0-100. The mean difference (MD)
between baseline scores and scores after 4 weeks of treatment were
measured. The study did not find a significant MD in global QoL
scores between those taking gemcitabine alone (MD 6.20) ver-
sus gemcitabine plus platinum (MD 0.09), P = 0.07. Heinemann
2006 found no difference between the treatment groups in either
the Spitzer index or pain intensity score, nor did Viret 2004 find
any difference in the EORTC-QLQ C30 results between treat-
ment groups. Li 2004 reported finding no difference in clinical
benefit but better quality of life outcomes in the gemcitabine alone
arm (3.8 months versus 5.6 months in QoL-adjusted life months
gained P < 0.001; Table 3).
In the one study that we could not include in the meta-analysis (Li
2004), there were no differences between the control and treat-
ment groups for OS (4.6 months versus 5.6 months) or PFS (2.8
months versus 2.8 months; Table 3).
The main source of bias identified in these studies was their non-
blinded study design. There was a high risk of attrition bias in
Louvet 2005 and insufficient details in Viret 2004 andWang 2002
reports to make a comprehensive assessment of risk of bias.
3.2 Gemcitabine plus fluoropyrimidine versus gemcitabine
alone
Ten studies reportedOS in 2718 participants. A benefit for adding
fluoropyrimidine to gemcitabine was detected (HR 0.88, 95% CI
0.81 to 0.95, P = 0.001; Analysis 3.1), with no statistical hetero-
geneity (I² = 0%). Eight studies reported PFS in 2608 partici-
pants and abenefit for the combination arm was also shown (HR
0.79, 95% CI 0.72 to 0.87, P < 0.001). There was moderate sta-
tistical heterogeneity with an I² of 34% (Analysis 3.2). The me-
dian survival times ranged from 5.4 months to 8.8 months in the
gemcitabine alone group and from 6.7 months to 13.7 months in
the combination group (Table 3). Ueno 2013 was a multi-armed
study that compared gemcitabine alone versus S1 alone versus
gemcitabine plus S1. The analysis in this review includes only the
gemcitabine alone and gemcitabine plus S1 arms.
Nine studies reported response rates in 2176 participants. Re-
sponses were more common in the combination group (228 re-
sponses in the combination group versus 124 responses in the
gemcitabine alone group), RR 1.78 (95% CI 1.29 to 2.47, P <
0.001; Analysis 3.3), with high statistical heterogeneity (I² = 52%).
Eight studies reported grade 3/4 AEs in 2158 participants in the
combination group versus the gemcitabine alone group, with the
combination treatment group tending to experience more AEs:
anaemia (97 events versus 89 events: RR 1.11, 95% CI 0.84 to
1.45, P = 0.47; Analysis 3.4), neutropenia (353 events versus 234
events: RR 1.53, 95% CI 1.34 to 1.74, P < 0.001; Analysis 3.5),
thrombocytopenia (122 events versus 81 events: RR 1.48, 95%
CI 1.00 to 2.18, P = 0.05; Analysis 3.6), nausea (61 events versus
47 events: RR 1.27, 95% CI 0.87 to 1.84, P = 0.22; Analysis 3.7),
and diarrhoea (55 events versus 23 events: RR 2.16, 95% CI 1.34
to 3.47, P = 0.002; Analysis 3.8).
Five studies recorded QoL data. Cunningham 2009 used the
Memorial pain assessment card, EORTC QLQ C30 and ESPAC
QoL questionnaires. Di Costanzo 2005 recorded mean disturbed
days and the mean days the person would like to cancel treatment.
Herrmann 2007 used a linear-analogue self-assessment (LASA)
indicators for clinical benefit response (CBR). Scheithauer 2003
recorded a combination of pain, KPS and weight, and Ueno 2013
recorded quality adjusted life years (QALYs). Cunningham 2009
did not find any significant differences in QoL between treatment
groups. Likewise, Di Costanzo 2005 did not show any differences
in QoL outcomes. Herrmann 2007 did not show a difference in
either CBR orQoL (measured by LASA); however, in those people
who did have a CBR, the duration was longer in the combination
arm (9.5 weeks versus 6.5 weeks, P < 0.02). Scheithauer 2003
demonstrated an improvement in pain response and KPS but not
weight gain in the combination arm, and Ueno 2013 showed a
statistically significant improvement in QALYs in the combina-
tion group: 0.401 versus 0.525, P < 0.001 (Table 3).
The main source of bias identified in this comparison was due
to the non-blinded study design. The risk of selection bias was
unclear in Berlin 2002; Herrmann 2007; Ohkawa 2004; Riess
2005 and Scheithauer 2003, but we did not consider that this
significantly affected the results.
3.3 Gemcitabine plus topoisomerase inhibitor versus
gemcitabine alone
Three studies reported OS data in 839 participants, giving an HR
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of 1.01 (95% CI 0.87 to 1.16, P = 0.92; Analysis 3.1), indicating
no difference between groups. There was no heterogeneity (I² =
0%). Two studies reported similar PFS in 709 participants (HR
0.91, 95% CI 0.78 to 1.07, P = 0.26, I² = 0%; Analysis 3.2). The
median survival times were very similar between the two groups
(Table 3). All studies reported response rates, with data on 729
participants (49 responses in the combined treatment group versus
22 responses in the gemcitabine alone group: RR 1.50, (95% CI
0.92 to 2.46, P = 0.11, I² = 0%; Analysis 3.3). The combination
arms were shown to be more toxic with data for grade 3/4 AEs in
797 participants: anaemia (41 events versus 37 events: RR 1.09,
95% CI 0.72 to 1.66, P = 0.68; Analysis 3.4), neutropenia (132
events versus 88 events: RR 1.54, 95% CI 1.04 to 2.30, P = 0.03;
Analysis 3.5), thrombocytopenia (63 events versus 31 events: RR
2.28, 95% CI 0.97 to 5.36, P = 0.06; Analysis 3.6), nausea (36
events versus 23 events: RR 1.55, 95% CI 0.94 to 2.55, P = 0.09;
Analysis 3.7) and diarrhoea (36 events versus 6 events: RR 3.47,
95% CI 0.74 to 16.33, P = 0.12; Analysis 3.8).
Rocha Lima 2004 was the only study to record QoL data (FACT-
Hep questionnaire) and reported no significant differences be-
tween the two groups (Table 3).
The main source of bias identified in this comparison was due to
the non-blinded study design, but we did not consider that this
affected the results.
3.4 Gemcitabine plus taxane versus gemcitabine alone
Von Hoff 2013 was the only study in this group, and trialists
analysed all 861 participants for OS, PFS and response rate. A
benefit in survival outcomes was demonstrated in the combina-
tion arm. For OS, the HR was 0.72 (95% CI 0.62 to 0.84; P <
0.001; Analysis 3.1), and for PFS, HR was 0.69 (95% CI 0.58
to 0.82; P < 0.001; Analysis 3.2). The median survival time was
8.5 months in the combination group versus 6.7 months in the
gemcitabine control (Table 3). There was a higher response rate in
the combination arm (99 responses versus 30 responses: RR 3.29,
95% CI 2.24 to 4.84, P < 0.001; Analysis 3.3). Data on grade 3/
4 AEs were available for 793 participants and overall, toxicity was
more common in the combination arm: anaemia (53 events ver-
sus 48 events: RR 1.06, 95% CI 0.73 to 1.52, P = 0.76; Analysis
3.4), neutropenia (153 events versus 103 events: RR 1.42, 95%
CI 1.16 to 1.75, P < 0.001; Analysis 3.5), thrombocytopenia (52
events versus 36 events: RR 1.38, 95% CI 0.93 to 2.07, P = 0.11;
Analysis 3.6), neuropathy (70 events versus 3 events: RR 22.35,
95% CI 7.10 to 70.40, P < 0.001; Analysis 3.9) and fatigue (70
events versus 27 events: RR 2.48, 95%CI 1.63 to 3.79, P < 0.001;
Analysis 3.10). The studies did not report on QoL.
Corrie 2017 was a unique study that we could not include in
this analysis, addressing nab-paclitaxel plus gemcitabine versus the
same agents given in a sequential dosing schedule. Here the stan-
dard arm had similar results to the nab-paclitaxel plus gemcitabine
arm of Von Hoff 2013, with a median survival of 7.9 months,
median PFS of 4.0 months and response rate of 33%.
Likewise, we could not include Lohr 2012 in the analysis as it was
a multi-armed study. It showed that overall survival for the gem-
citabine alone arm was 6.8 months, compared to 8.1 months in
combination with liposomal paclitaxel 11 mg/m², 8.7 months in
combination with liposomal paclitaxel 22 mg/m² and 9.3 months
in combination with liposomal paclitaxel 44 mg/m². When com-
paring each combination arm with gemcitabine alone the HRs all
crossed the line of null effect: for concomitant doses of 11 mg/m²:
HR 0.93 (95%CI 0.60 to 1.43); for 22mg/m²: HR 0.69 (95%CI
0.44 to 1.07); and for 44 mg/m²: HR 0.66 (95%CI 0.43 to 1.03).
PFS in the gemcitabine alone group was 2.7 months compared
with each of the combination arms: 4.1 months, 4.6 months and
4.4 months (11 mg/m², 22 mg/m² and 44 mg/m², respectively).
When comparing each experimental arm with gemcitabine alone
for PFS, the HRs were 0.84 (95% CI 0.44 to 1.28), 0.58 (95% CI
0.38 to 0.90) and 0.74 (95% CI 0.49 to 1.13), respectively. The
number of responses were similar in all groups (14%, 14%, 14%
and 16%, respectively). Neutropenia and fatigue were the com-
monest AEs and occurred at similar rates across the four groups.
The trials did not report QoL. Toxicity was more common in the
combination arm with a dose dependent increase in thrombocy-
topenia, chills and pyrexia.
Although there were insufficient details to make an assessment of
selection bias, overall we assessed the study as being at low risk of
bias, the main source being due to the non-blinded study design,
which we considered to not affect the results.
3.5 Gemcitabine plus other combinations of chemotherapy
versus gemcitabine alone
Two studies reported OS data on 166 participants which showed
improved survival in the combination group (HR 0.55, 95% CI
0.39 to 0.79, P = 0.001; Analysis 3.1). There was some statistical
heterogeneity (I² = 24%). Both studies reported PFS and again
showed a benefit to the combination arm, with an HR of 0.43
(95% CI 0.30 to 0.62, P < 0.001, I² = 17%; Analysis 3.2). Median
survival times were only available for Petrioli 2015, who reported
that the combined treatment group survived for a median of 11.9
months versus 7.1 months in the gemcitabine alone group (Table
3). Only Petrioli 2015 reported response rates in 67 participants
(12 responses versus 6 responses: RR 1.94, 95% CI 0.83 to 4.56,
P = 0.13; Analysis 3.3). The same study reported grade 3/4 AEs.
Although AEs were more common in the combination arm, the
small number of events makes it difficult to assess the real dif-
ference between the arms: anaemia (6 events versus 3 events: RR
1.94, 95% CI 0.53 to 7.13, P = 0.32; Analysis 3.4), neutropenia
(8 events versus 4 events: RR 1.94, 95%CI 0.65 to 5.83, P = 0.24;
Analysis 3.5), thrombocytopenia (10 events versus 5 events: RR
1.94, 95% CI 0.74 to 5.07, P = 0.11; Analysis 3.6) and nausea
(5 events versus 0 events: RR 10.69, 95% CI 0.61 to 185.91, P =
0.10; Analysis 3.7).
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Both studies reported QoL data. Petrioli 2015 used the EORTC
QLQ C30 and McGill Melzack questionnaires, and Reni 2005
used the EORTC-QLQ Pan 26 questionnaire. Petrioli 2015
showed that global QoL was improved in the combined treatment
group at two and four months. Reni 2005 stated that the sam-
ple size was insufficient to obtain statistical power to detect dif-
ferences between the control and treatment groups. However, the
treatment group had better average emotional functioning, over-
all QoL, cognitive measures, pain, fatigue, indigestion, dyspnoea,
appetite loss and flatulence, while sexual function and body image
were better in the control group (Table 3).
Petrioli 2015 didnot publish enough data tomake a full assessment
of selection bias and had a high risk of performance and detection
bias. Reni 2005 was a non-blinded study but otherwise had a low
risk of bias.
3.6 Gemcitabine plus other agent(s) versus gemcitabine
alone
Four studies assessed OS in 767 participants, with no differences
in survival detected (HR 0.79, 95% CI 0.56 to 1.10, P = 0.16;
I² = 62%; Analysis 3.1). Only Meng 2012 reported PFS data
in 76 people, with no differences seen, HR 1.05 (95% CI 0.68
to 1.62, P = 0.83; Analysis 3.2). Median survival times in the
gemcitabine group ranged from 5.2 months to 9.7 months and
in the combination group from 5.2 months to 10.4 months (
Table 3). Three studies reported response rates in 691 participants
(61 responses versus 22 responses: with RR 3.66, 95% CI 1.04
to 12.82, P = 0.04; Gansauge 2002; Meng 2012; Oettle 2005;
Analysis 3.3). Three studies reported haematological toxicity data
for grade 3/4 events in 688 participants revealing more anaemia
in the combination arm (Meng 2012; Oettle 2005; Ueno 2013 -
EPA study): anaemia (49 events versus 12 events: RR 3.58, 95%
CI 1.93 to 6.62, P < 0.001; Analysis 3.4), neutropenia (140 events
versus 45 events: RR2.02, 95%CI 0.88 to 4.66, P = 0.10; Analysis
3.5), and thrombocytopenia (55 events versus 23 events: RR 1.41,
95%CI 0.45 to 4.39, P = 0.56; Analysis 3.6). Four studies reported
on nausea in 748 participants (17 events versus 11 events: RR
1.25, 95% CI 0.48 to 3.26, P = 0.64; Analysis 3.7).
Two studies reported on QoL: Meng 2012 used the FACT-G and
MD Anderson Symptom Inventory questionnaires, and Oettle
2005 used the EORTC QLQ-C30 questionnaire. Meng 2012
did not find a difference in either of the scales used (FACT-G
and MD Anderson Symptom Inventory questionnaire) at eight
weeks. Oettle 2005 showed that people in the gemcitabine alone
group had lower financial difficulties and better physical and cog-
nitive functioning, but the combination armhad lower pain scores.
There was no clear trend in QoL scores between the treatment
groups, however (Table 3).
There was an unclear risk of selection bias in Gansauge 2002
and Meng 2012 due to insufficient details being published. Ueno
2013 - EPA study did not provide enough details to perform a
comprehensive assessment.
4 Fluoropyrimidine combinations versus
fluoropyrimidine alone
Four studies reported OS in 491 participants receiving either flu-
oropyrimidine combinations or fluoropyrimidine alone with no
differences in survival detected (HR 0.84, 95% CI 0.61 to 1.15,
P = 0.27; Analysis 4.1). There was high statistical heterogeneity
with an I² of 66%. Ducreux 2004, which studied 5FU with or
without oxaliplatin, showed a large benefit in the treatment group
in contrast to the other three studies, which did not show much
benefit with the combination arms. Only two studies reported
PFS in 255 participants, and there were no differences (HR 0.52,
95% CI 0.19 to 1.38, P = 0.19; Analysis 4.2), again, with large
statistical heterogeneity (I² = 89%). Median survival times ranged
from 3.7 months to 6.5 months in the combination group and
from 3.4 months to 5.25 months in the 5FU group (Table 4). All
four studies reported response rates, but there were no differences
between arms (32 responses versus 24 responses: RR 1.18, 95%
CI 0.52 to 2.68, P = 0.10; I² = 52%; Analysis 4.3). Two stud-
ies (N = 255) reported rates of grade 3/4 anaemia, neutropenia,
thrombocytopenia, nausea, and diarrhoea (Ducreux 2004;Maisey
2002). There were no significant differences between groups in:
anaemia (8 events versus 11 events: RR0.48, 95%CI 0.06 to 3.62,
P = 0.16; Analysis 4.4); neutropenia (7 events versus 0 events: RR
5.70, 95% CI 0.73 to 44.46, P = 0.10; Analysis 4.5); thrombo-
cytopenia (5 events versus 3 events: RR 1.40, 95% CI 0.34 to
5.80, P = 0.65; Analysis 4.6); nausea (7 events versus 5 events, RR
1.06, 95% CI 0.32 to 3.53, P = 0.93; Analysis 4.8); or diarrhoea
(6 events versus 6 events: RR 0.92, 95% CI 0.31 to 2.78, P =
0.89; Analysis 4.9). Maisey 2002 reported similar rates of grade 3/
4 fatigue in both arms (26 events versus 30 events: RR 0.91, 95%
CI 0.58 to 1.43, P = 0.68; Analysis 4.7).
One study recorded QoL data (Maisey 2002), using the EORTC-
QLQ C30 questionnaire, which did not demonstrate a difference
between the two groups at baseline, 12 weeks or 24 weeks (Table
4).
The main source of bias was in the non-blinded study design. We
assessed both Ducreux 2004 and Kovach 1974 as being at high
risk of attrition bias, and this may have affected the results.
5 Single studies addressing unique treatment
comparisons
Ten studies addressed unique comparisons that could not be cat-
egorised under the above-mentioned comparisons (Table 5).
Boeck 2008 showed that capecitabine plus gemcitabine had su-
perior median survival (9.0 months) and response rate (25%)
compared with 8.1 months/13% in the capecitabine/oxaliplatin
group and 6.9 months/13% in the gemcitabine/oxaliplatin group.
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Haematological AEs were more common in the gemcitabine-con-
taining regimens.
Kulke 2009 showed a similar OS in all four treatment groups,
ranging from 6.4months to 7.1months and response rates of 12%
to 14%. AEs were similar across treatment arms, with neutropenia
and fatigue being the most common.
Afchain 2009 found that a simplified gemcitabine/oxaliplatin reg-
imen was superior to a standard gemcitabine/oxaliplatin regimen
with an OS of 7.6 months versus 3.2 months and response rate
of 27% versus 10%. Peripheral neuropathy was more common in
the simplified arm, however.
Bukowski 1983 did not demonstrate a difference in OS for strep-
tozocin/MMC/5FU (SMF) versus MMC/5FU (18 weeks versus
17 weeks); however, there was an increase in response rate of 34%
versus 8%. There was more gastrointestinal and renal toxicity in
the SMF arm.
Hirao 2011 showed a slight increase in OS for the three-week
schedule of gemcitabine versus the four-week schedule (250 days
versus 206 days), but there was a similar response rate (17.1%
versus 14.2%). Thrombocytopeniawasmore common in the four-
week schedule.
Kelsen 1991 found that the SMF arm had a longer OS than the
cisplatin/ara-C/caffeine arm (10 months versus 5 months), but a
similar response rate (10% versus 6%). Nausea and vomiting were
more common in the caffeine-containing arm.
Levi 2004 showed that adding cisplatin to 5FU increased OS (8.3
months versus 5.4 months), but there was no difference between
the continuous versus the chronomodulated arms (6.1 months
versus 6.7 months). Cisplatin increased the rates of haematologi-
cal AEs, and the chronomodulated regimen increased rates of mu-
cositis.
Lutz 2005 did not demonstrate any striking differences between
gemcitabine/docetaxel and cisplatin/docetaxel (OS 7.0 months
versus 7.5 months); however, febrile neutropenia was more com-
mon in the cisplatin containing arm.
Moertel 1977 showed a slightly increased OS in the strepto-
zocin/5FU arm compared with streptozocin/cyclophosphamide
(13 weeks versus 9 weeks), with the cyclophosphamide arm expe-
riencing more haematological AEs.
Reni 2012 showed a similar OS between capecitabine/cisplatin/
gemcitabine/docetaxel (PDXG) and capecitabine/cisplatin/gemc-
itabine/epirubicin (PEXG) (10.7months versus 11months); how-
ever, there was a higher partial response rate in the PDXG group
(58% versus 33%). The PEXG arm had more neutropenia.
Topham 1991 found a slightly higher one-year survival rate in
the 5FU/epirubicin/MMC arm compared with epirubicin alone
(23.2% versus 15.4%), and the AEs were similar in both arms.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Various types of chemotherapy versus gemcitabine for advanced pancreatic cancer
Person or population: advanced pancreat ic cancer
Setting: f irst-line therapy
Intervention: various types of chemotherapy
Comparison: gemcitabine
Outcomes Anticipated risk of death* (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evi-
dence
(GRADE)
Comments Toxicity and QoL
Risk with gemc-
itabine
Risk with various
types of chemother-
apy
Overall survival - 5FU Study populat ion HR 1.69
(1.26 to 2.27)
126
(1 RCT)
⊕⊕⊕©
Moderatea
Only 1 study More toxicity was seen in
the gemcitabine arm. Clini-
cal benef it was improved in
the gemcitabine arm
825 per 1000 948 per 1000
(889 to 981)
Overall survival -
FOLFIRINOX
Study populat ion HR 0.51
(0.43 to 0.60)
652
(2 RCTs)
⊕⊕⊕©
Moderateb
- More toxicity was seen
in the FOLFIRINOX arm.
Longer t ime to degradat ion
of QoL in FOLFIRINOX arm
794 per 1000 554 per 1000
(494 to 613)
Overall survival -
Fixed dose rate gem-
citabine
Study populat ion HR 0.79
(0.66 to 0.94)
644
(2 RCTs)
⊕⊕⊕⊕
High
- More toxicity in the f ixed-
dose rate arm. QoL was not
tested880 per 1000 812 per 1000
(753 to 863)
Overall survival - CO-
101
Study populat ion HR 1.07
(0.86 to 1.34)
367
(1 RCT)
⊕⊕⊕©
Moderatec
Only 1 study Toxicity was sim ilar in both
arms, QoL was not tested
854 per 1000 872 per 1000
(809 to 924)
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Overall survival -
ZD9331
Study populat ion HR 0.86
(0.42 to 1.76)
55
(1 RCT)
⊕⊕⊕©
Moderatea,c
Only 1 study Toxicity was sim ilar in both
arms, QoL was not tested
560 per 1000 506 per 1000
(292 to 764)
Overall survival - Ex-
atecan
Study populat ion HR 1.27
(0.96 to 1.68)
339
(1 RCT)
⊕⊕⊕©
Moderatec
Only 1 study Toxicity was sim ilar in both
arms, QoL was superior in
the gemcitabine arm776 per 1000 851 per 1000
(763 to 919)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; HR: hazard rat io; RCT : randomised controlled trial.
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aSmall sample size; opt imal information size not met.
bModerate stat ist ical heterogeneity.
cConf idence interval includes both benef it and harm.
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Gemcitabine combinations versus gemcitabine alone for advanced pancreatic cancer
Person or population: advanced pancreat ic cancer
Setting: f irst-line therapy
Intervention: gemcitabine combinat ions
Comparison: gemcitabine alone
Outcomes Anticipated risk of death* (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evi-
dence
(GRADE)
Comments Toxicity and QoL
Risk with gemc-
itabine alone
Risk with gem-
citabine combina-
tions
Overall survival -
Gemcitabine plus
plat inum agent
Study populat ion HR 0.94
(0.81 to 1.08)
1140
(6 RCTs)
⊕⊕©©
Lowa,b
- More toxicity in the combina-
t ion arm with no dif ferences
shown in QoL705 per 1000 683 per 1000
(628 to 733)
Overall survival -
Gemcitabine plus
f luoropyrim idine
Study populat ion HR 0.89
(0.81 to 0.97)
2718
(10 RCTs)
⊕⊕⊕⊕
High
- More toxicity in the combina-
t ion arm. 2 studies showed
no dif ference in QoL, 2 stud-
ies showed an improved QoL
in the combinat ion arm
690 per 1000 648 per 1000
(613 to 679)
Overall survival -
Gemcitabine plus
topoisomerase in-
hibitor
Study populat ion HR 1.01
(0.87 to 1.16)
839
(3 RCTs)
⊕⊕⊕⊕
High
- More toxicity in the combina-
t ion arm. In 1 study, QoL was
not dif f erent between the 2
arms
800 per 1000 803 per 1000
(753 to 845)
Overall survival -
Gemcitabine plus
taxane
Study populat ion HR 0.72
(0.62 to 0.84)
861
(1 RCT)
⊕⊕⊕⊕
High
1 study only More toxicity in the combina-
t ion arm. QoL not measured
779 per 1000 663 per 1000
(608 to 719)
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Overall survival -
Gemcitabine plus
other combinat ions
of chemotherapy
Study populat ion HR 0.55
(0.39 to 0.79)
166
(2 RCTs)
⊕⊕©©
Lowc,d,e
- Toxicity measured in 1 study
and was not dif f erent. QoL
was shown to be improved
in the combinat ion arms in
both studies
850 per 1000 648 per 1000
(523 to 777)
Overall survival -
Gemcitabine plus
other agent(s)
Study populat ion HR 0.79
(0.56 to 1.10)
767
(4 RCTs)
⊕⊕©©
Lowb,f
There was an increase in
anaemia in the combinat ion
arm. 2 studies measured
QoL and it was sim ilar in
both treatment arms
825 per 1000 748 per 1000
(624 to 853)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; HR: hazard rat io; RCT : randomised controlled trial.
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aTwo studies were in abstract form and could not have full assessment completed.
bConf idence interval includes both benef it and harm.
cOne study did not publish suf f icient details to make a full assessment.
dThere was moderate stat ist ical heterogeneity.
eOptimal information size not met.
fHigh stat ist ical heterogeneity which is likely due to the dif ference in agents used in the treatment arms.
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Fluoropyrimidine combinations versus fluoropyrimidine alone for advanced pancreatic cancer
Person or population: advanced pancreat ic cancer
Setting: f irst line therapy
Intervention: f luoropyrim idine combinat ions
Comparison: f luoropyrim idine alone
Outcomes Anticipated risk of death* (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Toxicity and QoL
Risk with fluoropyrimi-
dine alone
Risk with fluoropyrimi-
dine combinations
Overall survival Study populat ion HR 0.84
(0.61 to 1.15)
491
(4 RCTs)
⊕⊕©©
Lowa,b
Toxicity was not dif f er-
ent between the 2 treat-
ment arms. QoL was
measured in 1 study
and showed an im-
provement in the com-
binat ion arm
838 per 1000 783 per 1000
(671 to 877)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; HR: hazard rat io; RCT : randomised controlled trial.
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aHigh stat ist ical heterogeneity.
bConf idence interval includes both benef it and harm.
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D I S C U S S I O N
Summary of main results
1 Anti-cancer therapy versus best supportive care
We could neither prove nor rule out a survival benefit for anti-
cancer therapy versus BSC alone (moderate-quality evidence due
to imprecision; Summary of findings for the main comparison).
This is in contrast to the previous version of this review, which
found a benefit in the odds for death at both 6 months (OR 0.37,
95% CI 0.25 to 0.57, P < 0.001) and 12 months (OR 0.46,
95% CI 0.25 to 0.84, P = 0.01). Due to the new protocol used
in this study, we excluded two studies that had featured in the
previous review because they included people without histological
confirmation (Mallinson 1980; Palmer 1994); this is the likely
cause of these discrepant results. The differences inmedian survival
were modest and ranged from 0.9 months in favour of BSC to 3.5
months in favour of anti-cancer therapy (Table 1).
There is evidence for improved QoL with the use of anti-cancer
therapy in one study (Glimelius 1996), with Xinopoulos 2008
showing an early benefit that was not sustained after month 5.
Readers should interpret these results with caution, as the included
studies span over 30 years, and Xinopoulos 2008 was the only
study to use contemporary chemotherapy regimens. As it is un-
likely that further studies will be conducted using BSC as the con-
trol arm, additional randomised data showing the effects of con-
temporary chemotherapy over BSC in the first-line setting may
never be generated.
2 Various types of chemotherapy versus gemcitabine
The one study addressing gemcitabine versus 5FU chemotherapy,
Burris 1997, showed inferior outcomes for OS (HR 1.69; P =
0.004), PFS (HR 1.47; P = 0.005) and QoL with the 5FU arm.
Summary of findings 2 shows a rating of moderate-quality evi-
dence due to only one small study being available for analysis.
These results demonstrate that using gemcitabine reduces the risk
of death by 41% and progression by 32% compared with 5FU
therapy. The absolute improvement in OS is modest at just over
one month. Gemcitabine may result in more grade 3/4 AEs. There
is an improvement in QoL (clinical benefit response).
The analysis of two studies comparing FOLFIRINOXversus gem-
citabine demonstrated an improvement in OS (HR 0.51; P <
0.001), PFS (HR 0.46; P < 0.001) and response rate (RR 3.38;
P < 0.001) but also significantly more neutropenia and throm-
bocytopenia (Conroy 2011; Singhal 2014). There was improved
QoL. Summary of findings 2 demonstrates the moderate quality
of evidence rating based on inconsistency. These results suggest
that FOLFIRINOX reduces the risk of death by 49%, reduces
the risk of progression by 54% and triples the rate of response
compared with gemcitabine. The absolute survival gains are still
modest, with OS in the gemcitabine alone arm ranging from 6.8
months to 7.4 months and in the FOLFIRINOX arms between
10.8 months to 11.1 months.
The two studies that assessed the effects of giving gemcitabine
at a fixed dose rate showed an improvement in OS (HR 0.79;
P = 0.009) but also more haematological toxicity (Poplin 2009;
Tempero 2003). Granted, the ’standard’ gemcitabine arms differed
between the two studies, but the study using a more intense con-
trol arm (gemcitabine 2200 mg/m² weekly) still found superiority
in the FDR-gem arm. Summary of findings 2 details a high qual-
ity of evidence rating. This analysis suggests that using FDR-gem
reduces the risk of death by 21%; however, the absolute survival
gains are again small, with OS in the standard infusional gemc-
itabine arm ranging from 4.9 months to 5.0 months and in the
FDR-gem arm from 6.2 months to 8.0 months.
The studies comparing exatecan, CO-101 and ZD9331 to gem-
citabine did not show a survival benefit (Cheverton 2004; Poplin
2013; Smith 2003). None of these studies showed a difference in
toxicity and in exatecan, analyses showed QoL to be superior in
the gemcitabine arm. We rated each comparison as having mod-
erate-quality evidence due to imprecision (Summary of findings
2).
3 Gemcitabine combination studies
3.1 Gemcitabine plus a platinum agent versus
gemcitabine alone
The analysis of seven studies has shown that the combination of
gemcitabine with a platinum agent did not significantly improve
OS (HR 0.94; P = 0.38) but may improve PFS (HR 0.80; P =
0.01) (Colucci 2002; Colucci 2010; Heinemann 2006; Louvet
2005; Viret 2004; Wang 2002). This equates to a reduction in
the risk of progression of 20%. Summary of findings 3 shows
that the quality of evidence in this analysis was low, due to two
studies being in abstract form and not publishing sufficient data to
make a full assessment, along with imprecision. These results are
in keeping with the findings of the previous review, which found
a benefit in 6-month mortality (OR 0.59, P = 0.001) but not
12-month mortality. We were not able to include all the studies
from the previous review (Li 2004 did not publish sufficient data);
however, we included two additional studies (Colucci 2010; Viret
2004). The addition of platinum improved response rates but
increased thrombocytopenia andnausea. Therewere no significant
differences found in QoL between the control and treatment arms
in the people tested. This suggests that while adding platinum
increases side effects, this does not translate into a worse QoL. The
median survival times were similar in the two groups (Table 3).
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3.2 Gemcitabine plus fluoropyrimidine versus
gemcitabine alone
The analysis of 10 studies shows that adding a fluoropyrimidine
agent can improveOS (HR0.88; P = 0.001), PFS (0.79; P < 0.001)
and response rate (RR 1.78; P < 0.001), but at the cost of increased
rates of neutropenia and diarrhoea (Berlin 2002; Cunningham
2009; Di Costanzo 2005; Herrmann 2007; Lee 2017; Ohkawa
2004; Ozaka 2012; Riess 2005; Scheithauer 2003; Ueno 2013).
Summary of findings 3 show that the quality of evidence is high.
This shows that the addition of 5FU reduces the risk of death by
12%, reduces the risk of progression by 21% and nearly doubles
the rate of response, but it also increases toxicity. Two studies did
not report any differences in QoL with the addition of a fluo-
ropyrimidine agent; however, two studies did report an improve-
ment, with Scheithauer 2003 showing less pain and Ueno 2013
showing an improvement in QALYs. The previous version of this
review did not find significant benefits for adding fluoropyrimi-
dine to gemcitabine; however, that version analysed only 5 studies,
compared to the 10 studied here. Because this analysis included
both intravenous and oral fluoropyrimidine agents, these results
must be interpreted with caution. Moreover, two studies used S1
(Ozaka 2012; Ueno 2013), and one study used UFT (Ohkawa
2004), agents that have not been well studied in non-Asian pop-
ulations. The absolute improvement in OS is small, ranging from
5.4 months to 8.8 months in the gemcitabine alone arm and 6.7
months to 13.7 months in the combination arm (Table 3).
3.3 Gemcitabine plus topoisomerase inhibitor versus
gemcitabine alone
The analysis of three studies shows that the addition of a topoi-
somerase inhibitor to gemcitabine does not significantly improve
OS (HR 1.01; P = 0.92) or PFS (HR 0.91; P = 0.26) (Abou-Alfa
2006; Rocha Lima 2004; Stathopoulos 2006). Response rates were
also not significantly improved (RR 1.50; P = 0.11); however, neu-
tropenia did. Only one study measured QoL and failed to find any
differences between the two groups. The median survival times
were similar in the two groups (Table 3).
We assessed the quality of evidence as high (Summary of findings
3).
3.4 Gemcitabine plus taxane versus gemcitabine
alone
Our search yielded only one study that we could analyse in this
category (VonHoff 2013), and it found that adding nab-paclitaxel
to gemcitabine significantly improved OS (HR 0.72; P < 0.001),
PFS (HR 0.69; P < 0.001) and response rates (RR 3.29; P <
0.001). Summary of findings 3 show that the quality of evidence
is high; however, there is only one study. This demonstrates that
the addition of nab-paclitaxel to gemcitabine reduces the risk of
death by 28%, reduces the risk of progression by 31% and more
than triples the rate of response. There is an increased risk of
neutropenia, neuropathy and fatigue, and QoL was not measured.
Although there is only one study in this analysis, there was also
another study, Corrie 2017, which we could not include; it used
gemcitabine plus nab-paclitaxel as the control group and published
similar OS, PFS and response data.
3.5 Gemcitabine plus other combinations of
chemotherapy versus gemcitabine alone
The two studies analysed showed that combining gemcitabine
with multiple other agents improves OS (HR 0.55; P = 0.001)
and PFS (HR 0.43; P < 0.001) (Petrioli 2015; Reni 2005). Only
one study reported response rates, which were not different be-
tween groups. Likewise, one study reported similar incidence of
AEs. QoL was improved in both studies. Summary of findings 3
shows the low rating for quality of evidence due to one study not
publishing enough data to make a full assessment and because of
inconsistency. Given that only one study reported response rates
and grade 3/4 AEs, the numbers of events in these analyses are
small, and the conclusions that we can draw here are limited. This
analysis suggests that the use of combination therapies contain-
ing gemcitabine may reduce the risk of death by 45% and reduce
the risk of progression by 57%; however, we cannot make any
assessment regarding the rates of side effects. There may be an im-
provement inQoL. Just one study reported median survival times,
showing OS in the gemcitabine arm to be 7.1 months compared
with 11.9 months in the combination arm (Table 3).
Multi-drug combinations including gemcitabine may be effective
in improving survival outcomes, and given the positive results of
the Conroy 2011 study, which uses FOLFIRINOX, the findings
add weight to the argument that intensive chemotherapy has a
place in the treatment of PC.
3.6 Gemcitabine plus other agent(s) versus
gemcitabine alone
This group contains studies that did not fall into any of the other
pooled analyses. The four studies analysed here are heterogenous
in terms of the agents used (Gansauge 2002; Meng 2012; Oettle
2005; Ueno 2013 - EPA study). The analysis shows that OS is
not significantly different in the combination arm. Three studies
show improved response rates but also increased anaemia. There
was high statistical heterogeneity seen in both survival analyses,
which is likely to be accounted for by the varied agents used. QoL
was not significantly different in the two studies that reported this
outcome.Median survival timeswere longer in theGansauge 2002
study but otherwise very similar (Table 3).
These data need to be interpreted with caution, as the studies
used a wide range of agents. The results for Ukrain in Gansauge
2002 are highly provocative and may warrant further study in
larger numbers, supported by a meta-analysis across different can-
cer types (Ernst 2005). We assessed the quality of evidence as low
due to imprecision and inconsistency (Summary of findings 3).
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4 Fluoropyrimidine combinations versus
fluoropyrimidine alone
This analysis showed that pooling data from studies that added
an agent to 5FU did not result in a significant benefit in OS
(HR 0.84; P = 0.27) or PFS (0.52; P = 0.19) compared to 5FU
alone (Ducreux 2004; Kovach 1974;Maisey 2002;Moertel 1979).
However, in these two analyses, there was high statistical hetero-
geneity (I² = 66% and 89%, respectively), likely due to the range
of agents tested. Three studies used fairly outdated chemothera-
pies (BCNU, MMC and streptozocin), whereas one study used
oxaliplatin (Ducreux 2004). This study accounts for most of the
heterogeneity seen, as it found a statistically significant benefit in
both OS and PFS in contrast to the other studies. Response rates
were not significantly improved (RR 1.18; P = 0.69), again with
high statistical heterogeneity that was mainly due to the Kovach
1974 study, testing BCNU and reporting higher responses in the
5FU alone group. Grade 3/4 AEs were not significantly different
between the two groups.OnlyMaisey 2002 assessedQoL, demon-
strating an improvement in dyspnoea.
The conclusions that we can draw from this analysis are limited. It
seems that from the results of the Ducreux 2004 study, oxaliplatin
plus 5FU is an active combination compared with 5FU alone and
does not measurably increase side effects.
The quality of evidence was assessed as low due to imprecision and
statistical heterogeneity (Summary of findings 4).
Overall completeness and applicability of
evidence
To our knowledge, this review contains a complete review of all
the available evidence up until the censor date. We have made
every attempt to conduct the analysis in a clinically relevant way
in order to fulfil the objective of assisting patients and clinicians
in decision-making.
Quality of the evidence
Two review authors independently assessed the risk of bias of the
individual studies using the GRADE criteria, and we tabulate
this information in Figure 2, Figure 3 and the ’Summary of find-
ings’ tables. Only four subgroup comparisons were of high quality,
whereas the remainder of the comparisons provided moderate- or
low-quality evidence. This was mainly due to inconsistency and
small sample sizes. Given PC is a rare condition which is com-
monly seen in the elderly, recruiting to clinical studies is incredibly
difficult. In addition, recent large scale sequencing studies have
revealed themarked genetic heterogeneity in PC, which is likely to
contribute to the inconsistent effects seen between studies (Bailey
2016). This should guide future studies and encourage stratified
study design.
Potential biases in the review process
In order to reduce the potential biases in the review process, two
separate review authors independently evaluated studies and ex-
tracted data, resolving disputes with adjudication by a third review
author. We did not identify any other potential biases.
Agreements and disagreements with other
studies or reviews
Unlike the previous version of this review (Yip 2009), we were
unable to replicate the benefit seen for anti-cancer therapy versus
best supportive care alone. As discussed in the main text, this was
mainly due to the fact we were unable to include all the previously
analysed studies due to lack of available time-to-event data.
We have added to the scope and results of the previous review
by widening the inclusion criteria and have been able to provide
wider recommendations.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Currently there is no way of rationally selecting the ’best’ chemo-
therapy regimen for people with pancreatic cancer. For decades,
gemcitabine has been the gold standard; however, there are now
several more efficacious options that treating clinicians can con-
sider. The treatment choice must be tailored to the person, taking
into account the their performance status and the side effect pro-
files of the chemotherapy agents. The results of this analysis shows
that in advanced pancreas cancer:
1. based on one study, gemcitabine is superior to 5FU alone,
reducing the risk of death and progression and improving QoL;
2. compared to gemcitabine alone, multi-drug combinations
improve survival outcomes and response rates in PC.
FOLFIRINOX, GEMOXEL and gemcitabine/cisplatin/
epirubicin and 5FU are active regimens. These data suggest that
in people who are fit, multi-drug regimens may be appropriate,
but the potential for increased toxicity must be taken into
account;
3. gemcitabine given using a fixed dose rate schedule improves
overall survival but increases toxicity compared with standard
dosing;
4. gemcitabine plus platinum-based chemotherapy does not
improve OS but does improve PFS and response rates;
5. gemcitabine plus fluoropyrimidine-based chemotherapy
improves survival and response rates, albeit by a small amount;
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6. based on one study, gemcitabine plus taxane improves
survival outcomes and response rates but increases toxicity.
Implications for research
The results of this analysis suggest that using multi-drug regimens
for advanced PChas the potential to improve outcomes. Thismust
be weighed against the increase in toxicity. Currently, there are no
effective biomarkers to predict in whom an aggressive approach is
warranted, and this should be an area of further research. In addi-
tion, this analysis shows that there are many different chemother-
apies which are beneficial in this disease, but currently there is
no way of rationally selecting the ’best’ chemotherapy regimen.
Biomarker development has the potential to stratify people early
in their disease course, inform clinical study design and avoid ex-
posing people to ineffective chemotherapy.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Abou-Alfa 2006
Methods Randomised phase III trial
Participants Study was conducted in North America in 349 participants with locally advanced/
metastatic pancreatic adenocarcinoma. The mean age in the gemcitabine + exatecan
group was 63 years, and the mean age in gemcitabine group 62.3 years. Previous radio-
therapy for locally advanced disease was allowed. 174 received gemcitabine. 175 received
gemcitabine + exatecan
Interventions Gemcitabine: 1000 mg/m² 7/8 weeks, then 3/4 weeks
Gemcitabine + exatecan: gemcitabine 1000 mg/m² and exatecan 2 mg/m² days 1 and 8
every 3 weeks
Outcomes Overall survival
Time to progression
Safety
Quality of life
Response rate
Progression-free survival
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details given
Allocation concealment (selection bias) Unclear risk Insufficient details published
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Overall survival primary endpoint
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants included in the survival analysis
Selective reporting (reporting bias) Low risk All outcomes described in the methods are reported in the
results
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Abou-Alfa 2006 (Continued)
Other bias Low risk No indication of other bias
Afchain 2009
Methods Randomised phase II study
Participants Study was conducted in France. 57 participants withmetastatic adenocarcinoma without
prior chemotherapy or radiotherapy. 20 participants received gemcitabine/oxaliplatin
and 37 participants received simplified gemcitabine/oxaliplatin. Mean age was 66.6
years in the gemcitabine/oxaliplatin group and 64.9 years in the simplified gemcitabine/
oxaliplatin group
Interventions Gemcitabine/oxaliplatin: gemcitabine 1000 mg/m² on day 1, oxaliplatin 100 mg/m²
day 2, every 2 weeks
Simplified regimen: gemcitabine 1000 mg/m² day 1, oxaliplatin 100 mg/m² day 1, every
2 weeks
Outcomes Progression-free survival
Overall survival
Response rate
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient details published
Allocation concealment (selection bias) Unclear risk Insufficient details published
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient details published
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants included in the efficacy analysis
Selective reporting (reporting bias) Low risk All outcomes described in themethods are reported in the
results
Other bias Low risk No indication of other bias
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Andren-Sandberg 1983
Methods Randomised study
Participants Study was conducted in Sweden. 47 participants with inoperable pancreatic cancer less
than 71 years old. 22 received best supportive care and 25 received 5FU + CCNU +
vincristine. The mean age was 58 years in the treatment group and 60 years in the best
supportive care group
Interventions 5FU: 500 mg orally days 2-5
CCNU: 40 mg/m² orally days 2 + 3
Vincristine: 1 mg/m² day 1
Given every 6 weeks
Outcomes Survival
Quality of life
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient details published
Allocation concealment (selection bias) Unclear risk Insufficient details published
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient details published
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants included in the survival analysis
Selective reporting (reporting bias) Low risk All outcomes described in themethods are reported in the results
Other bias Low risk No indication of other bias
Berlin 2002
Methods Randomised phase III trial
Participants Study was conducted in North America. 322 participants with unresectable pancreatic
ductal adenocarcinoma. Were allowed to have received adjuvant gemcitabine if com-
pleted > 6 months prior. Were allowed to have received radiotherapy if completed more
than 4 weeks prior. 162 received gemcitabine. 160 received gemcitabine + 5-fluorouracil
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Berlin 2002 (Continued)
(5FU). The median age in the gemcitabine + 5FU group was 65.8 years and 64.3 years
in the gemcitabine group
Interventions Gemcitabine 1000 mg/m² 3/4 weeks
Gemcitabine + 5FU: gemcitabine as above + 5FU 600 mg/m²/week bolus given 3/4
weeks
Outcomes Overall survival
Time to progression
Response rate
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details given
Allocation concealment (selection bias) Unclear risk No details given
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Low risk for primary endpoint (OS)
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants included in survival analysis
Selective reporting (reporting bias) Unclear risk Insufficient details published
Other bias Unclear risk No indication of other bias
Boeck 2008
Methods Randomised phase II trial
Participants Study was conducted in Germany. 190 participants with advanced pancreatic cancer.
61 received capecitabine + oxaliplatin (CapOx), 64 received capecitabine + gemcitabine
(CapGem) and 63 received gemcitabine + oxaliplatin (mGemOx). The median age was
62 years (CapOx), 63 years (CapGem) and 63 years (mGemOx) in the treatment groups
Interventions CapOx: capecitabine 1000mg/m² orally twice daily, days 1-14 every 3weeks + oxaliplatin
130 mg/m² day 1
CapGem: capecitabine 825 mg/m² orally twice daily, days 1-14 every 3 weeks + gemc-
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Boeck 2008 (Continued)
itabine 1000 mg/m² days 1 + 8
mGemOx: gemcitabine 1000 mg/m² days 1 + 8 + oxaliplatin 130 mg/m² day 8
Outcomes Progression-free survival after 3 months
Overall survival
Overall response rate
Clinical benefit response
Ca19.9 response
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient details published
Allocation concealment (selection bias) Unclear risk Insufficient details published
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
Blinding of outcome assessment (detection
bias)
All outcomes
High risk High risk for primary endpoint (PFS)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat population reported for survival analysis
Selective reporting (reporting bias) Low risk All outcomes described in the methods are reported in the
results
Other bias Low risk No indication of other bias
Bukowski 1983
Methods Randomised study
Participants Study was conducted in North America. 145 participants with inoperable pancreatic
adenocarcinoma with no previous chemotherapy or radiotherapy. 73 were given mito-
mycin C + 5FU (MF), 72 were given streptozocin, mitomycin C and 5FU (SMF). The
median age for participants in the SMF arm were 59 years and 59.5 years for those with
measurable and non-measurable disease respectively. In the MF arm the median age was
60 years and 62 years for those with measurable and non-measurable disease respectively
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Bukowski 1983 (Continued)
Interventions MF ’good risk’ - mitomycin C 20 mg/m² on day 1 + 5FU 1000 mg/m² days 1-4 and
29-32 every 56 days
MF ’poor risk’ - mitomycin C 15 mg/m² on day 1 with the same 5FU regimen above
SMF ’good risk’ - streptozocin 400 mg/m² days 1-4 and 29-32, mitomycin C 15 mg/
m² on day 1 and 5FU 1000 mg/m² days 1-4 and 29-32, every 56 days
SMF ’poor risk’ - mitomycin given at 10 mg/m² day 1, with streptozocin and 5FU given
as above
Outcomes Overall survival
Performance-free survival
Response rate
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient details published
Allocation concealment (selection bias) Unclear risk Insufficient details published
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Primary outcomemeasure not stated, no intention-to-treat anal-
ysis
Incomplete outcome data (attrition bias)
All outcomes
High risk Only participants with measurable disease were included in sur-
vival analysis
Selective reporting (reporting bias) High risk Participants with non-measurable disease not comprehensively
reported
Other bias Low risk No indication of other bias
Burris 1997
Methods Randomised trial
Participants Study was conducted in the United States and Canada. 126 participants with advanced,
symptomatic pancreas cancer with stabilised pain. 63 received 5-fluorouracil (5FU). 63
received gemcitabine. Median age in the 5FU arm was 61 years and 62 years in the
gemcitabine arm
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Burris 1997 (Continued)
Interventions 5FU 600 mg/m² weekly
Gemcitabine 1000 mg/m² 7/8 weeks then 3/4 weeks
Outcomes Clinical benefit
Response rate
Overall survival
Progression-free survival
Safety
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomization of patients with stabilized pain to treatment
with either gemcitabine or 5-FU occurred immediately before
starting study drug treatment and was performed at a central
location”
Allocation concealment (selection bias) Low risk “Randomization of patients with stabilized pain to treatment
with either gemcitabine or 5-FU occurred immediately before
starting study drug treatment and was performed at a central
location”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Treatment was single blind. The study drug was not blinded
to the investigator, because a rash was a potential side effect of
treatment with both 5-FU and gemcitabine”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk High risk for the primary endpoint (clinical benefit)
Incomplete outcome data (attrition bias)
All outcomes
Low risk All enrolled participants included in survival analysis
Selective reporting (reporting bias) Low risk All outcomes described in themethods are reported in the results
Other bias Low risk No indications of other bias
Cheverton 2004
Methods Randomised phase III study
Participants Study was conducted in Europe. 339 participants with locally advanced or metastatic
pancreatic cancer and no prior chemotherapy. 170 received gemcitabine. 169 received
exatecan. Of these 330 (165 vs 165) received treatment. Median age was not published
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Cheverton 2004 (Continued)
Interventions Gemcitabine 1000 mg/m² given 3/4 then 7/8 weeks
Exatecan 0.5 mg/m² daily for 5 days every 3 weeks
Outcomes Overall survival
Response rates
Time to tumour progression
Quality of life
Notes Abstract only
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient details published to make an assessment
Allocation concealment (selection bias) Unclear risk Insufficient details published to make an assessment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Low risk for primary endpoint (OS)
Incomplete outcome data (attrition bias)
All outcomes
Low risk All enrolled participants included in survival analysis (in-
tention-to-treat population reported)
Selective reporting (reporting bias) Low risk All outcomes described in the methods are reported in
the results
Other bias Low risk No indications of other bias
Colucci 2002
Methods Randomised phase II trial
Participants Study was conducted in Italy. 107 participants with locally advanced, metastatic pancre-
atic ductal adenocarcinoma with measurable disease and no prior therapy. 54 received
gemcitabine. 53 received gemcitabine + cisplatin. The median age in the gemcitabine +
cisplatin arm was 60 years, and it was 63 years in the gemcitabine alone arm
Interventions Gemcitabine 1000 mg/m² weekly × 7, then 2 weeks rest. Then 3/4 weeks
Gemcitabine + cisplatin: gemcitabine as above. Cisplatin 25 mg/m² days 1, 8, 15, 29,
36, 42 then 2 weeks rest. Then gemcitabine and cisplatin days 1, 8, 15 every 4 weeks
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Colucci 2002 (Continued)
Outcomes Overall response rate
Time to progression (assessed at week 7 and then every 2 cycles of treatment)
Overall survival
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details given
Allocation concealment (selection bias) Unclear risk Insufficient details published
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Time to progression was the primary endpoint
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat analysis was reported for the primary
endpoint
Selective reporting (reporting bias) Low risk All outcomes described in the methods are reported in the
results
Other bias Low risk No indication of other bias
Colucci 2010
Methods Randomised phase III trial
Participants Study conducted in Italy. 400 participants with unresectable or metastatic pancreatic
ductal adenocarcinoma with no prior chemotherapy. 199 received gemcitabine. 201
received gemcitabine + cisplatin. The median age of participants was 63 years
Interventions Gemcitabine: 1000 mg/m² 7/8 weeks then 3/4 weeks
Gemcitabine + cisplatin: gemcitabine as above. Cisplatin 25 mg/m² days 1, 8, 15, 29,
36, 42 then 1 week rest. Then cisplatin 25 mg/m² days 1, 8, 15 every 4 weeks
Outcomes Overall survival
Progression-free survival
Overall response rate
Toxicity
Clinical benefit
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Colucci 2010 (Continued)
Quality of life
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were randomly assigned to standard arm or ex-
perimental arm in a 1:1 ratio. Telephone random assign-
ment was performed centrally (Clinical Trials Unit, Na-
tional Cancer Institute, Napoli, Italy), by a computer-
driven minimization procedure”
Allocation concealment (selection bias) Low risk “Patients were randomly assigned to standard arm or ex-
perimental arm in a 1:1 ratio. Telephone random assign-
ment was performed centrally (Clinical Trials Unit, Na-
tional Cancer Institute, Napoli, Italy), by a computer-
driven minimization procedure”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Low risk for primary endpoint (OS)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat analysis
Selective reporting (reporting bias) Low risk All outcomes described in the methods are reported in the
results
Other bias Low risk No indication of other bias
Conroy 2011
Methods Randomised phase II/III study
Participants Study was conducted in France. 342 participants with measurable, metastatic pancreatic
ductal adenocarcinoma and no previous chemotherapy. 171 received gemcitabine. 171
received 5-fluorouracil (5FU) + oxaliplatin + irinotecan (FOLFIRINOX). The median
age was 61 in both treatment groups
Interventions Gemcitabine 1000 mg/m² 7/8 weeks then 3/4 weeks
FOLFIRINOX: 5FUbolus 400mg/m², 5FUCI 2400mg/m² over 46 hours + leucovorin
400 mg/m² + oxaliplatin 85 mg/m² + irinotecan 180 mg/m² every 2 weeks
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Conroy 2011 (Continued)
Outcomes Overall survival
Progression-free survival
Response rate
Safety
Quality of life
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomization was performed centrally in a 1:1 ratio
with stratification according to center, performance
status (0 vs. 1), and primary tumor localization”
Allocation concealment (selection bias) Low risk “Randomization was performed centrally in a 1:1 ratio
with stratification according to center, performance
status (0 vs. 1), and primary tumor localization”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Low risk for primary endpoint and other endpoints.
“Independent review of CT scans
was performed”
Incomplete outcome data (attrition bias)
All outcomes
Low risk “All analyses were performed on an intention-to-treat-
basis”
Selective reporting (reporting bias) Low risk All outcomes described in the methods are reported in
the results
Other bias Low risk No indications of other bias
Corrie 2017
Methods Randomised phase II study
Participants Study was conducted in the UK. 146 participants with metastatic pancreatic adeno-
carcinoma with no prior treatment. 75 received standard concomitant nab-paclitaxel
and gemcitabine and 71 received sequential administration of nab-paclitaxel and gemc-
itabine. Median age was 66 years
Interventions Standard regimen: nab-paclitaxel 125 mg/m² and gemcitabine 1000 mg/m² given im-
mediately after each other on days 1, 8, 15 of a 4 week cycle
Sequential regimen: nab-paclitaxel 125 mg/m² on days 1, 8, 15 and gemcitabine 1000
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Corrie 2017 (Continued)
mg/m² on days 2, 9, 16 of a 4-week cycle
Outcomes Progression-free survival
Safety
Response rate
Overall survival
Quality of life
Notes Abstract only
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Web based randomisation system with stratified block
randomisation
Allocation concealment (selection bias) Low risk No evidence of selection bias
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
Blinding of outcome assessment (detection
bias)
All outcomes
High risk High for the primary endpoint (PFS)
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants included in the survival analyses
Selective reporting (reporting bias) Low risk All outcomes described in themethods are reported in the
results
Other bias Low risk None found
Cullinan 1985
Methods Randomised trial
Participants Study was conducted inNorth America. 305 participants with unresectable or metastatic
pancreatic or gastric adenocarcinoma. Of the participants with pancreatic cancer, 50
received 5-fluorouracil (5FU), 44 received 5FU + doxorubicin (FA). 50 received 5FU
+ doxorubicin + mitomycin C (FAM). The majority of participants in the study were
between 50 to 69 years old
Interventions 5FU: 500 mg/m² days 1-5 week 1, 4 and 8, then every 5 weeks
FA: 5FU 400 mg/m² days 1-4 + doxorubicin 40 mg/m² day 1 week 1, 4 and 8, then
every 5 weeks
FAM: 5FU 600 mg/m² days 1, 8, 29, 36 + doxorubicin 30 mg/m² days 1 and 29 +
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Cullinan 1985 (Continued)
mitomycin C 10 mg/m² day 1, every 8 weeks
Outcomes Overall survival
Progression-free survival
Response rate
Toxicity
Symptom control
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient details published
Allocation concealment (selection bias) Unclear risk Insufficient details published
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Low risk for primary endpoint (OS)
Incomplete outcome data (attrition bias)
All outcomes
High risk 10 participants excluded from survival analysis
Selective reporting (reporting bias) Low risk All outcomes described in themethods are reported in the results
Other bias Low risk No indication of other bias
Cullinan 1990
Methods Randomised phase III trial
Participants Study was conducted in North America. 187 participants with measurable, metastatic
ductal or undifferentiated pancreatic cancer with no prior chemotherapy. 64 received 5-
fluorouracil (5FU). 61 received 5FU + cyclophosphamide + methotrexate + vincristine
(Mallison regimen). 59 received 5FU + doxorubicin + cisplatin (FAP). Median age for
the 5FU, Mallinson and FAP arm was 60, 62 and 62 years respectively
Interventions 5FU: 500 mg/m²/day for 5 days every 5 weeks
Mallinson: 5FU 270 mg/m²/day days 1-5 + cyclophosphamide 160 mg/m² days 1 + 5 +
methotrexate 11 mg/m² days 1 + 4 + vincristine 0.7 mg/m² days 2 + 5 then maintenance
with 5FU 350 mg/m² days 1-5 + mitomycin C 3.5 mg/m² days 1-5 every 5 weeks
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Cullinan 1990 (Continued)
FAP: 5FU 300 mg/m²/day days 1-5 + doxorubicin 40 mg/m² day 1 + cisplatin 60 mg/
m² day 1, every 5 weeks
Outcomes Overall survival
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient details published
Allocation concealment (selection bias) Unclear risk Insufficient details published
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Low risk for the primary endpoint (OS)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Survival analysis conducted on all enrolled patients
Selective reporting (reporting bias) Low risk Only OS listed specifically as an endpoint in the methods,
this is reported on all patients
Other bias Unclear risk No indication of other bias
Cunningham 2009
Methods Randomised phase III trial
Participants Study was conducted in the UK. 533 participants with locally advanced/metastatic pan-
creatic ductal adenocarcinoma. 266 received gemcitabine. 267 received gemcitabine +
capecitabine. Median age of participants was 62 years
Interventions Gemcitabine: 1000 mg/m² 7/8 weeks then 3/4 weeks
Gemcitabine + capecitabine: gemcitabine 1000 mg/m² 3/4 weeks + capecitabine 830
mg/m² twice daily orally for 3 weeks then 1 week rest
Outcomes Overall survival
Progression-free survival
Overall response rate
Toxicity
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Cunningham 2009 (Continued)
Quality of life
Pain
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were randomly assigned to each treatment arm
on a 1:1 basis according to a computer-generated variable-
size blocked randomization method. Randomization was
stratified by performance status (0, 1 versus 2) and extent
of disease”
Allocation concealment (selection bias) Low risk “Patients were randomly assigned to each treatment arm
on a 1:1 basis according to a computer-generated variable-
size blocked randomization method. Randomization was
stratified by performance status (0, 1 versus 2) and extent
of disease”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Low risk for primary endpoint (OS)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat population reported
Selective reporting (reporting bias) Low risk All outcomes described in the methods were reported in
the results
Other bias Low risk No indication of other bias
Di Costanzo 2005
Methods Randomised phase II trial
Participants Study was conducted in Italy. 94 participants with locally advanced/metastatic pancreatic
ductal adenocarcinoma with measurable disease. 48 received gemcitabine. 43 received
gemcitabine + 5-fluorouracil (5FU). Median age of participants was 63 years
Interventions Gemcitabine: 1000 mg/m² weekly for 7 weeks then 2 weeks rest, then 3/4 weeks
Gemcitabine + 5FU: Gemcitabine as above. 5FU 200 mg/m²/day for 6 weeks then 2
weeks rest, then 3/4 weeks
60Chemotherapy and radiotherapy for advanced pancreatic cancer (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Di Costanzo 2005 (Continued)
Outcomes Response rate
Overall survival
Safety
Quality of life
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were centrally randomised by the central office of
the ItalianOncologyGroup forClinical Research (GOIRC)
to receive: GEM alone (arm A) or in combination with CI
5-FU (arm B)”
Allocation concealment (selection bias) Low risk “Patients were centrally randomised by the central office of
the ItalianOncologyGroup forClinical Research (GOIRC)
to receive: GEM alone (arm A) or in combination with CI
5-FU (arm B)”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
Blinding of outcome assessment (detection
bias)
All outcomes
High risk High risk for the primary outcome (response rate)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Only patients “evaluable for response” were assessed for the
primary endpoint
Selective reporting (reporting bias) Low risk All outcomes described in the methods were reported in
the results
Other bias Low risk No indication of other bias
Ducreux 2004
Methods Randomised phase II study
Participants Study was conducted in France. 63 participants with locally advanced/metastatic pan-
creatic adenocarcinoma and measurable disease. Were allowed to have had previous 5FU
and radiotherapy if more than 3 months prior to randomisation. 17 received oxaliplatin,
31 received 5FU + oxaliplatin and 15 received 5FU alone. The mean age was 57 years
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Ducreux 2004 (Continued)
Interventions Oxaliplatin: 130 mg/m² every 3 weeks
5FU/ oxaliplatin: 5FU 1000 mg/m²/day, days 1-4 and oxaliplatin as above
5FU alone given as above
Outcomes Response rate
Notes The oxaliplatin alone arm was not included in the meta-analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Eligible patients in this open-label study were strati-
fied by center and disease stage (locally advanced versus
metastatic) and centralized block randomization was used
to assign patients to one of three arms”
Allocation concealment (selection bias) Low risk “Eligible patients in this open-label study were strati-
fied by center and disease stage (locally advanced versus
metastatic) and centralized block randomization was used
to assign patients to one of three arms”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk External radiologist used to assess tumour response
Incomplete outcome data (attrition bias)
All outcomes
High risk Only 56 participants were evaluable for response, 4 with-
drew prior to first assessment and 2 participants had base-
line assessments which were old or missing
Selective reporting (reporting bias) Unclear risk All outcomes described in the methods were reported in
the results
Other bias Low risk No indication of other bias
Frey 1981
Methods Randomised study
Participants Study was conducted in North America. 152 male participants with unresectable cancer
of the pancreas. 65 received 5-fluorouracil (5FU) andCCNU; 87 received best supportive
care. The majority of participants were between the age of 50 and 59 years
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Frey 1981 (Continued)
Interventions 5FU 9 mg/kg days 1-5 + CCNU 70 mg/m² day 1, every 6 weeks
Outcomes Overall survival
Toxicity
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details regarding the method of randomisation provided
Allocation concealment (selection bias) Low risk “Assignment of patients to treated or control groups in this
multi-institutional trial was made by means of sealed, sequen-
tially numbered envelopes distributed by a statistician from the
Follow-up Agency, National Academy of Sciences-National Re-
search Council.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Low risk for primary endpoint (OS)
Incomplete outcome data (attrition bias)
All outcomes
Low risk All enrolled participants included in survival analysis
Selective reporting (reporting bias) Low risk All outcomes described in the methods were reported in the
results
Other bias Low risk No indications of other bias
Gansauge 2002
Methods Randomised phase II trial
Participants Study was conducted in Germany. 90 participants with unresectable pancreatic ade-
nocarcinoma. 30 received gemcitabine. 30 received Ukrain (NSC-31570). 30 received
Ukrain + gemcitabine. The mean age for the gemcitabine, Ukrain and Gemcitabine +
Ukrain groups were 63.8, 60.6 and 58.2 respectively
Interventions Gemcitabine: 1000 mg/m² 7/8 weeks then 34 weeks
Ukrain: 20 mg weekly for 7 weeks, 1 week rest then 3/4 weeks up to 12 cycles
Gemcitabine + Ukrain: as above
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Gansauge 2002 (Continued)
Outcomes Overall survival
Notes This was a multi-armed study. Event rates were not available for the 3 arms. Only the
gemcitabine and gemcitabine + Ukrain arms analysed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient details published
Allocation concealment (selection bias) Unclear risk Insufficient details published
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient details published
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Low risk for primary endpoint (OS)
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants included in the survival analysis
Selective reporting (reporting bias) Low risk All outcomes described in the methods were reported in
the results
Other bias Low risk No indication of other bias
Glimelius 1996
Methods Randomised study
Participants Study was conducted in Sweden. 90 participants with non-curable pancreatic or biliary
tract cancer. 53 had pancreatic cancer. 29 received 5FU/LV +/- etoposide. 24 received
best supportive care. Median age for the chemotherapy and best supportive care arms
were 65 and 64 respectively
Interventions If participant was > 60 years, then 5FU/LV: 5FU 500 mg/m² + LV 60 mg/m² on days
1 + 2 every 14 days
If participant was < 60 years old, then 5FU/LV: 5FU 500 mg/m² + LV 60 mg/m² +
etoposide 120 mg/m²
Outcomes Overall survival
Quality of life
Objective responses
Toxicity
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Glimelius 1996 (Continued)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient details published
Allocation concealment (selection bias) Unclear risk Insufficient details published
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Low risk for primary endpoint (OS)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention to treat analysis reported
Selective reporting (reporting bias) Low risk All outcomes described in the methods were reported in the
results
Other bias Low risk No indication of other bias
Heinemann 2006
Methods Randomised phase III trial
Participants Study was conducted in Germany. 195 participants with locally advanced/metastatic
pancreatic adenocarcinoma with measurable disease. Previous radiotherapy was allowed
if not on the target lesion. 97 received gemcitabine. 98 received gemcitabine + cisplatin.
The median age of the gemcitabine + cisplatin and gemcitabine alone groups was 64 and
66 years respectively
Interventions Gemcitabine: 1000 mg/m² day 1, 8, 15 every 4 weeks
Gemcitabine + cisplatin: gemcitabine as above. Cisplatin 50 mg/m² days 1, 8, 15 every
4 weeks
Outcomes Overall survival
Progression-free survival
Response rate
Safety
Quality of life
Notes -
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Heinemann 2006 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Central random assignment was performed before the
start of treatment, and patients were assigned to one of the
treatment arms.”
Allocation concealment (selection bias) Low risk “Central random assignment was performed before the
start of treatment, and patients were assigned to one of the
treatment arms.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Low risk for primary endpoint (OS)
Incomplete outcome data (attrition bias)
All outcomes
Low risk “The primary outcome measure was OS, which was deter-
mined for all randomly assigned patients from the date of
random assignment to the date of death or last
contact.”
Selective reporting (reporting bias) Low risk All outcomes described in the methods were reported in
the results
Other bias Low risk No indication of other bias
Herrmann 2007
Methods Randomised phase III trial
Participants Study conducted in eight European countries. 319 participants with inoperable/
metastatic pancreatic ductal adenocarcinoma. 159 received gemcitabine. 160 received
gemcitabine + capecitabine. The median age was not stated
Interventions Gemcitabine: 1000 mg/m² 7/8 weeks then 3/4 weeks
Capecitabine: 650 mg/m² twice daily orally, days 1-14 every 3 weeks
Outcomes Overall survival
Progression-free survival
Overall response rate
Safety
Quality of life
Notes -
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Herrmann 2007 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Likely to be low risk but actual method of randomisation/
allocation not stated in publication
Allocation concealment (selection bias) Unclear risk Insufficient details published
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Low risk for the primary endpoint (OS)
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Intent-to-treat analysis was applied to the analysis of all
end points”
Selective reporting (reporting bias) Low risk No indication of reporting bias
Other bias Low risk No indication of other bias
Hirao 2011
Methods Randomised phase II trial
Participants Study was conducted in Japan. 90 participants with unresectable, metastatic pancreatic
ductal adenocarcinoma with no prior therapy. 45 received gemcitabine on a 3 week
schedule. 45 received gemcitabine on a 4-week schedule. The median age in the 4 week
and 3 week schedule was 67 years and 66 years, respectively
Interventions 3 weeks: gemcitabine 1000 mg/m² days 1 and 8
4 weeks: gemcitabine 1000 mg/m² days 1, 8 and 15
Outcomes Compliance rate
Overall survival
Progression-free survival
Toxicity
Response rate
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
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Hirao 2011 (Continued)
Random sequence generation (selection
bias)
Low risk “Randomization was performed centrally, and the random-
allocation sequence had been generated previously by a
statistician using a computer-generated random
code”
Allocation concealment (selection bias) Low risk “Randomization was performed centrally, and the random-
allocation sequence had been generated previously by a
statistician using a computer-generated random
code”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
Blinding of outcome assessment (detection
bias)
All outcomes
High risk High risk for primary endpoint (compliance rate)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat population included in analysis
Selective reporting (reporting bias) Low risk All outcomes described in the methods were reported in
the results
Other bias Low risk No indication of reporting bias
Huguier 2001
Methods Randomised study
Participants Study was conducted in France. 45 participants with unresectable pancreatic ductal
adenocarcinoma. 22 received 5-fluorouracil (5FU) + leucovorin (LV) + cisplatin; 23
received best supportive care. The median age of participants was 63.4 years
Interventions 5FU: 375 mg/m²/day days 1-5
LV 200 mg/m²/day days 1-5
Cisplatin 15 mg/m²/day days 1-5
Outcomes Overall survival
Side effects
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
68Chemotherapy and radiotherapy for advanced pancreatic cancer (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Huguier 2001 (Continued)
Random sequence generation (selection
bias)
Low risk “Assignment of patients to chemotherapy or control group used
a centralised random permuted block technique”
Allocation concealment (selection bias) Low risk “Assignment of patients to chemotherapy or control group used
a centralised random permuted block technique”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Low risk for primary endpoint (OS)
Incomplete outcome data (attrition bias)
All outcomes
Low risk All enrolled participants included in the survival analysis
Selective reporting (reporting bias) Low risk All outcomes described in the methods were reported in the
results
Other bias Low risk No indications of other bias
Kelsen 1991
Methods Phase III randomised study
Participants Study was conducted in North America. 82 participants with advanced pancreatic ade-
nocarcinoma and no prior therapy. 42 received streptozocin, mitomycin C and 5FU
(SMF). 50 received cisplatin, cytosine arabinoside and caffeine (CAC). The median age
of participants was 59 years
Interventions SMF: streptozocin 1 g/m² days 1, 8, 29 and 36 + mitomycin C 10 mg/m² day 1 + 5FU
600 mg/m² days 1, 8 and 36 every 8 weeks
CAC: cisplatin 100mg/m² day 1 + cytosine arabinoside 2 g/m² two doses day 1 + caffeine
400 mg/m² subcutaneous 2 doses day 1
Outcomes Response
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient details published
Allocation concealment (selection bias) Unclear risk Insufficient details published
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Kelsen 1991 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
Blinding of outcome assessment (detection
bias)
All outcomes
High risk High risk for primary outcome (response rate)
Incomplete outcome data (attrition bias)
All outcomes
High risk Not all participants were assessed for the primary outcome
measure
Selective reporting (reporting bias) Low risk All outcomes described in the methods were reported in
the results
Other bias Low risk No indication of other bias
Kovach 1974
Methods Randomised study
Participants Study was conducted in North America. 82 with unresectable pancreatic adenocarci-
noma and measurable disease. 31 received 5FU, 21 received 1,3-bis-(2-chloroethyl)-1-
nitrosurea (BCNU)and 30 received 5FU + BCNU
Interventions 5FU: 13.5 mg/kg/day for 5 days every 5 weeks
BCNU: 50 mg/m²/day for 5 days every 8 weeks
5FU + carmustine: 5FU 10 mg/kg/day for 5 days and BCNU 40 mg/m²/day for 5 days
every 8 weeks
Outcomes Not stated
Notes This is a multi-armed study. Event rates for each arm were not available. Only the 5FU
and 5FU + carmustine arms were analysed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient details published
Allocation concealment (selection bias) Unclear risk Insufficient details published
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
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Kovach 1974 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Primary outcome measure unclear
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear if all participants were included in survival analysis
Selective reporting (reporting bias) Low risk No indication of reporting bias
Other bias Low risk No indication of other bias
Kulke 2009
Methods Randomised phase II trial
Participants Study was conducted in North America. 245 participants with metastatic pancreatic
adenocarcinoma. Adjuvant 5-fluorouracil was permitted with completed > 2weeks prior.
62 received gemcitabine + cisplatin. 58 received gemcitabine. 65 received gemcitabine
+ docetaxel. 60 received gemcitabine + irinotecan. Median age of participants was 60.5
years
Interventions Gemcitabine + cisplatin: gemcitabine 1000 mg/m² weekly × 3, cisplatin 50 mg/m² days
1 and 15 every 4 weeks
Gemcitabine: 1500 mg/m² at 10 mg/m²/min, weekly × 3, every 4 weeks
Gemcitabine + docetaxel: gemcitabine 1000 mg/m² weekly × 3, docetaxel 40 mg/m²
days 1 + 8, every 4 weeks
Gemcitbine + irinotecan: gemcitabine 1000 mg/m² days 1 and 8, irinotecan 100 mg/
m² days 1 and 8 every 3 weeks
Outcomes Overall survival
Response rate
Time to progression
Toxicity
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient details published. “Patients were randomly as-
signed to receive one of the following four regimens: gemc-
itabine/cisplatin (arm A), fixed dose rate gemcitabine (arm
B), gemcitabine/docetaxel (armC), or gemcitabine/irinote-
can (arm D)”
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Kulke 2009 (Continued)
Allocation concealment (selection bias) Unclear risk Insufficient details published. “Patients were randomly as-
signed to receive one of the following four regimens: gemc-
itabine/cisplatin (arm A), fixed dose rate gemcitabine (arm
B), gemcitabine/docetaxel (armC), or gemcitabine/irinote-
can (arm D)”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Low risk for primary endpoint (OS)
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants included in the outcome analysis
Selective reporting (reporting bias) Low risk All outcomes described in the methods were reported in
the results
Other bias Low risk No indication of other bias
Lee 2017
Methods Phase III trial
Participants Study was conducted in Korea. 214 treatment naive participants with locally advanced
or metastatic pancreatic adenocarcinoma with ECOG 0-2. 108 participants received
gemcitabine + capecitabine and 106 participants received gemcitabine alone. Median
age was 54 years years
Interventions Gemcitabine 1000 mg/m² 3/4 weeks
Capecitabine 1600 mg/m² daily for 3/4 weeks
Outcomes Overall survival
Progression-free survival
Overall response rate
Disease control rate
Toxicity
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “We randomly assigned eligible patients to each treatment arm
on a 1:1 basis according to a computer-generated variable-size
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Lee 2017 (Continued)
blocked randomization method.”
Allocation concealment (selection bias) Low risk “We randomly assigned eligible patients to each treatment arm
on a 1:1 basis according to a computer-generated variable-size
blocked randomization method.”s
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Low risk for primary endpoint (OS)
Incomplete outcome data (attrition bias)
All outcomes
Low risk All patients included in the survival analysis
Selective reporting (reporting bias) Low risk All outcomes described in the methods were reported in the
results
Other bias Low risk None found
Levi 2004
Methods Randomised study
Participants Study was conducted in Europe. 107 participants with advanced pancreatic cancer.
Factorial design randomised participants to either 5FU given at a constant rate infusion
or chronomodulated infusion, with or without cisplatin. Median age of participants was
63 years
Interventions 5FU: 5 g/m² (cycle 1) or 6 g/m² (cycle 2) or 6.5 g/m² (cycle 3) either at a constant rate
infusion or chronomodulated (given between 10 pm and 10 am)
Cisplatin: 100 mg/m² once per cycle
Outcomes OS
Notes Abstract only
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient details published
Allocation concealment (selection bias) Unclear risk Insufficient details published
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Levi 2004 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient details published
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Low risk for primary endpoint (OS)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient details published
Selective reporting (reporting bias) Unclear risk Insufficient details published
Other bias Unclear risk Insufficient details published
Li 2004
Methods Randomised study
Participants Study was conducted in China. 46 participants with metastatic pancreatic adenocarci-
noma. 25 received gemcitabine. 21 received gemcitabine + cisplatin
Interventions Gemcitabine: 1000 mg/m² IV 3/4 weeks
Cisplatin: 25 mg/m²/week, 3/4 weeks
Outcomes Overall survival
Notes Abstract only
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient details published
Allocation concealment (selection bias) Unclear risk Insufficient details published
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient details published
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Low risk for primary endpoint (OS)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient details published
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Li 2004 (Continued)
Selective reporting (reporting bias) Unclear risk Insufficient details published
Other bias Unclear risk Insufficient details published
Lohr 2012
Methods Randomised phase II trial
Participants Study was conducted in Europe. 200 participants with locally advanced/unresectable or
metastatic pancreatic adenocarcinoma. 50 received gemcitabine. 50 received liposomal-
paclitaxel (ET) 11 mg/m². 50 received ET 22 mg/m². 50 received ET 44 mg/m². The
median age for the gemcitabine alone, ET 11mg/m2, ET 22mg/m2 and ET 44mg/m2
group was 59.5, 63, 61 and 62.5 years, respectively.
Interventions Gemcitabine: 1000 mg/m² weekly × 7
ET: Dose given twice weekly × 14
Outcomes Overall survival
Progression-free survival
Response rate
Quality of life
Adverse events
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were centrally randomized”
Allocation concealment (selection bias) Low risk “Patients were centrally randomized”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Low risk for primary endpoint (OS)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk PFS for intention-to-treat population not reported - only
the “modified intention to treat” population
Selective reporting (reporting bias) Low risk All outcomes described in the methods were reported in
the results
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Lohr 2012 (Continued)
Other bias Low risk No indication of other bias
Louvet 2005
Methods Randomised phase III trial
Participants Study was conducted in France. 326 participants with unresectable/metastatic pancreatic
ductal adenocarcinoma with measurable disease. 156 received gemcitabine. 157 received
gemcitabine + oxaliplatin. The median age was 60.1 years and 61.3 years in the gemc-
itabine and gemcitabine + oxaliplatin groups respectively
Interventions Gemcitabine 1000 mg/m² 7/8 weeks then 3/4 weeks
Gemcitabine + oxaliplatin: gemcitabine 1000 mg/m² day 1 + oxaliplatin 100 mg/m² day
2, every 2 weeks
Outcomes Overall survival
Clinical benefit
Progression-free survival
Safety
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomization was performed centrally, and the mini-
mization method was used to balance treatment allocation
according to center, stage of disease (locally advanced v
metastatic), and PS (0 or 1 v 2).”
Allocation concealment (selection bias) Low risk “Randomization was performed centrally, and the mini-
mization method was used to balance treatment allocation
according to center, stage of disease (locally advanced v
metastatic), and PS (0 or 1 v 2).”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Low risk for primary endpoint (OS)
Incomplete outcome data (attrition bias)
All outcomes
High risk Only ’per protocol’ participants analysed
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Louvet 2005 (Continued)
Selective reporting (reporting bias) Low risk All outcomes described in the methods were reported in
the results
Other bias Low risk No indication of other bias
Lutz 2005
Methods Randomised phase II trial
Participants Study was conducted in Europe. 96 participants with metastatic or locally advanced
pancreatic ductal adenocarcinoma with no previous treatment. 49 received gemcitabine
+ docetaxel. 47 received cisplatin + docetaxel. The median age of participants was 58
years and 59 years in the gemcitabine + docetaxel and cisplatin and docetaxel groups
respectively
Interventions Gemcitabine + docetaxel: gemcitabine 800 mg/m² days 1 and 8 + docetaxel 85 mg/m²
day 8 every 3 weeks
Cisplatin + docetaxel: cisplatin 75 mg/m² day 1 every 3 weeks
Outcomes Tumour response
Rates of febrile neutropenia
Duration of response
Progression-free survival
Overall survival
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were centrally randomly assigned at the EORTC
Data Center, Brussels, Belgium, and stratified using the
minimization technique according to institution, perfor-
mance status (0 v 1), and extent of disease (metastatic v
locoregionally advanced)”
Allocation concealment (selection bias) Low risk “Patients were centrally randomly assigned at the EORTC
Data Center, Brussels, Belgium, and stratified using the
minimization technique according to institution, perfor-
mance status (0 v 1), and extent of disease (metastatic v
locoregionally advanced)”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
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Lutz 2005 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk High risk for primary endpoint (tumour response)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat population included in analysis
Selective reporting (reporting bias) Low risk All outcomes described in the methods were reported in
the results
Other bias Low risk No indication of other bias
Maisey 2002
Methods Randomised phase III trial
Participants Study was conducted in the UK. 209 participants with locally advanced/metastatic pan-
creatic ductal adenocarcinoma. 107 received 5-fluorouracil (5FU). 102 received 5FU +
mitomycin C (MMC). The median age of participants was 62 years and 61 years in the
5FU and 5FU + MMC groups respectively
Interventions 5FU 300 mg/m²/day via protracted venous infusion (PVI) for 12 weeks. If no progres-
sion, another 12 weeks
5FU + MMC: 5FU 300 mg/m²/day + MMC 10 mg/m² every 6 weeks × 4 cycles
Outcomes Response rate
Survival
Toxicity
QoL
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “...patients were randomly assigned to treatment with PVI
5-FU or PVI 5-FU/MMC on a 1:1 basis according to
a computer generated randomization code. The patients
were randomized centrally in blocks of six and stratified
by center”
Allocation concealment (selection bias) Low risk “...patients were randomly assigned to treatment with PVI
5-FU or PVI 5-FU/MMC on a 1:1 basis according to
a computer generated randomization code. The patients
were randomized centrally in blocks of six and stratified
by center”
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Maisey 2002 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
Blinding of outcome assessment (detection
bias)
All outcomes
High risk High risk for primary endpoint (response rate)
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants included in the survival analysis
Selective reporting (reporting bias) Low risk All outcomes described in the methods were reported in
the results
Other bias Low risk No indication of other bias
Meng 2012
Methods Randomised, placebo controlled, phase II trial
Participants Study was conducted in China. 76 participants with unresectable pancreatic adenocar-
cinoma with measurable disease. 37 received gemcitabine + placebo. 39 received gemc-
itabine + huachansu. The median age of participants was 60.9 years
Interventions Gemcitabine + placebo: 1000 mg/m² 3/4 weeks + saline
Gemcitabine + huachansu: gemcitabine as above, huachansu 20 mL/m² 5 days per week,
3 weeks on, 1 week off
Outcomes 4 month progression-free survival
Overall survival
Overall response rate
Time to progression
Toxicity
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient details published - “Patients
were randomised using a Bayesian algo-
rithm”
Allocation concealment (selection bias) Unclear risk Insufficient details published - “Patients
were randomised using a Bayesian algo-
rithm”
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Meng 2012 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo-controlled study
Blinding of outcome assessment (detection
bias)
All outcomes
High risk High risk for primary endpoint (PFS at 4
months)
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants included in the survival
analysis
Selective reporting (reporting bias) Low risk All outcomes described in the methods
were reported in the results
Other bias Low risk No indication of other bias
Moertel 1977
Methods Randomised trial
Participants Study was conducted in North America. 88 participants with unresectable pancreatic
ductal adenocarcinomawithmeasurable disease. 40 received streptozocin +5-fluorouracil
(5FU). 48 received streptozocin and cyclophosphamide. Most participants were aged
between 50 to 59 years old
Interventions Streptozocin 500 mg/m² days 1-5
5FU 400 mg/m² days 1-5 every 6 weeks
Cyclophosphamide 1000 mg/m² days 1 and 21 every 6 weeks
Outcomes Not stated
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient details published
Allocation concealment (selection bias) Unclear risk Insufficient details published
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
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Moertel 1977 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Participants who died early or who were unable to continue their
assigned treatment were declared to have progressive disease
Incomplete outcome data (attrition bias)
All outcomes
High risk Only 74 participants included in survival analysis
Selective reporting (reporting bias) Low risk All outcomes described in the methods were reported in the
results
Other bias Low risk No indication of other bias
Moertel 1979
Methods Randomised trial
Participants Study conducted in North American. 176 participants with metastatic pancreatic ductal
adenocarcinoma. 89 received 5-fluorouracil (5FU). 87 received 5FU + streptozocin.
Details on the age of participants not stated
Interventions 5FU 450 mg/m² days 1-5 every 5 weeks
5FU + streptozocin: 5FU 400 mg/m² days 1-5 + streptozocin 400 mg/m² days 1-5 every
5 weeks
Participants were also randomised +/- spironolactone 50 mg 3 times per day
Outcomes Survival
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient details published
Allocation concealment (selection bias) Unclear risk Insufficient details published
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient details published
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants included in the survival analysis
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Moertel 1979 (Continued)
Selective reporting (reporting bias) High risk Toxicity data scarcely reported
Other bias Low risk No indication of other bias
Oettle 2005
Methods Randomised phase III trial
Participants Study was conducted in Germany. 565 participants with locally advanced/metastatic
pancreatic adenocarcinoma with measurable disease. Radiotherapy permitted if com-
pleted > 4 weeks prior. 282 received gemcitabine. 283 received gemcitabine + peme-
trexed. The median age of participants was 63 years
Interventions Gemcitabine (G): 1000 mg/m² 3/4 weeks
Gemcitabine + pemetrexed (PG): gemcitabine 1250 mg/m² days 1 and 8, pemetrexed
500 mg/m² day 8, every 21 days
Outcomes Overall survival
Progression-free survival
Time to treatment failure
Response rate
Quality of life
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Eligible patients were randomly assigned using a central-
ized, automated randomization procedure to either the PG
arm or the G arm”
Allocation concealment (selection bias) Low risk “Eligible patients were randomly assigned using a central-
ized, automated
randomization procedure to either the PG arm or the G
arm”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Low risk for primary endpoint (OS)
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants included in the survival analysis
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Oettle 2005 (Continued)
Selective reporting (reporting bias) Low risk All outcomes described in the methods were reported in
the results
Other bias Low risk No indication of other bias
Ohkawa 2004
Methods Randomised trial
Participants Study was conducted in Japan. 19 participants with advanced pancreatic ductal adeno-
carcinoma with no previous treatment. 9 received gemcitabine. 10 received gemcitabine
+ tegafur-uracil (UFT). The median age of participants for the gemcitabine alone and
gemcitabine + UFT groups was 58.4 years and 60.5 years respectively
Interventions Gemcitabine: 1000 mg/m² 3/4 weeks.
UFT 300 mg/day continuous
Outcomes Response rate
Survival time
Time to progression
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient details published
Allocation concealment (selection bias) Unclear risk Insufficient details published
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
Blinding of outcome assessment (detection
bias)
All outcomes
High risk High risk for primary endpoint (response rate)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient details published
Selective reporting (reporting bias) Unclear risk Insufficient details published
Other bias Low risk No indication of other bias
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Ozaka 2012
Methods Randomised phase II trial
Participants Study was conducted in Japan. 112 participants with locally advanced/metastatic pan-
creatic ductal adenocarcinoma with measurable disease. 59 received gemcitabine. 53 re-
ceived gemcitabine + S1. The median age of participants was 64 years
Interventions Gemcitabine: 1000 mg/m² 3/4 weeks
Gemcitabine + S1: gemcitabine 1000 mg/m² day 1 and 8, S1 80 mg/m² twice daily
orally, days 1-14 every 3 weeks
Outcomes Response rate
Toxicity
Clinical benefit rate
Progression-free survival
Overall survival
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Random assignment was performed centrally by a web-
based assistant system (Xexible license assisted data server,
JACCRO, Tokyo), using a computer-driven minimization
procedure”
Allocation concealment (selection bias) Low risk “Random assignment was performed centrally by a web-
based assistant system (Xexible license assisted data server,
JACCRO, Tokyo), using a computer-driven minimization
procedure”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
Blinding of outcome assessment (detection
bias)
All outcomes
High risk High risk for primary endpoint (response rate)
Incomplete outcome data (attrition bias)
All outcomes
High risk Intention-to-treat population not reported for PFS
Selective reporting (reporting bias) Low risk All outcomes described in the methods were reported in
the results
Other bias Low risk No indication of other bias
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Petrioli 2015
Methods Randomised phase II study
Participants Study was conducted in Italy. 67 participants with metastatic, histologically proven
pancreatic cancer and ECOG ≤ 2 and no prior chemotherapy. 33 given gemcitabine
alone and 34 given gemcitabine + oxaliplatin + capecitabine (GEMOXEL). The median
age of participants in the GEMOXEL and gemcitabine groups was 69 years and 67 years,
respectively
Interventions Gemcitabine: 1000 mg/m² for 7/8 weeks then days 1, 8 and 15 every 28 days
GEMOXEL: gemcitabine 1000 mg/m² days 1, 8, 15 and 22. Oxaliplatin 100 mg/m²
day 2, capectiabine 1500 mg/m²/day in 2 divided doses, days 1-14 every 21 days
Outcomes Disease control rate in per protocol population
Safety
Progression-free survival
Quality of life
Overall survival
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient details published
Allocation concealment (selection bias) Unclear risk Insufficient details published
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
Blinding of outcome assessment (detection
bias)
All outcomes
High risk High risk for primary endpoint (disease control rate)
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants included in the survival analysis
Selective reporting (reporting bias) Low risk All outcomes described in the methods were reported in
the results
Other bias Low risk No indication of other bias
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Poplin 2009
Methods Randomised phase III trial
Participants Study was conducted in North America. 824 participants with locally advanced/
metastatic pancreatic ductal adenocarcinoma with measurable disease. Were allowed to
have had adjuvant radiotherapy if completed more than 4 weeks prior. 275 received
standard gemcitabine. 277 received fixed dose rate gemcitabine (FDR). 272 received
gemcitabine + oxaliplatin. The median age was 64 years, 61 years and 63 years for the
gemcitabine, FDR and gemcitabine + oxaliplatin groups, respectively
Interventions Gemcitabine: 1000 mg/m² over 30 min 7/8 weeks then 3/4 weeks
FDR: gemcitabine 1500 mg/m² given over 150 min infusion day 1, 8, 15 every 4 weeks
Gemcitabine + oxaliplatin: gemcitabine 1000 mg/m² over 100 min day 1 + oxaliplatin
100 mg/m² day 2, every 2 weeks
Outcomes Overall survival
Response rate
Progression-free survival
Symptoms
Notes Gemcitabine + oxaliplatin arm has not been analysed as the gemcitabine dose schedule
is not standard
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were randomly assigned to treatment using a dy-
namic balancing algorithm that stratified for performance
status, 0 to 1 and versus 2, and for locally advanced versus
metastatic disease”
Allocation concealment (selection bias) Unclear risk “Patients were randomly assigned to treatment using a dy-
namic balancing algorithm that stratified for performance
status, 0 to 1 and versus 2, and for locally advanced versus
metastatic disease”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Low risk for primary endpoint (OS)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat population included in survival analysis
Selective reporting (reporting bias) Low risk All outcomes described in the methods were reported in
the results
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Poplin 2009 (Continued)
Other bias Low risk No indication of other bias
Poplin 2013
Methods Randomised, multicentre, phase II trial
Participants This was an international study. 367 participants with metastatic pancreatic ductal ade-
nocarcinoma. 185 received gemcitabine. 182 received lipid-drug conjugate of gemc-
itabine (CO-101). The median age of participants in the low hENT1 group was 62
years, and was 61 years in the high hENT group
Interventions Gemcitabine 100 mg/m² 7/8 weeks then 3/4 weeks
CO-101 120 mg/m² 3/4 weeks
Outcomes Overall survival in low hENT1 participants
Overall survival
Progression-free survival
Response rate
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Treatment on the Low hENT1 in Adenocar-
cinomaof the Pancreas (LEAP) studywas ran-
domly assigned (1:1 to gemcitabine or CO-
101; Fig 1), and treatment allocation was
stratified for Eastern Cooperative Oncology
Group (ECOG) performances status (PS; 0 v
1) and geographic location (North America v
South America v Australia v Eastern Europe
v Western Europe).”
Allocation concealment (selection bias) Low risk “Treatment on the Low hENT1 in Adenocar-
cinomaof the Pancreas (LEAP) studywas ran-
domly assigned (1:1 to gemcitabine or CO-
101; Fig 1), and treatment allocation was
stratified for Eastern Cooperative Oncology
Group (ECOG) performances status (PS; 0 v
1) and geographic location (North America v
South America v Australia v Eastern Europe
v Western Europe).”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
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Poplin 2013 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Low risk for primary endpoint (OS)
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants included in the analyses
Selective reporting (reporting bias) Low risk All outcomes described in the methods were
reported in the results
Other bias Low risk No indications of other bias
Reni 2005
Methods Randomised phase III trial
Participants Study was conducted in Italy. 99 participants with locally advanced/metastatic pancre-
atic adenocarcinoma with measurable disease. 47 received gemcitabine. 52 received cis-
platin, epirubicin, gemcitabine and 5-fluorouracil (5FU) (PEGF). The median age of
participants was 62 years and 59 years in the PEGF and gemcitabine groups respectively
Interventions Gemcitabine: 1000 mg/m² 7/8 weeks then 3/4 weeks
PEGF: cisplatin 40 mg/m² day 1, epirubicin 40 mg/m² day 1, gemcitabine 600 mg/m²
days 1 and 8, 5FU 200 mg/m²/day every 28 days
Outcomes Progression-free survival
Overall survival
Response rate
Safety
Quality of life
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomisationwas done by a secretary at a central loca-
tion by a phone call. The random-allocation sequence had
been generated previously by a statistician (LG) by use of
a computer-generated random code.”
Allocation concealment (selection bias) Low risk “Randomisationwas done by a secretary at a central loca-
tion by a phone call. The random-allocation sequence had
been generated previously by a statistician (LG) by use of
a computer-generated random code.”
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Reni 2005 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk PFS was primary outcome, but radiologist evaluating pro-
gression was blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants included in the survival analysis
Selective reporting (reporting bias) Low risk All outcomes described in the methods were reported in
the results
Other bias Low risk No indication of other bias
Reni 2012
Methods Randomised phase II trial
Participants Study was conducted in Italy. 105 participants with unresectable/metastatic pancreatic
ductal adenocarcinoma. 53 participants had capecitabine, cisplatin, gemcitabine and
docetaxel (PDXG). 52 participants had capecitabine, epirubicin, cisplatin, gemcitabine
(PEXG). The median age of participants was 61 years and 59 years in the PDXG and
PEXG arms, respectively
Interventions PDXG: capecitabine 1250 mg/m² days 1-28, cisplatin 30 mg/m² days 1 and 15, gemc-
itabine 800 mg/m² days 1 and 15, docetaxel 25 mg/m² days 1 and 15 every 4 weeks
PEXG: capecitabine as above, cisplatin as above, gemcitabine as above, epirubicin 30
mg/m² days 1 and 15 every 4 weeks
Outcomes Progression-free survival at 6 months
Overall survival
Toxicity
Response rate
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients fulfilling all inclusion criteria were registered by
the attending physician at an independent Contract Re-
searchOrganization (CRO) that performed randomization
on a 1:1 basis to either arm A or B. Patients were stratified
according to stage of disease (III vs. IV)”
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Reni 2012 (Continued)
Allocation concealment (selection bias) Unclear risk “Patients fulfilling all inclusion criteria were registered by
the attending physician at an independent Contract Re-
searchOrganization (CRO) that performed randomization
on a 1:1 basis to either arm A or B. Patients were stratified
according to stage of disease (III vs. IV)”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk PFS primary outcome but radiologists blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat population included in survival analysis
Selective reporting (reporting bias) Low risk All outcomes described in the methods were reported in
the results
Other bias Low risk No indication of other bias
Riess 2005
Methods Randomised phase III trial
Participants 473 participants with locally advanced/metastatic pancreatic ductal adenocarcinoma
with no prior therapy. 238 received gemcitabine. 235 received gemcitabine + 5-fluo-
rouracil (5FU) + folinic acid (FA)
Interventions Gemcitabine: 1000 mg/m² 7/8 weeks, then 3/4 weeks
Gemcitabine + 5FU + FA: gemcitabine 1000 mg/m² + 5FU 750 mg/m² as a 24 hour
infusion + FA 200 mg/m² days 1, 8, 15 every 6 weeks
Outcomes Overall survival
Time to progression
Toxicity
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details given
Allocation concealment (selection bias) Unclear risk No details given
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Riess 2005 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Low risk for primary endpoint (OS)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient details published
Selective reporting (reporting bias) Unclear risk Insufficient details published
Other bias Low risk No indication of other bias
Rocha Lima 2004
Methods Randomised phase III trial
Participants Study was conducted in North America. 360 participants with locally advanced/
metastatic pancreatic adenocarcinoma with measurable disease. Adjuvant radiotherapy
and 5-fluorouracil (5FU) were permitted. 180 received gemcitabine. 180 received gem-
citabine + irinotecan. The median age of participants was 63.2 years and 60.2 years in
the gemcitabine + irinotecan and the gemcitabine alone group, respectively
Interventions Gemcitabine: 1000 mg/m² 7/8 weeks then 3/4 weeks
Gemcitabine + irinotecan: gemcitabine 1000 mg/m² and irinotecan 100 mg/m² days 1
and 8, every 21 days
Outcomes Overall survival
Quality of life
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were centrally randomly assigned and stratified
by ECOGperformance status (0, 1, or 2), extent of disease
(locally advanced ormetastatic), andprevious radiotherapy
for pancreatic cancer (yes or no).”
Allocation concealment (selection bias) Low risk “Patients were centrally randomly assigned and stratified
by ECOGperformance status (0, 1, or 2), extent of disease
(locally advanced ormetastatic), andprevious radiotherapy
for pancreatic cancer (yes or no).”
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Rocha Lima 2004 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Low risk for primary endpoint (OS)
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants were included in the survival analysis
Selective reporting (reporting bias) Low risk All outcomes described in the methods were reported in
the results
Other bias Low risk No indication of other bias
Scheithauer 2003
Methods Randomised phase II trial
Participants Study was conducted in Austria. 83 participants with metastatic pancreatic ductal ade-
nocarcinoma. Adjuvant 5-fluorouracil (5FU) and radiotherapy (RT) was permitted if
completed > 6 months prior to randomisation. 42 received gemcitabine. 41 received
gemcitabine + capecitabine. The median age of participants was 66 years and 64 years
in the gemcitabine alone and the gemcitabine + capecitabine groups respectively
Interventions Gemcitabine: 2200 mg/m² day 1, every 2 weeks
Gemcitabine + capecitabine: gemcitabine as above, capecitabine 2500 mg/m²/day orally
days 1-7 every 2 weeks
Outcomes Progression-free survival
Overall survival
Response rate
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient details published. “Patients were then assigned
to one treatment regimen by the central office located at
the University in Vienna”
Allocation concealment (selection bias) Unclear risk Insufficient details published. “Patients were then assigned
to one treatment regimen by the central office located at
the University in Vienna”
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Scheithauer 2003 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk PFS primary endpoint but independently reviewed
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants included in the survival analysis
Selective reporting (reporting bias) Low risk All outcomes described in the methods were reported in
the results
Other bias Low risk No indication of other bias
Singhal 2014
Methods Phase III randomised trial
Participants 310 participants with metastatic PC. Half received FOLFIRINOX and half received
gemcitabine. Details on age of participants not published
Interventions FOLFIRINOX: Oxaliplatin 85 mg/m² + irinotecan 180 mg/m² + LV 400 mg/m² + 5FU
400 mg/m² bolus + 5FU 2400 mg/m² as 46 hours continuous infusion every 2 weeks
Gemcitabine: 1000 mg/m² days 1, 8, 15 every 28 days
Outcomes Overall survival
Progression-free survival
Response rate
Quality of life
Adverse events
Notes Abstract only
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient details published
Allocation concealment (selection bias) Unclear risk Insufficient details published
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
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Singhal 2014 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Low risk for primary endpoint (OS)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient details published
Selective reporting (reporting bias) Unclear risk Insufficient details published
Other bias Unclear risk Insufficient details published
Smith 2003
Methods Randomised phase II/III study
Participants Study was conducted in the UK. 55 participants with locally advanced or metastatic
pancreatic adenocarcinoma with no prior treatment. 30 received ZD9331, 25 received
gemcitabine alone. The median age of participants was 59.8 years and 60.8 years in the
ZD9331 and gemcitabine arms respectively
Interventions ZD9331: 130 mg/m² days 1, 8 every 21 days
Gemcitabine: 1000 mg/m² weekly, 7/8 weeks, then 3/4 weeks
Outcomes Tumour response
Clinical benefit response
PFS
OS
Notes Study supported by Astra Zeneca Ltd
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient details published - “Patientswere then ran-
domised to receive either ZD9331 or gemcitabine and
were stratified by centre...”
Allocation concealment (selection bias) Unclear risk Insufficient details published - “Patientswere then ran-
domised to receive either ZD9331 or gemcitabine and
were stratified by centre...”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
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Smith 2003 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Low risk for primary endpoint (OS)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat population included in survival
analysis
Selective reporting (reporting bias) Low risk All outcomes described in the methods were reported
in the results
Other bias Low risk No indication of other bias
Stathopoulos 2006
Methods Randomised phase III trial
Participants Study was conducted in Greece. 130 participants with locally advanced/metastatic pan-
creatic adenocarcinoma and no prior therapy. 70 received gemcitabine. 60 received gem-
citabine + irinotecan. The median age of participants was 64 years
Interventions Gemcitabine: 900 mg/m², 3/4 weeks
Gemcitabine + irinotecan: gemcitabine 900 mg/m² days 1 and 8, irinotecan 300 mg/m²
day 8, every 3 weeks
Outcomes Overall survival
Response rate
Progression-free survival
Toxicity
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were centrally randomised by computer at a one-
to-one ratio to receive
either monotherapy (arm G) with gemcitabine”
Allocation concealment (selection bias) Low risk “Patients were centrally randomised by computer at a one-
to-one ratio to receive
either monotherapy (arm G) with gemcitabine”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
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Stathopoulos 2006 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Low risk for primary endpoint (OS)
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants analysed for primary outcome
Selective reporting (reporting bias) Low risk All outcomes described in the methods were reported in
the results
Other bias Low risk No indication of other bias
Takada 1998
Methods Randomised study
Participants Study was conducted in Japan. 83 participants with unresectable pancreatic adenocar-
cinoma or biliary tract carcinoma, aged < 75 years. Of the participants with pancreatic
cancer, 28 received 5-fluorouracil (5FU), doxorubicin and mitomycin C (MMC), and
24 received palliative surgery. The median age in the chemotherapy arm was 62.8 years
and was 61.5 years in the palliative surgery arm
Interventions 5FU 200 mg/m²
Doxorubicin 15 mg/m²
MMC 5 mg/m² given weekly × 4, then 1 week break. 2 cycles given
Outcomes Overall survival
Response rates
Performance status
Adverse events
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk “Patients were assigned at random to the therapy group or the
control group using the envelope method in each facility...”
Allocation concealment (selection bias) Low risk “Registration procedures were conducted by telephoning the
Study Group Office when the envelope was opened”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
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Takada 1998 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Low risk for primary endpoint (OS)
Incomplete outcome data (attrition bias)
All outcomes
Low risk All enrolled participants included in survival analysis
Selective reporting (reporting bias) Low risk All outcomes described in the methods were reported in the
results
Other bias Low risk No indications of other bias
Tempero 2003
Methods Randomised phase II trial
Participants Studywas conducted inNorth America. 92 participants with locally advanced/metastatic
pancreatic ductal adenocarcinoma. 49 received dose-intense gemcitabine. 43 received
fixed dose rate infusion gemcitabine (FDR). The median age of participants was 62 years
Interventions Dose-intense gemcitabine: 2200 mg/m² IV over 30 min given days 1, 8, 15 every 28
days
FDR: 1500 mg/m² given at 10 mg/m²/min given days 1, 8, 15 every 28 days
Outcomes Time to treatment failure
Time to progression
Median survival
Response rate
Toxicity
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient details published - “Patients were randomly as-
signed to the following two treatment arms”
Allocation concealment (selection bias) Unclear risk Insufficient details published
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Low risk for primary endpoint (OS)
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Tempero 2003 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants analysed for the primary endpoint
Selective reporting (reporting bias) Low risk All outcomes described in the methods were reported in
the results
Other bias Low risk No indications of other bias
Topham 1991
Methods Randomised trial
Participants Study was conducted in the UK. 62 participants with locally advanced or metastatic pan-
creatic adenocarcinoma. 32 were given epirubicin alone, 30 were given 5FU + epirubicin
+ mitomycin C (FEM). No details on the median ages of participants was published
Interventions Epirubicin: 100 mg IV every 4 weeks
FEM: 5FU 1g IV days 1 and 28, epirubicin 600 mg IV days 1 + 8, mitomycin C 10 mg
day 1 every 8 weeks
Outcomes Not stated
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient details published
Allocation concealment (selection bias) Unclear risk Insufficient details published
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Insufficient details published. Unclear what the primary end-
point was
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat population included in survival analysis
Selective reporting (reporting bias) Unclear risk Endpoints not clearly stated in the methods.
Other bias Low risk No indication of other bias
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Ueno 2013
Methods Randomised phase III trial
Participants Study was conducted in Japan. 832 participants with locally advanced/metastatic pan-
creatic ductal adenocarcinoma, ECOG 0-1. 277 received gemcitabine. 280 received S1.
275 received gemcitabine + S1. Half the patients were under 65 years old and half were
65 years old or more
Interventions Gemcitabine: 1000 mg/m² 3/4 weeks
S1: orally, twice daily. Body surface area (BSA) < 1.25 m², 80 mg/day; BSA 1.25 m² to
1.5 m², 100 mg/day; BSA > 1.5 m², 120 mg/day. Days 1-28, every 42 days
Gemcitabine + S1: gemcitabine 1000 mg/m² days 1 and 8, S1 (dosing as above), days
1-14 every 21 days
Outcomes Overall survival
Progression-free survival
Overall response rate
Safety
Quality of life
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Random assignment was performed centrally with strat-
ification by extent of disease (locally advanced disease v
metastatic disease) and institution using the minimization
method”
Allocation concealment (selection bias) Low risk “Random assignment was performed centrally with strat-
ification by extent of disease (locally advanced disease v
metastatic disease) and institution using the minimization
method”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Low risk for primary endpoint (OS)
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants were included in the survival analysis
Selective reporting (reporting bias) Low risk All outcomes described in the methods were reported in
the results
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Ueno 2013 (Continued)
Other bias Low risk No indication of other bias
Ueno 2013 - EPA study
Methods Randomised phase II trial
Participants Study was conducted in Japan. 66 participants with advanced pancreatic adenocarci-
noma. 23 received gemcitabine. 43 received gemcitabine + EPA enriched oral supple-
ment. Median ages of participants were not published
Interventions Gemcitabine: 1000 mg/m² 3/4 weeks
Gemcitabine + EPA: gemcitabine as above. EPA 1 tablet orally, daily continuous
Outcomes 1-year survival
Notes Abstract only
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient details published
Allocation concealment (selection bias) Unclear risk Insufficient details published
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient details published
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient details published
Selective reporting (reporting bias) Unclear risk Insufficient details published
Other bias Low risk No indication of other bias
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Viret 2004
Methods Randomised phase II trial
Participants Study was conducted in France. 83 participants with stage III/IV pancreatic ductal
adenocarcinoma. 41 received gemcitabine. 42 received gemcitabine + cisplatin. Median
age was 63 years and 61.5 years in the gemcitabine alone and the gemcitabine + cisplatin
arms respectively
Interventions Gemcitabine 1000 mg/m² 7/8 weeks then 3/4 weeks
Gemcitabine + cisplatin: gemcitabine 1000 mg/m² weekly × 3, cisplatin 75 mg/m² day
15 every 4 weeks
Outcomes Time to treatment failure
Toxicity
Overall survival
Reponse rate
Quality of life
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient details published
Allocation concealment (selection bias) Unclear risk Insufficient details published
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non blinded study
Blinding of outcome assessment (detection
bias)
All outcomes
High risk High risk for primary endpoint (time to treatment failure)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient details published
Selective reporting (reporting bias) Low risk All outcomes described in the methods were reported in
the results
Other bias Unclear risk Insufficient details published
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Von Hoff 2013
Methods Randomised phase III trial
Participants This was an international study. 861 participants with metastatic pancreatic ductal ade-
nocarcinoma with measurable disease and no prior therapy. 43 received gemcitabine.
431 received gemcitabine + nab-paclitaxel. The median age of participants was 63 years
Interventions Gemcitabine: 1000 mg/m² 7/8 weeks then 3/4 weeks
Gemcitabine + nab-paclitaxel: nab-paclitaxel 125 mg/m² followed by gemcitabine 1000
mg/m² days 1, 8, 15 every 4 weeks
Outcomes Overall survival
Progression-free survival
Response rate
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Likely to be low, but insufficient details published- “In this
international, multicenter, open-label, randomized, phase
3 study, we randomly assigned eligible patients, in a 1:1
ratio”
Allocation concealment (selection bias) Unclear risk Likely to be low, but insufficient details published - “In this
international, multicenter, open-label, randomized, phase
3 study, we randomly assigned eligible patients, in a 1:1
ratio”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Low risk for primary endpoint (OS)
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants included in the survival analysis
Selective reporting (reporting bias) Low risk All outcomes described in the methods were reported in
the results
Other bias Low risk No indication of other bias
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Wang 2002
Methods Randomised phase III trial
Participants 42 participants with measurable or evaluable stage III/IV pancreatic cancer. 20 received
gemcitabine. 22 participants with gemcitabine + cisplatin
Interventions Gemcitabine 1000 mg/m² 7/8 weeks then 3/4 weeks
Gemcitabine + cisplatin: gemcitabine 1000 mg/m² 3/4 weeks + cisplatin 60 mg/m² day
15 every 3 every 4 weeks
Outcomes Clinical benefit
Duration of clinical benefit
Duration of response
Time to progression
Survival
Toxicity
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient details published
Allocation concealment (selection bias) Unclear risk Insufficient details published
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient details published
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient details published
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient details published
Selective reporting (reporting bias) Unclear risk Insufficient details published
Other bias Unclear risk Insufficient details published
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Xinopoulos 2008
Methods Randomised study
Participants Study was conducted in Greece. 49 participants with locally advanced PC with normal
liver function tests after biliary stent insertion. 33 received no further treatment after
stent insertion, 16 received gemcitabine. Median age of participants not published
Interventions Gemcitabine 1000 mg/m² weekly × 3, then 1 week off
Outcomes Overall survival
Quality of life
Requirement for 2nd stent insertion
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients’ allocation into the 2 arms was based on a sequence of
random binary numbers (i.e.111100111010...) that was devel-
oped in a computer based program”
Allocation concealment (selection bias) Low risk “Patients’ allocation into the 2 arms was based on a sequence of
random binary numbers (i.e.111100111010...) that was devel-
oped in a computer based program”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Low risk for primary endpoint (OS)
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants included in the survival analysis
Selective reporting (reporting bias) Low risk All outcomes described in the methods were reported in the
results
Other bias Low risk No indications of other bias
5FU: 5-fluorouracil; IV: intravenous; OS: overall survival; PFS: progression-free survival: QoL: quality of life.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abdel Wahab 1999 May include participants who did not have histological confirmation of their tumour. An attempt to
contact authors was made
Aigner 1998 Participants with locally advanced pancreatic cancer (addressed in another Cochrane Review)
Alberts 2005 Biological agent (addressed in another Cochrane Review)
Andersen 1981 Not all participants had advanced pancreatic cancer.
Ardalan 1988 Survival was not an endpoint.
Astsaturov 2011 Second.line treatment (addressed in another Cochrane Review)
Baker 1976 The survival data of the subgroup of participants with pancreatic cancer are not published separately
Benavides 2014 Biological agent (addressed in another Cochrane Review)
Benson 2014 Biological agent (addressed in another Cochrane Review)
Benson 2017 Biological agent - addressed in another review
Berglund 2010 Cross-over study.
Bramhall 2001 Biological agent (addressed in another Cochrane Review)
Bramhall 2002 Biological agent (addressed in another Cochrane Review)
Buanes 2009 Immunotherapy (addressed in another Cochrane Review)
Bukowski 1993 Non-randomised study
Burtness 2016 Biological agent (addressed in another Cochrane Review)
Cantore 2004 Second-line treatment (addressed in another Cochrane Review)
Cascinu 2008 Biological agent (addressed in another Cochrane Review)
Cascinu 2013 Biological agent (addressed in another Cochrane Review)
Catenacci 2013 Biological agent (addressed in another Cochrane Review)
Chai 2013 Immunotherapy (addressed in another Cochrane Review)
Chauffert 2008 Participants with locally advanced pancreatic cancer (addressed in another Cochrane Review)
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(Continued)
Chen 2006 Biological agent (addressed in another Cochrane Review)
Chung 2004 Participants with locally advanced pancreatic cancer (addressed in another Cochrane Review)
Chung 2015 Second-line treatment (addressed in another Cochrane Review)
Ciuleanu 2009 Second-line treatment (addressed in another Cochrane Review)
Cohen 2005 Participants with locally advanced pancreatic cancer (addressed in another Cochrane Review)
Cohen 2010 Insufficient data published
Dahan 2010 Cross-over study
Dalgleish 2015 Immunotherapy (addressed in another Cochrane Review)
Deplanque 2015 Biological agent (addressed in another Cochrane Review)
Ducreux 2002 Contains ampullary cancers
Duffy 2015 Second-line study - addressed in another review (ongoing study)
El-Khoueiry 2012 Biological agent (addressed in another Cochrane Review)
Evans 2014 Participants with locally advanced pancreatic cancer (addressed in another Cochrane Review)
Friess 2006 Biological agent (addressed in another Cochrane Review)
Fuchs 2015 Biological agent (addressed in another Cochrane Review)
Fukutomi 2015 Participants with locally advanced pancreatic cancer (addressed in another Cochrane Review)
Gill 2014 Second-line treatment (addressed in another Cochrane Review)
Gilliam 2012 Immunotherapy (addressed in another Cochrane Review)
GISTG 1985 (radiotherapy) Locally advanced study (addressed in another Cochrane Review)
GITSG 1979 Preliminary results only. Included acinar and undifferentiated pathologies
GITSG 1985 Insufficient data published
GITSG 1988 Participants with acinar pathology included
Gong 2007 Non-randomised study
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(Continued)
Gonçalves 2012 Biological agent (addressed in another Cochrane Review)
Haas 2015 Biological agent - addressed in another review (ongoing study)
Hammel 2013 Participants with locally advanced pancreatic cancer (addressed in another Cochrane Review)
Han 2006 Participants with locally advanced pancreatic cancer (addressed in another Cochrane Review)
Hazel 1981 Participants with locally advanced pancreatic cancer (addressed in another Cochrane Review)
Heinemann 2013 Biological agent (addressed in another Cochrane Review)
Heinemann 2013 (GUT) Cross-over study
Herman 2013 Participants with locally advanced pancreatic cancer (addressed in another Cochrane Review)
Hingorani 2015 Biological agent - addressed in another review (ongoing study)
Horton 1981 Cross-over study
Hurwitz 2015 Second-line treatment (addressed in another Cochrane Review)
Hurwitz 2015 (JANUS 1) Biological agent - addressed in another review (ongoing study)
Infante 2013 Biological agent (addressed in another Cochrane Review)
Ioka 2009 Participants with locally advanced pancreatic cancer (addressed in another Cochrane Review)
Ioka 2013 Second-line treatment (addressed in another Cochrane Review)
Jacobs 2004 Second-line treatment (addressed in another Cochrane Review)
Javle 2011 Cross-over study
Johnson 2001 Not all participants had a histological diagnosis
Kim 2011 Insufficient data published
Kindler 2008 Biological agent (addressed in another Cochrane Review)
Kindler 2010 Biological agent (addressed in another Cochrane Review)
Kindler 2011 Biological agent (addressed in another Cochrane Review)
Kindler 2012 Biological agent (addressed in another Cochrane Review)
Kindler 2015 Biological agent - addressed in another review
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Klaassen 1985 Participants with locally advanced pancreatic cancer (addressed in another Cochrane Review)
Ko 2012 Biological agent (addressed in another Cochrane Review)
Ko 2016 Biological agent - addressed in another review
Lasalvia-Prisco 2012 Immunotherapy (addressed in another Cochrane Review)
Le (Ipilimumab) 2013 Second-line treatment (addressed in another Cochrane Review)
Le 2013 Immunotherapy (addressed in another Cochrane Review)
Le 2015 Immunotherapy agent - addressed in another review
Li 2003 Participants with locally advanced pancreatic cancer (addressed in another Cochrane Review)
Li 2016 Locally advanced study (address in another Cochrane Review)
Linstadt 1988 Participants with locally advanced pancreatic cancer (addressed in another Cochrane Review)
Loehrer 2011 Participants with locally advanced pancreatic cancer (addressed in another Cochrane Review)
Lokich 1979 Included participants with acinar pathology
Lygidakis 1995 Not all participants had advanced pancreatic cancer
Mallinson 1980 Not all participants had histologically confirmed pancreatic ductal adenocarcinoma (PDAC)
Meyer 2008 Survival was not an endpoint
Middleton 2014 Immunotherapy (addressed in another Cochrane Review)
Mitry 2006 Non-randomised study
Mizuno 2013 May include adenosquamous participants. An attempt to contact authors was made
Modiano 2012 Biological agent (addressed in another Cochrane Review)
Moertel 1981 Participants with acinar and undifferentiated pathology were included
Moore 2003 Biological agent (addressed in another Cochrane Review)
Moore 2007 Biological agent (addressed in another Cochrane Review)
Mukherjee 2013 Participants with locally advanced pancreatic cancer (addressed in another Cochrane Review)
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Nakai 2012 Not all participants had histologically confirmed PDAC
Nio 2010 Retrospective study
O’Neil 2015 Biological agent (addressed in another Cochrane Review)
O’Reilly 2013 Biological agent - addressed in another review (ongoing study)
O’Reilly 2015 Second-line study - addressed in another review (ongoing study)
Oberic 2011 Insufficient data published
Oster 1986 Participants with acinar pathology were included
Palmer 1994 Not all participants had a histologically confirmed PDAC
Pandya 2013 Biological agent (addressed in another Cochrane Review)
Pelzer 2011 Second-line treatment (addressed in another Cochrane Review)
Philip 2010 Biological agent (addressed in another Cochrane Review)
Philip 2014 Biological agent (addressed in another Cochrane Review)
Propper 2014 Second-line treatment (addressed in another Cochrane Review)
Queisser 1979 Insufficient information published
Ramanathan 2011 Insufficient data published
Reni 2009 Retrospective analysis
Reni 2013 Second-line treatment (addressed in another Cochrane Review)
Richards 2011 Biological agent (addressed in another Cochrane Review)
Richly 2013 Biological agent (addressed in another Cochrane Review)
Riess 2010 Biological agent (addressed in another Cochrane Review)
Rougier 2013 Biological agent (addressed in another Cochrane Review)
Ryan 2013 Biological agent (addressed in another Cochrane Review)
Saif 2009 Biological agent (addressed in another Cochrane Review)
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Sakata 1992 Insufficient information published - pancreas cancer subgroup not reported separately
Schein 1978 Participants with acinar and undifferentiated pathology were included
Schmitz-Winnenthal 2013 Overall survival not an endpoint
Senzer 2006 Insufficient data published
Shapiro 2005 Insufficient data published
Shinchi 2002 Participants with locally advanced pancreatic cancer (addressed in another Cochrane Review)
Shinchi 2014 Participants with locally advanced pancreatic cancer (addressed in another Cochrane Review)
Spano 2008 Biological agent (addressed in another Cochrane Review)
Strumberg 2013 Biological agent (addressed in another Cochrane Review)
Sudo 2014 Included adenosquamous pathology
Sultana 2009 Insufficient data published
Sun 2011 Insufficient data published
Sunamura 2004 Participants with locally advanced pancreatic cancer (addressed in another Cochrane Review)
Tagliaferri 2013 Insufficient data published
Takada 1994 Includes participants with biliary tract cancer. Subgroup analysis of pancreatic cancer participants not
available
Topham 1993 Preliminary results only
Trouilloud 2012 Insufficient data published
Tuinmann 2008 Interim analysis only. Full results not published
Ulrich-Pur 2003 Second-line treatment (addressed in another Cochrane Review)
Van Cutsem 2004 Biological agent (addressed in another Cochrane Review)
Van Cutsem 2009 Biological agent (addressed in another Cochrane Review)
Van Cutsem 2013 Insufficient data published
Van Cutsem 2014 Biological agent (addressed in another Cochrane Review)
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Van Cutsem 2015 Biological agent (addressed in another Cochrane Review)
Von Hoff 1990 Immunotherapy (addressed in another Cochrane Review)
Von Hoff 2014 Second-line treatment (addressed in another Cochrane Review)
Voorthuizen 2006 Biological agent (addressed in another Cochrane Review)
Wagener 2002 Immunotherapy (addressed in another Cochrane Review)
Wang 2000 All participants had locally advanced PC (addressed in another Cochrane Review)
Wang 2004 All participants had locally advanced PC (addressed in another Cochrane Review)
Wang 2015 Biological agent (addressed in another Cochrane Review)
Wiedenmann 2008 Biological agent (addressed in another Cochrane Review)
Wilkowski 2009 Participants with locally advanced pancreatic cancer (addressed in another Cochrane Review)
Wolpin 2013 Biological agent (addressed in another Cochrane Review)
Wright 2006 Immunotherapy (addressed in another Cochrane Review)
Yamaue 2015 Biological agent (addressed in another Cochrane Review)
Yongxiang 2001 Non-randomised study
Yoo 2009 Second-line treatment (addressed in another Cochrane Review)
Zemskov 2000 Non-randomised study
Zhang 2007 All participants had locally advanced PC (addressed in another Cochrane Review)
PC: pancreatic cancer; PDAC: pancreatic ductal adenocarcinoma.
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D A T A A N D A N A L Y S E S
Comparison 1. Anti-cancer therapy versus best supportive care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall survival 4 298 Hazard Ratio (Random, 95% CI) 1.08 [0.88, 1.33]
Comparison 2. Various types of chemotherapy versus gemcitabine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall survival 8 Hazard Ratio (Random, 95% CI) Subtotals only
1.1 5-FU 1 126 Hazard Ratio (Random, 95% CI) 1.69 [1.26, 2.27]
1.2 FOLFIRINOX 2 652 Hazard Ratio (Random, 95% CI) 0.51 [0.43, 0.60]
1.3 CO-101 1 367 Hazard Ratio (Random, 95% CI) 1.07 [0.86, 1.34]
1.4 ZD9331 1 55 Hazard Ratio (Random, 95% CI) 0.86 [0.42, 1.76]
1.5 Fixed dose rate
gemcitabine
2 644 Hazard Ratio (Random, 95% CI) 0.79 [0.66, 0.94]
1.6 Exatecan 1 339 Hazard Ratio (Random, 95% CI) 1.27 [0.96, 1.68]
2 Progression-free survival 5 Hazard Ratio (Random, 95% CI) Subtotals only
2.1 5-FU 1 126 Hazard Ratio (Random, 95% CI) 1.47 [1.12, 1.92]
2.2 FOLFIRINOX 2 652 Hazard Ratio (Random, 95% CI) 0.46 [0.38, 0.57]
2.3 ZD9331 1 55 Hazard Ratio (Random, 95% CI) 0.78 [0.46, 1.32]
2.4 Fixed dose rate
gemcitabine
1 552 Hazard Ratio (Random, 95% CI) 0.88 [0.77, 1.01]
3 Degradation of QoL at 6 months 2 Hazard Ratio (Random, 95% CI) 0.46 [0.35, 0.61]
4 Response rates 7 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 5-FU 1 126 Risk Ratio (M-H, Random, 95% CI) 0.14 [0.01, 2.71]
4.2 FOLFIRINOX 1 342 Risk Ratio (M-H, Random, 95% CI) 3.38 [2.01, 5.65]
4.3 CO-101 1 358 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.43, 1.04]
4.4 ZD9331 1 55 Risk Ratio (M-H, Random, 95% CI) 0.42 [0.04, 4.33]
4.5 Fixed dose rate
gemcitabine
2 644 Risk Ratio (M-H, Random, 95% CI) 1.59 [0.91, 2.79]
4.6 Exatecan (DX-8951f ) 1 276 Risk Ratio (M-H, Random, 95% CI) 0.10 [0.01, 0.78]
5 Grade 3/4 anaemia 7 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 5-FU 1 126 Risk Ratio (M-H, Random, 95% CI) 0.08 [0.00, 1.34]
5.2 FOLFIRINOX 1 342 Risk Ratio (M-H, Random, 95% CI) 1.3 [0.59, 2.88]
5.3 CO-101 1 360 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.59, 1.73]
5.4 ZD9331 1 55 Risk Ratio (M-H, Random, 95% CI) 0.28 [0.01, 6.58]
5.5 Fixed dose rate
gemcitabine
2 644 Risk Ratio (M-H, Random, 95% CI) 1.79 [1.22, 2.63]
5.6 Exatecan 1 330 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.43, 2.34]
6 Grade 3/4 neutropenia 7 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 5-FU 1 126 Risk Ratio (M-H, Random, 95% CI) 0.19 [0.06, 0.61]
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6.2 FOLFIRINOX 1 342 Risk Ratio (M-H, Random, 95% CI) 2.14 [1.52, 3.01]
6.3 CO-101 1 360 Risk Ratio (M-H, Random, 95% CI) 1.31 [0.83, 2.07]
6.4 ZD9331 1 55 Risk Ratio (M-H, Random, 95% CI) 4.17 [0.52, 33.37]
6.5 Fixed dose rate
gemcitabine
2 644 Risk Ratio (M-H, Random, 95% CI) 1.85 [1.53, 2.23]
6.6 Exatecan 1 330 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.64, 1.55]
7 Grade 3/4 thrombocytopenia 7 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 5-FU 1 126 Risk Ratio (M-H, Random, 95% CI) 0.17 [0.02, 1.34]
7.2 FOLFIRINOX 1 342 Risk Ratio (M-H, Random, 95% CI) 2.5 [0.99, 6.29]
7.3 CO-101 1 360 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.51, 2.34]
7.4 ZD9331 1 55 Risk Ratio (M-H, Random, 95% CI) 3.33 [0.40, 27.94]
7.5 Fixed dose rate
gemcitabine
2 644 Risk Ratio (M-H, Random, 95% CI) 2.77 [1.99, 3.86]
7.6 Exatecan 1 330 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.37, 1.54]
8 Grade 3/4 nausea 5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
8.1 5-FU 1 126 Risk Ratio (M-H, Random, 95% CI) 0.38 [0.10, 1.35]
8.2 ZD9331 1 55 Risk Ratio (M-H, Random, 95% CI) 2.52 [0.11, 59.18]
8.3 Fixed dose rate
gemcitabine
2 644 Risk Ratio (M-H, Random, 95% CI) 1.52 [0.94, 2.46]
8.4 Exatecan 1 330 Risk Ratio (M-H, Random, 95% CI) 1.75 [0.52, 5.86]
9 Grade 3/4 diarrhoea 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
9.1 5-FU 1 126 Risk Ratio (M-H, Random, 95% CI) 3.0 [0.32, 28.07]
9.2 ZD9331 1 55 Risk Ratio (M-H, Random, 95% CI) 0.28 [0.01, 6.58]
9.3 Fixed dose rate
gemcitabine
2 644 Risk Ratio (M-H, Random, 95% CI) 0.44 [0.16, 1.23]
Comparison 3. Gemcitabine combinations versus gemcitabine alone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall survival 26 Hazard Ratio (Random, 95% CI) Subtotals only
1.1 Gemcitabine plus
platinum agent
6 1140 Hazard Ratio (Random, 95% CI) 0.94 [0.81, 1.08]
1.2 Gemcitabine plus
fluoropyrimidine
10 2718 Hazard Ratio (Random, 95% CI) 0.88 [0.81, 0.95]
1.3 Gemcitabine plus
topoisomerase inhibitor
3 839 Hazard Ratio (Random, 95% CI) 1.01 [0.87, 1.16]
1.4 Gemcitabine plus taxane 1 861 Hazard Ratio (Random, 95% CI) 0.72 [0.62, 0.84]
1.5 Gemcitabine plus other
combinations of chemotherapy
2 166 Hazard Ratio (Random, 95% CI) 0.55 [0.39, 0.79]
1.6 Gemcitabine plus other
agent(s)
4 767 Hazard Ratio (Random, 95% CI) 0.79 [0.56, 1.10]
2 Progression-free survival 18 Hazard Ratio (Random, 95% CI) Subtotals only
2.1 Gemcitabine plus
platinum agent
4 1015 Hazard Ratio (Random, 95% CI) 0.80 [0.68, 0.95]
2.2 Gemcitabine plus
fluoropyrimidine
8 2608 Hazard Ratio (Random, 95% CI) 0.79 [0.72, 0.87]
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2.3 Gemcitabine plus
topoisomerase inhibitor
2 709 Hazard Ratio (Random, 95% CI) 0.91 [0.78, 1.07]
2.4 Gemcitabine plus taxane 1 861 Hazard Ratio (Random, 95% CI) 0.69 [0.58, 0.82]
2.5 Gemcitabine plus other
combinations of chemotherapy
2 166 Hazard Ratio (Random, 95% CI) 0.43 [0.30, 0.62]
2.6 Gemcitabine plus other
agent(s)
1 76 Hazard Ratio (Random, 95% CI) 1.05 [0.68, 1.62]
3 Response rates 24 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Gemcitabine plus
platinum agent
7 1186 Risk Ratio (M-H, Random, 95% CI) 1.48 [1.11, 1.98]
3.2 Gemcitabine plus
fluoropyrimidine
9 2176 Risk Ratio (M-H, Random, 95% CI) 1.78 [1.29, 2.47]
3.3 Gemcitabine plus
topoisomerase inhibitor
3 729 Risk Ratio (M-H, Random, 95% CI) 1.50 [0.92, 2.46]
3.4 Gemcitabine plus taxane 1 861 Risk Ratio (M-H, Random, 95% CI) 3.29 [2.24, 4.84]
3.5 Gemcitabane plus other
combinations of chemotherapy
1 67 Risk Ratio (M-H, Random, 95% CI) 1.94 [0.83, 4.56]
3.6 Gemcitabine plus other
agent(s)
3 691 Risk Ratio (M-H, Random, 95% CI) 3.66 [1.04, 12.82]
4 Grade 3/4 anaemia 23 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Gemcitabine plus
platinum agent
7 1156 Risk Ratio (M-H, Random, 95% CI) 1.41 [0.87, 2.31]
4.2 Gemcitabine plus
fluoropyrimidine
8 2158 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.84, 1.45]
4.3 Gemcitabine plus
topoisomerase inhibitor
3 797 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.72, 1.66]
4.4 Gemcitabine plus taxane 1 793 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.73, 1.52]
4.5 Gemcitabine plus other
combinations of chemotherapy
1 67 Risk Ratio (M-H, Random, 95% CI) 1.94 [0.53, 7.13]
4.6 Gemcitabine plus other
agent(s)
3 688 Risk Ratio (M-H, Random, 95% CI) 3.58 [1.93, 6.62]
5 Grade 3/4 neutropenia 23 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Gemcitabine plus
platinum agent
6 961 Risk Ratio (M-H, Random, 95% CI) 1.34 [0.90, 1.97]
5.2 Gemcitabine plus
fluoropyrimidine
9 2177 Risk Ratio (M-H, Random, 95% CI) 1.53 [1.34, 1.74]
5.3 Gemcitabine plus
topoisomerase inhibitor
3 797 Risk Ratio (M-H, Random, 95% CI) 1.54 [1.04, 2.30]
5.4 Gemcitabine plus taxane 1 793 Risk Ratio (M-H, Random, 95% CI) 1.42 [1.16, 1.75]
5.5 Gemcitabine plus other
combinations of chemotherapy
1 67 Risk Ratio (M-H, Random, 95% CI) 1.94 [0.65, 5.83]
5.6 Gemcitabine plus other
agent(s)
3 688 Risk Ratio (M-H, Random, 95% CI) 2.02 [0.88, 4.66]
6 Grade 3/4 thrombocytopenia 23 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 Gemcitabine plus
platinum agent
6 1110 Risk Ratio (M-H, Random, 95% CI) 1.96 [1.00, 3.84]
6.2 Gemcitabine plus
fluoropyrimidine
9 2177 Risk Ratio (M-H, Random, 95% CI) 1.48 [1.00, 2.18]
6.3 Gemcitabine plus
topoisomerase inhibitor
3 797 Risk Ratio (M-H, Random, 95% CI) 2.28 [0.97, 5.36]
6.4 Gemcitabine plus taxane 1 793 Risk Ratio (M-H, Random, 95% CI) 1.38 [0.93, 2.07]
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6.5 Gemcitabine plus other
combinations of chemotherapy
1 67 Risk Ratio (M-H, Random, 95% CI) 1.94 [0.74, 5.07]
6.6 Gemcitabine plus other
agent(s)
3 688 Risk Ratio (M-H, Random, 95% CI) 1.41 [0.45, 4.39]
7 Grade 3/4 nausea 21 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 Gemcitabine plus
platinum agent
6 1110 Risk Ratio (M-H, Random, 95% CI) 2.28 [1.40, 3.71]
7.2 Gemcitabine plus
fluoropyrimidine
7 2075 Risk Ratio (M-H, Random, 95% CI) 1.27 [0.87, 1.84]
7.3 Gemcitabine plus
topoisomerase inhibitor
3 797 Risk Ratio (M-H, Random, 95% CI) 1.55 [0.94, 2.55]
7.4 Gemcitabine plus other
combinations of chemotherapy
1 67 Risk Ratio (M-H, Random, 95% CI) 10.69 [0.61, 185.91]
7.5 Gemcitabine plus other
agent(s)
4 748 Risk Ratio (M-H, Random, 95% CI) 1.25 [0.48, 3.26]
8 Grade 3/4 diarrhoea 17 Risk Ratio (M-H, Random, 95% CI) Subtotals only
8.1 Gemcitabine plus
platinum agent
6 1110 Risk Ratio (M-H, Random, 95% CI) 1.48 [0.62, 3.53]
8.2 Gemcitabine plus
fluoropyrimidine
8 2087 Risk Ratio (M-H, Random, 95% CI) 2.16 [1.34, 3.47]
8.3 Gemcitabine plus
topoisomerase inhibitor
3 797 Risk Ratio (M-H, Random, 95% CI) 3.47 [0.74, 16.33]
9 Grade 3/4 neuropathy 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
9.1 Gemcitabine plus taxane 1 793 Risk Ratio (M-H, Random, 95% CI) 22.35 [7.10, 70.40]
10 Grade 3/4 fatigue 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
10.1 Gemcitabine plus taxane 1 793 Risk Ratio (M-H, Random, 95% CI) 2.48 [1.63, 3.79]
Comparison 4. Fluoropyrimidine combinations versus fluoropyrimidine alone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall survival 4 491 Hazard Ratio (Random, 95% CI) 0.84 [0.61, 1.15]
2 Progression-free survival 2 255 Hazard Ratio (Random, 95% CI) 0.52 [0.19, 1.38]
3 Response rates 4 410 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.52, 2.68]
4 Grade 3/4 anaemia 2 255 Risk Ratio (M-H, Random, 95% CI) 0.48 [0.06, 3.62]
5 Grade 3/4 neutropenia 2 255 Risk Ratio (M-H, Random, 95% CI) 5.70 [0.73, 44.46]
6 Grade 3/4 thrombocytopenia 2 255 Risk Ratio (M-H, Random, 95% CI) 1.40 [0.34, 5.80]
7 Grade 3/4 fatigue 1 209 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.58, 1.43]
8 Grade 3/4 nausea 2 255 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.32, 3.53]
9 Grade 3/4 diarrhoea 2 255 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.31, 2.78]
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Analysis 1.1. Comparison 1 Anti-cancer therapy versus best supportive care, Outcome 1 Overall survival.
Review: Chemotherapy and radiotherapy for advanced pancreatic cancer
Comparison: 1 Anti-cancer therapy versus best supportive care
Outcome: 1 Overall survival
Study or subgroup Anti-cancer therapy Best supportive care log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Frey 1981 65 87 0.2311 (0.166) 39.3 % 1.26 [ 0.91, 1.74 ]
Huguier 2001 22 23 -0.0513 (0.2606) 15.9 % 0.95 [ 0.57, 1.58 ]
Takada 1998 28 24 -0.0834 (0.2443) 18.1 % 0.92 [ 0.57, 1.49 ]
Xinopoulos 2008 16 33 0.0488 (0.2018) 26.6 % 1.05 [ 0.71, 1.56 ]
Total (95% CI) 131 167 100.0 % 1.08 [ 0.88, 1.33 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.55, df = 3 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
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Analysis 2.1. Comparison 2 Various types of chemotherapy versus gemcitabine, Outcome 1 Overall survival.
Review: Chemotherapy and radiotherapy for advanced pancreatic cancer
Comparison: 2 Various types of chemotherapy versus gemcitabine
Outcome: 1 Overall survival
Study or subgroup Other Gemcitabine log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 5-FU
Burris 1997 63 63 0.5276 (0.1497) 100.0 % 1.69 [ 1.26, 2.27 ]
Subtotal (95% CI) 63 63 100.0 % 1.69 [ 1.26, 2.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.52 (P = 0.00042)
2 FOLFIRINOX
Conroy 2011 171 171 -0.5621 (0.1206) 36.3 % 0.57 [ 0.45, 0.72 ]
Singhal 2014 155 155 -0.734 (0.0804) 63.7 % 0.48 [ 0.41, 0.56 ]
Subtotal (95% CI) 326 326 100.0 % 0.51 [ 0.43, 0.60 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 1.41, df = 1 (P = 0.24); I2 =29%
Test for overall effect: Z = 8.12 (P < 0.00001)
3 CO-101
Poplin 2013 182 185 0.0695 (0.1148) 100.0 % 1.07 [ 0.86, 1.34 ]
Subtotal (95% CI) 182 185 100.0 % 1.07 [ 0.86, 1.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
4 ZD9331
Smith 2003 30 25 -0.1508 (0.3657) 100.0 % 0.86 [ 0.42, 1.76 ]
Subtotal (95% CI) 30 25 100.0 % 0.86 [ 0.42, 1.76 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
5 Fixed dose rate gemcitabine
Poplin 2009 277 275 -0.1863 (0.1093) 67.9 % 0.83 [ 0.67, 1.03 ]
Tempero 2003 43 49 -0.3425 (0.1589) 32.1 % 0.71 [ 0.52, 0.97 ]
Subtotal (95% CI) 320 324 100.0 % 0.79 [ 0.66, 0.94 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.66, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 2.63 (P = 0.0086)
6 Exatecan
Cheverton 2004 169 170 0.239 (0.1424) 100.0 % 1.27 [ 0.96, 1.68 ]
Subtotal (95% CI) 169 170 100.0 % 1.27 [ 0.96, 1.68 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.68 (P = 0.093)
Test for subgroup differences: Chi2 = 71.35, df = 5 (P = 0.00), I2 =93%
0.05 0.2 1 5 20
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Analysis 2.2. Comparison 2 Various types of chemotherapy versus gemcitabine, Outcome 2 Progression-
free survival.
Review: Chemotherapy and radiotherapy for advanced pancreatic cancer
Comparison: 2 Various types of chemotherapy versus gemcitabine
Outcome: 2 Progression-free survival
Study or subgroup Other Gemcitabine log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 5-FU
Burris 1997 63 63 0.3857 (0.1369) 100.0 % 1.47 [ 1.12, 1.92 ]
Subtotal (95% CI) 63 63 100.0 % 1.47 [ 1.12, 1.92 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.82 (P = 0.0048)
2 FOLFIRINOX
Conroy 2011 171 171 -0.755 (0.1221) 75.2 % 0.47 [ 0.37, 0.60 ]
Singhal 2014 155 155 -0.821 (0.2127) 24.8 % 0.44 [ 0.29, 0.67 ]
Subtotal (95% CI) 326 326 100.0 % 0.46 [ 0.38, 0.57 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 7.28 (P < 0.00001)
3 ZD9331
Smith 2003 30 25 -0.2485 (0.2694) 100.0 % 0.78 [ 0.46, 1.32 ]
Subtotal (95% CI) 30 25 100.0 % 0.78 [ 0.46, 1.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
4 Fixed dose rate gemcitabine
Poplin 2009 277 275 -0.1278 (0.0681) 100.0 % 0.88 [ 0.77, 1.01 ]
Subtotal (95% CI) 277 275 100.0 % 0.88 [ 0.77, 1.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.88 (P = 0.061)
Test for subgroup differences: Chi2 = 48.51, df = 3 (P = 0.00), I2 =94%
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Analysis 2.3. Comparison 2 Various types of chemotherapy versus gemcitabine, Outcome 3 Degradation of
QoL at 6 months.
Review: Chemotherapy and radiotherapy for advanced pancreatic cancer
Comparison: 2 Various types of chemotherapy versus gemcitabine
Outcome: 3 Degradation of QoL at 6 months
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Conroy 2011 -0.755 (0.2032) 51.8 % 0.47 [ 0.32, 0.70 ]
Singhal 2014 -0.7985 (0.2106) 48.2 % 0.45 [ 0.30, 0.68 ]
Total (95% CI) 100.0 % 0.46 [ 0.35, 0.61 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 5.31 (P < 0.00001)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
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Analysis 2.4. Comparison 2 Various types of chemotherapy versus gemcitabine, Outcome 4 Response rates.
Review: Chemotherapy and radiotherapy for advanced pancreatic cancer
Comparison: 2 Various types of chemotherapy versus gemcitabine
Outcome: 4 Response rates
Study or subgroup Other Gemcitabine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 5-FU
Burris 1997 0/63 3/63 100.0 % 0.14 [ 0.01, 2.71 ]
Subtotal (95% CI) 63 63 100.0 % 0.14 [ 0.01, 2.71 ]
Total events: 0 (Other), 3 (Gemcitabine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
2 FOLFIRINOX
Conroy 2011 54/171 16/171 100.0 % 3.38 [ 2.01, 5.65 ]
Subtotal (95% CI) 171 171 100.0 % 3.38 [ 2.01, 5.65 ]
Total events: 54 (Other), 16 (Gemcitabine)
Heterogeneity: not applicable
Test for overall effect: Z = 4.62 (P < 0.00001)
3 CO-101
Poplin 2013 27/182 39/176 100.0 % 0.67 [ 0.43, 1.04 ]
Subtotal (95% CI) 182 176 100.0 % 0.67 [ 0.43, 1.04 ]
Total events: 27 (Other), 39 (Gemcitabine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.77 (P = 0.077)
4 ZD9331
Smith 2003 1/30 2/25 100.0 % 0.42 [ 0.04, 4.33 ]
Subtotal (95% CI) 30 25 100.0 % 0.42 [ 0.04, 4.33 ]
Total events: 1 (Other), 2 (Gemcitabine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.46)
5 Fixed dose rate gemcitabine
Poplin 2009 29/277 17/275 94.4 % 1.69 [ 0.95, 3.01 ]
Tempero 2003 1/43 2/49 5.6 % 0.57 [ 0.05, 6.07 ]
Subtotal (95% CI) 320 324 100.0 % 1.59 [ 0.91, 2.79 ]
Total events: 30 (Other), 19 (Gemcitabine)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.77, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 1.63 (P = 0.10)
6 Exatecan (DX-8951f)
Cheverton 2004 1/137 10/139 100.0 % 0.10 [ 0.01, 0.78 ]
0.001 0.01 0.1 1 10 100 1000
Favours gemcitabine Favours other chemo
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(. . . Continued)
Study or subgroup Other Gemcitabine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 137 139 100.0 % 0.10 [ 0.01, 0.78 ]
Total events: 1 (Other), 10 (Gemcitabine)
Heterogeneity: not applicable
Test for overall effect: Z = 2.20 (P = 0.028)
Test for subgroup differences: Chi2 = 31.24, df = 5 (P = 0.00), I2 =84%
0.001 0.01 0.1 1 10 100 1000
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Analysis 2.5. Comparison 2 Various types of chemotherapy versus gemcitabine, Outcome 5 Grade 3/4
anaemia.
Review: Chemotherapy and radiotherapy for advanced pancreatic cancer
Comparison: 2 Various types of chemotherapy versus gemcitabine
Outcome: 5 Grade 3/4 anaemia
Study or subgroup Other chemotherapy Gemcitabine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 5-FU
Burris 1997 0/63 6/63 100.0 % 0.08 [ 0.00, 1.34 ]
Subtotal (95% CI) 63 63 100.0 % 0.08 [ 0.00, 1.34 ]
Total events: 0 (Other chemotherapy), 6 (Gemcitabine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.76 (P = 0.078)
2 FOLFIRINOX
Conroy 2011 13/171 10/171 100.0 % 1.30 [ 0.59, 2.88 ]
Subtotal (95% CI) 171 171 100.0 % 1.30 [ 0.59, 2.88 ]
Total events: 13 (Other chemotherapy), 10 (Gemcitabine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
3 CO-101
Poplin 2013 23/179 23/181 100.0 % 1.01 [ 0.59, 1.73 ]
0.001 0.01 0.1 1 10 100 1000
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Study or subgroup Other chemotherapy Gemcitabine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 179 181 100.0 % 1.01 [ 0.59, 1.73 ]
Total events: 23 (Other chemotherapy), 23 (Gemcitabine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
4 ZD9331
Smith 2003 0/30 1/25 100.0 % 0.28 [ 0.01, 6.58 ]
Subtotal (95% CI) 30 25 100.0 % 0.28 [ 0.01, 6.58 ]
Total events: 0 (Other chemotherapy), 1 (Gemcitabine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
5 Fixed dose rate gemcitabine
Poplin 2009 52/277 26/275 76.8 % 1.99 [ 1.28, 3.08 ]
Tempero 2003 10/43 9/49 23.2 % 1.27 [ 0.57, 2.82 ]
Subtotal (95% CI) 320 324 100.0 % 1.79 [ 1.22, 2.63 ]
Total events: 62 (Other chemotherapy), 35 (Gemcitabine)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.93, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 2.95 (P = 0.0031)
6 Exatecan
Cheverton 2004 10/165 10/165 100.0 % 1.00 [ 0.43, 2.34 ]
Subtotal (95% CI) 165 165 100.0 % 1.00 [ 0.43, 2.34 ]
Total events: 10 (Other chemotherapy), 10 (Gemcitabine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Chi2 = 8.46, df = 5 (P = 0.13), I2 =41%
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Analysis 2.6. Comparison 2 Various types of chemotherapy versus gemcitabine, Outcome 6 Grade 3/4
neutropenia.
Review: Chemotherapy and radiotherapy for advanced pancreatic cancer
Comparison: 2 Various types of chemotherapy versus gemcitabine
Outcome: 6 Grade 3/4 neutropenia
Study or subgroup Other Gemcitabine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 5-FU
Burris 1997 3/63 16/63 100.0 % 0.19 [ 0.06, 0.61 ]
Subtotal (95% CI) 63 63 100.0 % 0.19 [ 0.06, 0.61 ]
Total events: 3 (Other), 16 (Gemcitabine)
Heterogeneity: not applicable
Test for overall effect: Z = 2.77 (P = 0.0055)
2 FOLFIRINOX
Conroy 2011 75/171 35/171 100.0 % 2.14 [ 1.52, 3.01 ]
Subtotal (95% CI) 171 171 100.0 % 2.14 [ 1.52, 3.01 ]
Total events: 75 (Other), 35 (Gemcitabine)
Heterogeneity: not applicable
Test for overall effect: Z = 4.38 (P = 0.000012)
3 CO-101
Poplin 2013 35/179 27/181 100.0 % 1.31 [ 0.83, 2.07 ]
Subtotal (95% CI) 179 181 100.0 % 1.31 [ 0.83, 2.07 ]
Total events: 35 (Other), 27 (Gemcitabine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.16 (P = 0.25)
4 ZD9331
Smith 2003 5/30 1/25 100.0 % 4.17 [ 0.52, 33.37 ]
Subtotal (95% CI) 30 25 100.0 % 4.17 [ 0.52, 33.37 ]
Total events: 5 (Other), 1 (Gemcitabine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.34 (P = 0.18)
5 Fixed dose rate gemcitabine
Poplin 2009 162/277 87/275 88.6 % 1.85 [ 1.51, 2.26 ]
Tempero 2003 21/43 13/49 11.4 % 1.84 [ 1.05, 3.21 ]
Subtotal (95% CI) 320 324 100.0 % 1.85 [ 1.53, 2.23 ]
Total events: 183 (Other), 100 (Gemcitabine)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 6.39 (P < 0.00001)
6 Exatecan
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Study or subgroup Other Gemcitabine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Cheverton 2004 32/165 32/165 100.0 % 1.00 [ 0.64, 1.55 ]
Subtotal (95% CI) 165 165 100.0 % 1.00 [ 0.64, 1.55 ]
Total events: 32 (Other), 32 (Gemcitabine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Chi2 = 23.34, df = 5 (P = 0.00), I2 =79%
0.01 0.1 1 10 100
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Analysis 2.7. Comparison 2 Various types of chemotherapy versus gemcitabine, Outcome 7 Grade 3/4
thrombocytopenia.
Review: Chemotherapy and radiotherapy for advanced pancreatic cancer
Comparison: 2 Various types of chemotherapy versus gemcitabine
Outcome: 7 Grade 3/4 thrombocytopenia
Study or subgroup Other Gemcitabine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 5-FU
Burris 1997 1/63 6/63 100.0 % 0.17 [ 0.02, 1.34 ]
Subtotal (95% CI) 63 63 100.0 % 0.17 [ 0.02, 1.34 ]
Total events: 1 (Other), 6 (Gemcitabine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.68 (P = 0.093)
2 FOLFIRINOX
Conroy 2011 15/171 6/171 100.0 % 2.50 [ 0.99, 6.29 ]
Subtotal (95% CI) 171 171 100.0 % 2.50 [ 0.99, 6.29 ]
Total events: 15 (Other), 6 (Gemcitabine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.95 (P = 0.052)
3 CO-101
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Study or subgroup Other Gemcitabine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Poplin 2013 13/179 12/181 100.0 % 1.10 [ 0.51, 2.34 ]
Subtotal (95% CI) 179 181 100.0 % 1.10 [ 0.51, 2.34 ]
Total events: 13 (Other), 12 (Gemcitabine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
4 ZD9331
Smith 2003 4/30 1/25 100.0 % 3.33 [ 0.40, 27.94 ]
Subtotal (95% CI) 30 25 100.0 % 3.33 [ 0.40, 27.94 ]
Total events: 4 (Other), 1 (Gemcitabine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
5 Fixed dose rate gemcitabine
Poplin 2009 91/277 34/275 86.8 % 2.66 [ 1.86, 3.80 ]
Tempero 2003 16/43 5/49 13.2 % 3.65 [ 1.46, 9.12 ]
Subtotal (95% CI) 320 324 100.0 % 2.77 [ 1.99, 3.86 ]
Total events: 107 (Other), 39 (Gemcitabine)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.40, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 6.00 (P < 0.00001)
6 Exatecan
Cheverton 2004 12/165 16/165 100.0 % 0.75 [ 0.37, 1.54 ]
Subtotal (95% CI) 165 165 100.0 % 0.75 [ 0.37, 1.54 ]
Total events: 12 (Other), 16 (Gemcitabine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
Test for subgroup differences: Chi2 = 19.19, df = 5 (P = 0.00), I2 =74%
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Analysis 2.8. Comparison 2 Various types of chemotherapy versus gemcitabine, Outcome 8 Grade 3/4
nausea.
Review: Chemotherapy and radiotherapy for advanced pancreatic cancer
Comparison: 2 Various types of chemotherapy versus gemcitabine
Outcome: 8 Grade 3/4 nausea
Study or subgroup Other Gemcitabine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 5-FU
Burris 1997 3/63 8/63 100.0 % 0.38 [ 0.10, 1.35 ]
Subtotal (95% CI) 63 63 100.0 % 0.38 [ 0.10, 1.35 ]
Total events: 3 (Other), 8 (Gemcitabine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.50 (P = 0.13)
2 ZD9331
Smith 2003 1/30 0/25 100.0 % 2.52 [ 0.11, 59.18 ]
Subtotal (95% CI) 30 25 100.0 % 2.52 [ 0.11, 59.18 ]
Total events: 1 (Other), 0 (Gemcitabine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
3 Fixed dose rate gemcitabine
Poplin 2009 28/277 18/275 71.5 % 1.54 [ 0.87, 2.73 ]
Tempero 2003 9/43 7/49 28.5 % 1.47 [ 0.60, 3.60 ]
Subtotal (95% CI) 320 324 100.0 % 1.52 [ 0.94, 2.46 ]
Total events: 37 (Other), 25 (Gemcitabine)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 1.71 (P = 0.087)
4 Exatecan
Cheverton 2004 7/165 4/165 100.0 % 1.75 [ 0.52, 5.86 ]
Subtotal (95% CI) 165 165 100.0 % 1.75 [ 0.52, 5.86 ]
Total events: 7 (Other), 4 (Gemcitabine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Chi2 = 4.41, df = 3 (P = 0.22), I2 =32%
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Analysis 2.9. Comparison 2 Various types of chemotherapy versus gemcitabine, Outcome 9 Grade 3/4
diarrhoea.
Review: Chemotherapy and radiotherapy for advanced pancreatic cancer
Comparison: 2 Various types of chemotherapy versus gemcitabine
Outcome: 9 Grade 3/4 diarrhoea
Study or subgroup Other Gemcitabine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 5-FU
Burris 1997 3/63 1/63 100.0 % 3.00 [ 0.32, 28.07 ]
Subtotal (95% CI) 63 63 100.0 % 3.00 [ 0.32, 28.07 ]
Total events: 3 (Other), 1 (Gemcitabine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
2 ZD9331
Smith 2003 0/30 1/25 100.0 % 0.28 [ 0.01, 6.58 ]
Subtotal (95% CI) 30 25 100.0 % 0.28 [ 0.01, 6.58 ]
Total events: 0 (Other), 1 (Gemcitabine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
3 Fixed dose rate gemcitabine
Poplin 2009 3/277 8/275 61.0 % 0.37 [ 0.10, 1.39 ]
Tempero 2003 2/43 4/49 39.0 % 0.57 [ 0.11, 2.96 ]
Subtotal (95% CI) 320 324 100.0 % 0.44 [ 0.16, 1.23 ]
Total events: 5 (Other), 12 (Gemcitabine)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.16, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 1.57 (P = 0.12)
Test for subgroup differences: Chi2 = 2.56, df = 2 (P = 0.28), I2 =22%
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Analysis 3.1. Comparison 3 Gemcitabine combinations versus gemcitabine alone, Outcome 1 Overall
survival.
Review: Chemotherapy and radiotherapy for advanced pancreatic cancer
Comparison: 3 Gemcitabine combinations versus gemcitabine alone
Outcome: 1 Overall survival
Study or subgroup
Gemcitabine
combinations Gemcitabine alone log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Gemcitabine plus platinum agent
Colucci 2002 53 54 -0.1393 (0.2069) 11.2 % 0.87 [ 0.58, 1.31 ]
Colucci 2010 201 199 0.0953 (0.1081) 32.1 % 1.10 [ 0.89, 1.36 ]
Heinemann 2006 98 97 -0.2231 (0.1468) 20.1 % 0.80 [ 0.60, 1.07 ]
Louvet 2005 157 156 -0.1625 (0.1291) 24.7 % 0.85 [ 0.66, 1.09 ]
Viret 2004 42 41 -0.0834 (0.2267) 9.5 % 0.92 [ 0.59, 1.43 ]
Wang 2002 22 20 0.5596 (0.4603) 2.5 % 1.75 [ 0.71, 4.31 ]
Subtotal (95% CI) 573 567 100.0 % 0.94 [ 0.81, 1.08 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 5.90, df = 5 (P = 0.32); I2 =15%
Test for overall effect: Z = 0.88 (P = 0.38)
2 Gemcitabine plus fluoropyrimidine
Berlin 2002 160 162 -0.1985 (0.1185) 11.9 % 0.82 [ 0.65, 1.03 ]
Cunningham 2009 267 266 -0.1508 (0.0907) 20.3 % 0.86 [ 0.72, 1.03 ]
Di Costanzo 2005 43 48 0.0198 (0.2069) 3.9 % 1.02 [ 0.68, 1.53 ]
Herrmann 2007 160 159 -0.1393 (0.1333) 9.4 % 0.87 [ 0.67, 1.13 ]
Lee 2017 108 106 -0.1985 (0.1031) 15.7 % 0.82 [ 0.67, 1.00 ]
Ohkawa 2004 10 9 0.47 (0.5177) 0.6 % 1.60 [ 0.58, 4.41 ]
Ozaka 2012 53 59 -0.462 (0.2192) 3.5 % 0.63 [ 0.41, 0.97 ]
Riess 2005 235 238 0.0392 (0.097) 17.8 % 1.04 [ 0.86, 1.26 ]
Scheithauer 2003 41 42 -0.3011 (0.2426) 2.8 % 0.74 [ 0.46, 1.19 ]
Ueno 2013 (1) 275 277 -0.1278 (0.1095) 14.0 % 0.88 [ 0.71, 1.09 ]
Subtotal (95% CI) 1352 1366 100.0 % 0.88 [ 0.81, 0.95 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 8.53, df = 9 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 3.19 (P = 0.0014)
3 Gemcitabine plus topoisomerase inhibitor
Abou-Alfa 2006 175 174 -0.0101 (0.1151) 41.2 % 0.99 [ 0.79, 1.24 ]
Rocha Lima 2004 180 180 0.0296 (0.1101) 45.0 % 1.03 [ 0.83, 1.28 ]
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Study or subgroup
Gemcitabine
combinations Gemcitabine alone log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Stathopoulos 2006 60 70 -0.0101 (0.1992) 13.8 % 0.99 [ 0.67, 1.46 ]
Subtotal (95% CI) 415 424 100.0 % 1.01 [ 0.87, 1.16 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 2 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 0.11 (P = 0.92)
4 Gemcitabine plus taxane
Von Hoff 2013 431 430 -0.3285 (0.0763) 100.0 % 0.72 [ 0.62, 0.84 ]
Subtotal (95% CI) 431 430 100.0 % 0.72 [ 0.62, 0.84 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.31 (P = 0.000017)
5 Gemcitabine plus other combinations of chemotherapy
Petrioli 2015 34 33 -0.7985 (0.2421) 44.8 % 0.45 [ 0.28, 0.72 ]
Reni 2005 52 47 -0.4308 (0.2108) 55.2 % 0.65 [ 0.43, 0.98 ]
Subtotal (95% CI) 86 80 100.0 % 0.55 [ 0.39, 0.79 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 1.31, df = 1 (P = 0.25); I2 =24%
Test for overall effect: Z = 3.26 (P = 0.0011)
6 Gemcitabine plus other agent(s)
Gansauge 2002 (2) 30 30 -0.9416 (0.3158) 17.4 % 0.39 [ 0.21, 0.72 ]
Meng 2012 39 37 -0.0834 (0.2097) 25.9 % 0.92 [ 0.61, 1.39 ]
Oettle 2005 283 282 -0.0202 (0.1052) 36.6 % 0.98 [ 0.80, 1.20 ]
Ueno 2013 EPA study 43 23 -0.2357 (0.2759) 20.2 % 0.79 [ 0.46, 1.36 ]
Subtotal (95% CI) 395 372 100.0 % 0.79 [ 0.56, 1.10 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 7.87, df = 3 (P = 0.05); I2 =62%
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Chi2 = 17.77, df = 5 (P = 0.00), I2 =72%
0.2 0.5 1 2 5
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(1) This is a multi-armed study. Only these two arms have been analysed.
(2) This is a multi-armed study. Only these two arms have been analysed
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Analysis 3.2. Comparison 3 Gemcitabine combinations versus gemcitabine alone, Outcome 2 Progression-
free survival.
Review: Chemotherapy and radiotherapy for advanced pancreatic cancer
Comparison: 3 Gemcitabine combinations versus gemcitabine alone
Outcome: 2 Progression-free survival
Study or subgroup
Gemcitabine
combinations Gemcitabine alone log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Gemcitabine plus platinum agent
Colucci 2002 53 54 -0.4005 (0.1392) 22.8 % 0.67 [ 0.51, 0.88 ]
Colucci 2010 201 199 -0.0305 (0.0983) 32.2 % 0.97 [ 0.80, 1.18 ]
Heinemann 2006 98 97 -0.2877 (0.14) 22.7 % 0.75 [ 0.57, 0.99 ]
Louvet 2005 157 156 -0.2485 (0.1424) 22.2 % 0.78 [ 0.59, 1.03 ]
Subtotal (95% CI) 509 506 100.0 % 0.80 [ 0.68, 0.95 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 5.56, df = 3 (P = 0.14); I2 =46%
Test for overall effect: Z = 2.54 (P = 0.011)
2 Gemcitabine plus fluoropyrimidine
Berlin 2002 160 162 -0.2614 (0.1105) 12.6 % 0.77 [ 0.62, 0.96 ]
Cunningham 2009 267 266 -0.2485 (0.0852) 17.2 % 0.78 [ 0.66, 0.92 ]
Herrmann 2007 160 159 -0.1508 (0.1198) 11.2 % 0.86 [ 0.68, 1.09 ]
Lee 2017 108 106 -0.1393 (0.0895) 16.3 % 0.87 [ 0.73, 1.04 ]
Ozaka 2012 53 59 -0.5276 (0.1734) 6.3 % 0.59 [ 0.42, 0.83 ]
Riess 2005 235 238 -0.0726 (0.0963) 15.0 % 0.93 [ 0.77, 1.12 ]
Scheithauer 2003 41 42 -0.1863 (0.1571) 7.5 % 0.83 [ 0.61, 1.13 ]
Ueno 2013 (1) 275 277 -0.4155 (0.1024) 13.9 % 0.66 [ 0.54, 0.81 ]
Subtotal (95% CI) 1299 1309 100.0 % 0.79 [ 0.72, 0.87 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 10.56, df = 7 (P = 0.16); I2 =34%
Test for overall effect: Z = 4.83 (P < 0.00001)
3 Gemcitabine plus topoisomerase inhibitor
Abou-Alfa 2006 175 174 -0.0726 (0.1098) 55.5 % 0.93 [ 0.75, 1.15 ]
Rocha Lima 2004 180 180 -0.1165 (0.1225) 44.5 % 0.89 [ 0.70, 1.13 ]
Subtotal (95% CI) 355 354 100.0 % 0.91 [ 0.78, 1.07 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 1.13 (P = 0.26)
4 Gemcitabine plus taxane
Von Hoff 2013 431 430 -0.3711 (0.0886) 100.0 % 0.69 [ 0.58, 0.82 ]
0.2 0.5 1 2 5
Favours gem combinations Favours gem alone
(Continued . . . )
130Chemotherapy and radiotherapy for advanced pancreatic cancer (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup
Gemcitabine
combinations Gemcitabine alone log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 431 430 100.0 % 0.69 [ 0.58, 0.82 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.19 (P = 0.000028)
5 Gemcitabine plus other combinations of chemotherapy
Petrioli 2015 34 33 -1.0498 (0.2606) 43.4 % 0.35 [ 0.21, 0.58 ]
Reni 2005 52 47 -0.6733 (0.2221) 56.6 % 0.51 [ 0.33, 0.79 ]
Subtotal (95% CI) 86 80 100.0 % 0.43 [ 0.30, 0.62 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 1.21, df = 1 (P = 0.27); I2 =17%
Test for overall effect: Z = 4.48 (P < 0.00001)
6 Gemcitabine plus other agent(s)
Meng 2012 39 37 0.0488 (0.2207) 100.0 % 1.05 [ 0.68, 1.62 ]
Subtotal (95% CI) 39 37 100.0 % 1.05 [ 0.68, 1.62 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.83)
Test for subgroup differences: Chi2 = 17.48, df = 5 (P = 0.00), I2 =71%
0.2 0.5 1 2 5
Favours gem combinations Favours gem alone
(1) This is a multi-armed study. Only these two arms have been analysed
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Analysis 3.3. Comparison 3 Gemcitabine combinations versus gemcitabine alone, Outcome 3 Response
rates.
Review: Chemotherapy and radiotherapy for advanced pancreatic cancer
Comparison: 3 Gemcitabine combinations versus gemcitabine alone
Outcome: 3 Response rates
Study or subgroup
Gemcitabine
combinations Gemcitabine alone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Gemcitabine plus platinum agent
Colucci 2002 14/53 5/54 9.2 % 2.85 [ 1.11, 7.36 ]
Colucci 2010 26/201 20/199 27.3 % 1.29 [ 0.74, 2.23 ]
Heinemann 2006 11/98 9/97 11.8 % 1.21 [ 0.52, 2.79 ]
Li 2004 2/21 3/25 2.9 % 0.79 [ 0.15, 4.31 ]
Louvet 2005 42/157 27/156 44.6 % 1.55 [ 1.01, 2.38 ]
Viret 2004 3/42 2/41 2.7 % 1.46 [ 0.26, 8.31 ]
Wang 2002 2/22 1/20 1.5 % 1.82 [ 0.18, 18.55 ]
Subtotal (95% CI) 594 592 100.0 % 1.48 [ 1.11, 1.98 ]
Total events: 100 (Gemcitabine combinations), 67 (Gemcitabine alone)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.90, df = 6 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 2.69 (P = 0.0070)
2 Gemcitabine plus fluoropyrimidine
Berlin 2002 11/160 9/162 9.2 % 1.24 [ 0.53, 2.91 ]
Cunningham 2009 51/267 33/266 17.9 % 1.54 [ 1.03, 2.31 ]
Di Costanzo 2005 17/43 18/48 15.1 % 1.05 [ 0.63, 1.77 ]
Herrmann 2007 15/160 12/159 11.1 % 1.24 [ 0.60, 2.57 ]
Lee 2017 38/108 10/106 12.6 % 3.73 [ 1.96, 7.09 ]
Ohkawa 2004 3/10 0/9 1.3 % 6.36 [ 0.37, 108.56 ]
Ozaka 2012 15/53 4/59 7.0 % 4.17 [ 1.48, 11.80 ]
Scheithauer 2003 7/41 6/42 7.4 % 1.20 [ 0.44, 3.25 ]
Ueno 2013 71/242 32/241 18.5 % 2.21 [ 1.52, 3.22 ]
Subtotal (95% CI) 1084 1092 100.0 % 1.78 [ 1.29, 2.47 ]
Total events: 228 (Gemcitabine combinations), 124 (Gemcitabine alone)
Heterogeneity: Tau2 = 0.11; Chi2 = 16.58, df = 8 (P = 0.03); I2 =52%
Test for overall effect: Z = 3.48 (P = 0.00051)
3 Gemcitabine plus topoisomerase inhibitor
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Study or subgroup
Gemcitabine
combinations Gemcitabine alone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Abou-Alfa 2006 11/175 8/174 31.1 % 1.37 [ 0.56, 3.32 ]
Rocha Lima 2004 29/180 7/70 40.4 % 1.61 [ 0.74, 3.51 ]
Stathopoulos 2006 9/60 7/70 28.5 % 1.50 [ 0.59, 3.79 ]
Subtotal (95% CI) 415 314 100.0 % 1.50 [ 0.92, 2.46 ]
Total events: 49 (Gemcitabine combinations), 22 (Gemcitabine alone)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 2 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 1.61 (P = 0.11)
4 Gemcitabine plus taxane
Von Hoff 2013 99/431 30/430 100.0 % 3.29 [ 2.24, 4.84 ]
Subtotal (95% CI) 431 430 100.0 % 3.29 [ 2.24, 4.84 ]
Total events: 99 (Gemcitabine combinations), 30 (Gemcitabine alone)
Heterogeneity: not applicable
Test for overall effect: Z = 6.05 (P < 0.00001)
5 Gemcitabane plus other combinations of chemotherapy
Petrioli 2015 12/34 6/33 100.0 % 1.94 [ 0.83, 4.56 ]
Subtotal (95% CI) 34 33 100.0 % 1.94 [ 0.83, 4.56 ]
Total events: 12 (Gemcitabine combinations), 6 (Gemcitabine alone)
Heterogeneity: not applicable
Test for overall effect: Z = 1.52 (P = 0.13)
6 Gemcitabine plus other agent(s)
Gansauge 2002 16/30 1/30 24.4 % 16.00 [ 2.26, 113.12 ]
Meng 2012 3/34 1/32 20.9 % 2.82 [ 0.31, 25.77 ]
Oettle 2005 42/283 20/282 54.7 % 2.09 [ 1.26, 3.47 ]
Subtotal (95% CI) 347 344 100.0 % 3.66 [ 1.04, 12.82 ]
Total events: 61 (Gemcitabine combinations), 22 (Gemcitabine alone)
Heterogeneity: Tau2 = 0.68; Chi2 = 4.24, df = 2 (P = 0.12); I2 =53%
Test for overall effect: Z = 2.03 (P = 0.043)
Test for subgroup differences: Chi2 = 12.71, df = 5 (P = 0.03), I2 =61%
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Analysis 3.4. Comparison 3 Gemcitabine combinations versus gemcitabine alone, Outcome 4 Grade 3/4
anaemia.
Review: Chemotherapy and radiotherapy for advanced pancreatic cancer
Comparison: 3 Gemcitabine combinations versus gemcitabine alone
Outcome: 4 Grade 3/4 anaemia
Study or subgroup
Gemcitabine
combinations Gemcitabine alone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Gemcitabine plus platinum agent
Colucci 2002 3/51 2/53 6.7 % 1.56 [ 0.27, 8.95 ]
Colucci 2010 9/186 2/189 8.5 % 4.57 [ 1.00, 20.88 ]
Heinemann 2006 13/98 10/97 21.4 % 1.29 [ 0.59, 2.79 ]
Li 2004 2/21 2/25 6.0 % 1.19 [ 0.18, 7.74 ]
Louvet 2005 10/157 16/156 21.9 % 0.62 [ 0.29, 1.33 ]
Viret 2004 16/42 11/41 25.9 % 1.42 [ 0.75, 2.68 ]
Wang 2002 9/21 2/19 9.7 % 4.07 [ 1.00, 16.52 ]
Subtotal (95% CI) 576 580 100.0 % 1.41 [ 0.87, 2.31 ]
Total events: 62 (Gemcitabine combinations), 45 (Gemcitabine alone)
Heterogeneity: Tau2 = 0.14; Chi2 = 8.99, df = 6 (P = 0.17); I2 =33%
Test for overall effect: Z = 1.38 (P = 0.17)
2 Gemcitabine plus fluoropyrimidine
Berlin 2002 16/158 16/158 17.2 % 1.00 [ 0.52, 1.93 ]
Cunningham 2009 9/251 14/247 11.1 % 0.63 [ 0.28, 1.43 ]
Di Costanzo 2005 3/41 3/49 3.1 % 1.20 [ 0.25, 5.61 ]
Herrmann 2007 12/159 10/156 11.3 % 1.18 [ 0.52, 2.65 ]
Lee 2017 5/103 4/101 4.5 % 1.23 [ 0.34, 4.43 ]
Ozaka 2012 4/53 3/59 3.5 % 1.48 [ 0.35, 6.33 ]
Scheithauer 2003 2/41 0/42 0.8 % 5.12 [ 0.25, 103.48 ]
Ueno 2013 46/267 39/273 48.4 % 1.21 [ 0.82, 1.78 ]
Subtotal (95% CI) 1073 1085 100.0 % 1.11 [ 0.84, 1.45 ]
Total events: 97 (Gemcitabine combinations), 89 (Gemcitabine alone)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.28, df = 7 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 0.72 (P = 0.47)
3 Gemcitabine plus topoisomerase inhibitor
Abou-Alfa 2006 10/168 12/157 26.8 % 0.78 [ 0.35, 1.75 ]
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Study or subgroup
Gemcitabine
combinations Gemcitabine alone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Rocha Lima 2004 28/173 22/169 66.0 % 1.24 [ 0.74, 2.08 ]
Stathopoulos 2006 3/60 3/70 7.2 % 1.17 [ 0.24, 5.57 ]
Subtotal (95% CI) 401 396 100.0 % 1.09 [ 0.72, 1.66 ]
Total events: 41 (Gemcitabine combinations), 37 (Gemcitabine alone)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.92, df = 2 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.41 (P = 0.68)
4 Gemcitabine plus taxane
Von Hoff 2013 53/405 48/388 100.0 % 1.06 [ 0.73, 1.52 ]
Subtotal (95% CI) 405 388 100.0 % 1.06 [ 0.73, 1.52 ]
Total events: 53 (Gemcitabine combinations), 48 (Gemcitabine alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.30 (P = 0.76)
5 Gemcitabine plus other combinations of chemotherapy
Petrioli 2015 6/34 3/33 100.0 % 1.94 [ 0.53, 7.13 ]
Subtotal (95% CI) 34 33 100.0 % 1.94 [ 0.53, 7.13 ]
Total events: 6 (Gemcitabine combinations), 3 (Gemcitabine alone)
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
6 Gemcitabine plus other agent(s)
Meng 2012 5/39 2/37 15.2 % 2.37 [ 0.49, 11.48 ]
Oettle 2005 38/273 8/273 68.4 % 4.75 [ 2.26, 9.99 ]
Ueno 2013 EPA study 6/43 2/23 16.4 % 1.60 [ 0.35, 7.32 ]
Subtotal (95% CI) 355 333 100.0 % 3.58 [ 1.93, 6.62 ]
Total events: 49 (Gemcitabine combinations), 12 (Gemcitabine alone)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.91, df = 2 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 4.06 (P = 0.000049)
Test for subgroup differences: Chi2 = 13.88, df = 5 (P = 0.02), I2 =64%
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Analysis 3.5. Comparison 3 Gemcitabine combinations versus gemcitabine alone, Outcome 5 Grade 3/4
neutropenia.
Review: Chemotherapy and radiotherapy for advanced pancreatic cancer
Comparison: 3 Gemcitabine combinations versus gemcitabine alone
Outcome: 5 Grade 3/4 neutropenia
Study or subgroup
Gemcitabine
combinations Gemcitabine alone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Gemcitabine plus platinum agent
Colucci 2002 9/51 5/53 10.3 % 1.87 [ 0.67, 5.21 ]
Colucci 2010 46/186 26/189 24.4 % 1.80 [ 1.16, 2.78 ]
Li 2004 4/21 2/25 5.1 % 2.38 [ 0.48, 11.74 ]
Louvet 2005 32/157 43/156 25.6 % 0.74 [ 0.50, 1.10 ]
Viret 2004 24/42 16/41 23.5 % 1.46 [ 0.92, 2.33 ]
Wang 2002 7/21 5/19 11.1 % 1.27 [ 0.48, 3.33 ]
Subtotal (95% CI) 478 483 100.0 % 1.34 [ 0.90, 1.97 ]
Total events: 122 (Gemcitabine combinations), 97 (Gemcitabine alone)
Heterogeneity: Tau2 = 0.11; Chi2 = 10.94, df = 5 (P = 0.05); I2 =54%
Test for overall effect: Z = 1.46 (P = 0.14)
2 Gemcitabine plus fluoropyrimidine
Berlin 2002 11/158 8/158 2.2 % 1.38 [ 0.57, 3.33 ]
Cunningham 2009 87/251 54/247 19.9 % 1.59 [ 1.19, 2.12 ]
Di Costanzo 2005 1/41 1/49 0.2 % 1.20 [ 0.08, 18.52 ]
Herrmann 2007 36/159 30/156 9.1 % 1.18 [ 0.76, 1.81 ]
Lee 2017 18/103 12/101 3.7 % 1.47 [ 0.75, 2.89 ]
Ohkawa 2004 1/10 1/9 0.2 % 0.90 [ 0.07, 12.38 ]
Ozaka 2012 29/53 13/59 5.8 % 2.48 [ 1.45, 4.26 ]
Scheithauer 2003 4/41 3/42 0.8 % 1.37 [ 0.33, 5.73 ]
Ueno 2013 166/267 112/273 58.1 % 1.52 [ 1.28, 1.80 ]
Subtotal (95% CI) 1083 1094 100.0 % 1.53 [ 1.34, 1.74 ]
Total events: 353 (Gemcitabine combinations), 234 (Gemcitabine alone)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.87, df = 8 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 6.41 (P < 0.00001)
3 Gemcitabine plus topoisomerase inhibitor
Abou-Alfa 2006 51/168 23/157 34.1 % 2.07 [ 1.33, 3.22 ]
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Study or subgroup
Gemcitabine
combinations Gemcitabine alone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Rocha Lima 2004 65/173 54/169 44.5 % 1.18 [ 0.88, 1.57 ]
Stathopoulos 2006 16/60 11/70 21.4 % 1.70 [ 0.85, 3.37 ]
Subtotal (95% CI) 401 396 100.0 % 1.54 [ 1.04, 2.30 ]
Total events: 132 (Gemcitabine combinations), 88 (Gemcitabine alone)
Heterogeneity: Tau2 = 0.07; Chi2 = 4.75, df = 2 (P = 0.09); I2 =58%
Test for overall effect: Z = 2.13 (P = 0.033)
4 Gemcitabine plus taxane
Von Hoff 2013 153/405 103/388 100.0 % 1.42 [ 1.16, 1.75 ]
Subtotal (95% CI) 405 388 100.0 % 1.42 [ 1.16, 1.75 ]
Total events: 153 (Gemcitabine combinations), 103 (Gemcitabine alone)
Heterogeneity: not applicable
Test for overall effect: Z = 3.33 (P = 0.00086)
5 Gemcitabine plus other combinations of chemotherapy
Petrioli 2015 8/34 4/33 100.0 % 1.94 [ 0.65, 5.83 ]
Subtotal (95% CI) 34 33 100.0 % 1.94 [ 0.65, 5.83 ]
Total events: 8 (Gemcitabine combinations), 4 (Gemcitabine alone)
Heterogeneity: not applicable
Test for overall effect: Z = 1.18 (P = 0.24)
6 Gemcitabine plus other agent(s)
Meng 2012 8/39 7/37 30.8 % 1.08 [ 0.44, 2.69 ]
Oettle 2005 123/273 35/273 45.1 % 3.51 [ 2.51, 4.92 ]
Ueno 2013 EPA study 9/43 3/23 24.1 % 1.60 [ 0.48, 5.35 ]
Subtotal (95% CI) 355 333 100.0 % 2.02 [ 0.88, 4.66 ]
Total events: 140 (Gemcitabine combinations), 45 (Gemcitabine alone)
Heterogeneity: Tau2 = 0.37; Chi2 = 6.69, df = 2 (P = 0.04); I2 =70%
Test for overall effect: Z = 1.66 (P = 0.097)
Test for subgroup differences: Chi2 = 1.39, df = 5 (P = 0.92), I2 =0.0%
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Analysis 3.6. Comparison 3 Gemcitabine combinations versus gemcitabine alone, Outcome 6 Grade 3/4
thrombocytopenia.
Review: Chemotherapy and radiotherapy for advanced pancreatic cancer
Comparison: 3 Gemcitabine combinations versus gemcitabine alone
Outcome: 6 Grade 3/4 thrombocytopenia
Study or subgroup
Gemcitabine
combinations Gemcitabine alone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Gemcitabine plus platinum agent
Colucci 2002 1/51 1/53 5.0 % 1.04 [ 0.07, 16.18 ]
Colucci 2010 29/186 10/189 22.9 % 2.95 [ 1.48, 5.87 ]
Heinemann 2006 4/98 10/97 16.3 % 0.40 [ 0.13, 1.22 ]
Louvet 2005 22/157 5/156 18.9 % 4.37 [ 1.70, 11.25 ]
Viret 2004 14/42 5/41 19.2 % 2.73 [ 1.08, 6.90 ]
Wang 2002 8/21 4/19 17.7 % 1.81 [ 0.65, 5.06 ]
Subtotal (95% CI) 555 555 100.0 % 1.96 [ 1.00, 3.84 ]
Total events: 78 (Gemcitabine combinations), 35 (Gemcitabine alone)
Heterogeneity: Tau2 = 0.39; Chi2 = 12.28, df = 5 (P = 0.03); I2 =59%
Test for overall effect: Z = 1.97 (P = 0.049)
2 Gemcitabine plus fluoropyrimidine
Berlin 2002 30/158 16/158 22.6 % 1.88 [ 1.07, 3.30 ]
Cunningham 2009 28/251 14/247 20.7 % 1.97 [ 1.06, 3.65 ]
Di Costanzo 2005 1/41 0/49 1.5 % 3.57 [ 0.15, 85.39 ]
Herrmann 2007 7/159 12/156 13.0 % 0.57 [ 0.23, 1.42 ]
Lee 2017 1/103 5/101 3.1 % 0.20 [ 0.02, 1.65 ]
Ohkawa 2004 1/10 0/9 1.6 % 2.73 [ 0.12, 59.57 ]
Ozaka 2012 8/53 3/59 7.7 % 2.97 [ 0.83, 10.61 ]
Scheithauer 2003 0/41 1/42 1.5 % 0.34 [ 0.01, 8.14 ]
Ueno 2013 46/267 30/273 28.3 % 1.57 [ 1.02, 2.41 ]
Subtotal (95% CI) 1083 1094 100.0 % 1.48 [ 1.00, 2.18 ]
Total events: 122 (Gemcitabine combinations), 81 (Gemcitabine alone)
Heterogeneity: Tau2 = 0.09; Chi2 = 11.59, df = 8 (P = 0.17); I2 =31%
Test for overall effect: Z = 1.95 (P = 0.052)
3 Gemcitabine plus topoisomerase inhibitor
Abou-Alfa 2006 26/168 7/157 40.2 % 3.47 [ 1.55, 7.77 ]
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Study or subgroup
Gemcitabine
combinations Gemcitabine alone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Rocha Lima 2004 34/173 24/169 52.4 % 1.38 [ 0.86, 2.23 ]
Stathopoulos 2006 3/60 0/70 7.4 % 8.15 [ 0.43, 154.64 ]
Subtotal (95% CI) 401 396 100.0 % 2.28 [ 0.97, 5.36 ]
Total events: 63 (Gemcitabine combinations), 31 (Gemcitabine alone)
Heterogeneity: Tau2 = 0.30; Chi2 = 4.86, df = 2 (P = 0.09); I2 =59%
Test for overall effect: Z = 1.90 (P = 0.058)
4 Gemcitabine plus taxane
Von Hoff 2013 52/405 36/388 100.0 % 1.38 [ 0.93, 2.07 ]
Subtotal (95% CI) 405 388 100.0 % 1.38 [ 0.93, 2.07 ]
Total events: 52 (Gemcitabine combinations), 36 (Gemcitabine alone)
Heterogeneity: not applicable
Test for overall effect: Z = 1.59 (P = 0.11)
5 Gemcitabine plus other combinations of chemotherapy
Petrioli 2015 10/34 5/33 100.0 % 1.94 [ 0.74, 5.07 ]
Subtotal (95% CI) 34 33 100.0 % 1.94 [ 0.74, 5.07 ]
Total events: 10 (Gemcitabine combinations), 5 (Gemcitabine alone)
Heterogeneity: not applicable
Test for overall effect: Z = 1.35 (P = 0.18)
6 Gemcitabine plus other agent(s)
Meng 2012 2/39 4/37 25.6 % 0.47 [ 0.09, 2.44 ]
Oettle 2005 49/273 17/273 48.6 % 2.88 [ 1.70, 4.88 ]
Ueno 2013 EPA study 4/43 2/23 25.8 % 1.07 [ 0.21, 5.41 ]
Subtotal (95% CI) 355 333 100.0 % 1.41 [ 0.45, 4.39 ]
Total events: 55 (Gemcitabine combinations), 23 (Gemcitabine alone)
Heterogeneity: Tau2 = 0.62; Chi2 = 5.14, df = 2 (P = 0.08); I2 =61%
Test for overall effect: Z = 0.59 (P = 0.56)
Test for subgroup differences: Chi2 = 1.87, df = 5 (P = 0.87), I2 =0.0%
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Analysis 3.7. Comparison 3 Gemcitabine combinations versus gemcitabine alone, Outcome 7 Grade 3/4
nausea.
Review: Chemotherapy and radiotherapy for advanced pancreatic cancer
Comparison: 3 Gemcitabine combinations versus gemcitabine alone
Outcome: 7 Grade 3/4 nausea
Study or subgroup
Gemcitabine
combinations Gemcitabine alone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Gemcitabine plus platinum agent
Colucci 2002 1/51 1/53 3.2 % 1.04 [ 0.07, 16.18 ]
Colucci 2010 5/186 2/189 9.0 % 2.54 [ 0.50, 12.93 ]
Heinemann 2006 22/98 6/97 32.4 % 3.63 [ 1.54, 8.56 ]
Louvet 2005 16/157 9/156 38.6 % 1.77 [ 0.80, 3.88 ]
Viret 2004 6/42 2/41 10.0 % 2.93 [ 0.63, 13.68 ]
Wang 2002 2/21 2/19 6.9 % 0.90 [ 0.14, 5.81 ]
Subtotal (95% CI) 555 555 100.0 % 2.28 [ 1.40, 3.71 ]
Total events: 52 (Gemcitabine combinations), 22 (Gemcitabine alone)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.93, df = 5 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 3.30 (P = 0.00096)
2 Gemcitabine plus fluoropyrimidine
Berlin 2002 13/158 16/158 28.6 % 0.81 [ 0.40, 1.63 ]
Cunningham 2009 17/251 15/247 30.9 % 1.12 [ 0.57, 2.18 ]
Di Costanzo 2005 1/41 0/49 1.4 % 3.57 [ 0.15, 85.39 ]
Herrmann 2007 11/159 7/156 16.4 % 1.54 [ 0.61, 3.87 ]
Lee 2017 5/103 3/101 7.1 % 1.63 [ 0.40, 6.66 ]
Ozaka 2012 2/53 1/59 2.5 % 2.23 [ 0.21, 23.86 ]
Ueno 2013 12/267 5/273 13.1 % 2.45 [ 0.88, 6.87 ]
Subtotal (95% CI) 1032 1043 100.0 % 1.27 [ 0.87, 1.84 ]
Total events: 61 (Gemcitabine combinations), 47 (Gemcitabine alone)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.22, df = 6 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 1.24 (P = 0.22)
3 Gemcitabine plus topoisomerase inhibitor
Abou-Alfa 2006 6/168 4/157 16.1 % 1.40 [ 0.40, 4.87 ]
Rocha Lima 2004 29/173 17/169 79.5 % 1.67 [ 0.95, 2.92 ]
Stathopoulos 2006 1/60 2/70 4.4 % 0.58 [ 0.05, 6.27 ]
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Study or subgroup
Gemcitabine
combinations Gemcitabine alone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 401 396 100.0 % 1.55 [ 0.94, 2.55 ]
Total events: 36 (Gemcitabine combinations), 23 (Gemcitabine alone)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.74, df = 2 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 1.71 (P = 0.087)
4 Gemcitabine plus other combinations of chemotherapy
Petrioli 2015 5/34 0/33 100.0 % 10.69 [ 0.61, 185.91 ]
Subtotal (95% CI) 34 33 100.0 % 10.69 [ 0.61, 185.91 ]
Total events: 5 (Gemcitabine combinations), 0 (Gemcitabine alone)
Heterogeneity: not applicable
Test for overall effect: Z = 1.63 (P = 0.10)
5 Gemcitabine plus other agent(s)
Gansauge 2002 1/30 3/30 16.8 % 0.33 [ 0.04, 3.03 ]
Meng 2012 2/39 0/37 9.5 % 4.75 [ 0.24, 95.76 ]
Oettle 2005 9/273 8/273 63.1 % 1.13 [ 0.44, 2.87 ]
Ueno 2013 EPA study 5/43 0/23 10.5 % 6.00 [ 0.35, 103.94 ]
Subtotal (95% CI) 385 363 100.0 % 1.25 [ 0.48, 3.26 ]
Total events: 17 (Gemcitabine combinations), 11 (Gemcitabine alone)
Heterogeneity: Tau2 = 0.15; Chi2 = 3.41, df = 3 (P = 0.33); I2 =12%
Test for overall effect: Z = 0.46 (P = 0.64)
Test for subgroup differences: Chi2 = 5.45, df = 4 (P = 0.24), I2 =27%
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Analysis 3.8. Comparison 3 Gemcitabine combinations versus gemcitabine alone, Outcome 8 Grade 3/4
diarrhoea.
Review: Chemotherapy and radiotherapy for advanced pancreatic cancer
Comparison: 3 Gemcitabine combinations versus gemcitabine alone
Outcome: 8 Grade 3/4 diarrhoea
Study or subgroup
Gemcitabine
combinations Gemcitabine alone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Gemcitabine plus platinum agent
Colucci 2002 2/51 0/53 7.3 % 5.19 [ 0.26, 105.59 ]
Colucci 2010 1/186 3/189 11.9 % 0.34 [ 0.04, 3.23 ]
Heinemann 2006 3/98 5/97 23.2 % 0.59 [ 0.15, 2.42 ]
Louvet 2005 9/157 2/156 21.1 % 4.47 [ 0.98, 20.36 ]
Viret 2004 6/42 2/41 20.6 % 2.93 [ 0.63, 13.68 ]
Wang 2002 2/21 2/19 15.9 % 0.90 [ 0.14, 5.81 ]
Subtotal (95% CI) 555 555 100.0 % 1.48 [ 0.62, 3.53 ]
Total events: 23 (Gemcitabine combinations), 14 (Gemcitabine alone)
Heterogeneity: Tau2 = 0.34; Chi2 = 7.04, df = 5 (P = 0.22); I2 =29%
Test for overall effect: Z = 0.88 (P = 0.38)
2 Gemcitabine plus fluoropyrimidine
Berlin 2002 16/158 6/158 27.2 % 2.67 [ 1.07, 6.64 ]
Cunningham 2009 12/251 11/247 35.4 % 1.07 [ 0.48, 2.39 ]
Herrmann 2007 8/159 3/156 13.2 % 2.62 [ 0.71, 9.68 ]
Lee 2017 2/103 0/101 2.5 % 4.90 [ 0.24, 100.89 ]
Ohkawa 2004 1/10 0/9 2.4 % 2.73 [ 0.12, 59.57 ]
Ozaka 2012 2/53 0/59 2.5 % 5.56 [ 0.27, 113.16 ]
Scheithauer 2003 2/41 0/42 2.5 % 5.12 [ 0.25, 103.48 ]
Ueno 2013 12/267 3/273 14.4 % 4.09 [ 1.17, 14.33 ]
Subtotal (95% CI) 1042 1045 100.0 % 2.16 [ 1.34, 3.47 ]
Total events: 55 (Gemcitabine combinations), 23 (Gemcitabine alone)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.27, df = 7 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 3.17 (P = 0.0015)
3 Gemcitabine plus topoisomerase inhibitor
Abou-Alfa 2006 2/168 1/157 24.6 % 1.87 [ 0.17, 20.41 ]
Rocha Lima 2004 32/173 3/169 44.5 % 10.42 [ 3.25, 33.38 ]
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(Continued . . . )
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(. . . Continued)
Study or subgroup
Gemcitabine
combinations Gemcitabine alone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Stathopoulos 2006 2/60 2/70 30.9 % 1.17 [ 0.17, 8.03 ]
Subtotal (95% CI) 401 396 100.0 % 3.47 [ 0.74, 16.33 ]
Total events: 36 (Gemcitabine combinations), 6 (Gemcitabine alone)
Heterogeneity: Tau2 = 1.05; Chi2 = 4.56, df = 2 (P = 0.10); I2 =56%
Test for overall effect: Z = 1.57 (P = 0.12)
Test for subgroup differences: Chi2 = 1.02, df = 2 (P = 0.60), I2 =0.0%
0.01 0.1 1 10 100
Gemcitabine more toxic Favours gem alone
Analysis 3.9. Comparison 3 Gemcitabine combinations versus gemcitabine alone, Outcome 9 Grade 3/4
neuropathy.
Review: Chemotherapy and radiotherapy for advanced pancreatic cancer
Comparison: 3 Gemcitabine combinations versus gemcitabine alone
Outcome: 9 Grade 3/4 neuropathy
Study or subgroup
Gemcitabine
combinations Gemcitabine alone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Gemcitabine plus taxane
Von Hoff 2013 70/405 3/388 100.0 % 22.35 [ 7.10, 70.40 ]
Subtotal (95% CI) 405 388 100.0 % 22.35 [ 7.10, 70.40 ]
Total events: 70 (Gemcitabine combinations), 3 (Gemcitabine alone)
Heterogeneity: not applicable
Test for overall effect: Z = 5.31 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 3.10. Comparison 3 Gemcitabine combinations versus gemcitabine alone, Outcome 10 Grade 3/4
fatigue.
Review: Chemotherapy and radiotherapy for advanced pancreatic cancer
Comparison: 3 Gemcitabine combinations versus gemcitabine alone
Outcome: 10 Grade 3/4 fatigue
Study or subgroup
Gemcitabine
combinations Gemcitabine alone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Gemcitabine plus taxane
Von Hoff 2013 70/405 27/388 100.0 % 2.48 [ 1.63, 3.79 ]
Subtotal (95% CI) 405 388 100.0 % 2.48 [ 1.63, 3.79 ]
Total events: 70 (Gemcitabine combinations), 27 (Gemcitabine alone)
Heterogeneity: not applicable
Test for overall effect: Z = 4.23 (P = 0.000023)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 4.1. Comparison 4 Fluoropyrimidine combinations versus fluoropyrimidine alone, Outcome 1
Overall survival.
Review: Chemotherapy and radiotherapy for advanced pancreatic cancer
Comparison: 4 Fluoropyrimidine combinations versus fluoropyrimidine alone
Outcome: 1 Overall survival
Study or subgroup 5FU combination 5FU alone log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Ducreux 2004 (1) 31 15 -1.0498 (0.3393) 14.8 % 0.35 [ 0.18, 0.68 ]
Kovach 1974 (2) 30 30 0.0198 (0.254) 20.6 % 1.02 [ 0.62, 1.68 ]
Maisey 2002 102 107 -0.1054 (0.1282) 32.7 % 0.90 [ 0.70, 1.16 ]
Moertel 1979 87 89 0.0198 (0.1369) 31.8 % 1.02 [ 0.78, 1.33 ]
Total (95% CI) 250 241 100.0 % 0.84 [ 0.61, 1.15 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 8.83, df = 3 (P = 0.03); I2 =66%
Test for overall effect: Z = 1.10 (P = 0.27)
Test for subgroup differences: Not applicable
0.02 0.1 1 10 50
Favours 5FU combinations Favours 5FU alone
(1) This is a multi-armed study, only the 5FU v 5FU + oxaliplatin arms have been analysed
(2) This is a multi-armed study, only these two arms have been analysed
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Analysis 4.2. Comparison 4 Fluoropyrimidine combinations versus fluoropyrimidine alone, Outcome 2
Progression-free survival.
Review: Chemotherapy and radiotherapy for advanced pancreatic cancer
Comparison: 4 Fluoropyrimidine combinations versus fluoropyrimidine alone
Outcome: 2 Progression-free survival
Study or subgroup 5FU combination 5FU alone log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Ducreux 2004 31 15 -1.204 (0.3207) 45.5 % 0.30 [ 0.16, 0.56 ]
Maisey 2002 102 107 -0.1985 (0.1107) 54.5 % 0.82 [ 0.66, 1.02 ]
Total (95% CI) 133 122 100.0 % 0.52 [ 0.19, 1.38 ]
Heterogeneity: Tau2 = 0.45; Chi2 = 8.78, df = 1 (P = 0.003); I2 =89%
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Not applicable
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Favours 5FU combinations Favours 5FU alone
Analysis 4.3. Comparison 4 Fluoropyrimidine combinations versus fluoropyrimidine alone, Outcome 3
Response rates.
Review: Chemotherapy and radiotherapy for advanced pancreatic cancer
Comparison: 4 Fluoropyrimidine combinations versus fluoropyrimidine alone
Outcome: 3 Response rates
Study or subgroup 5FU combination 5FU alone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ducreux 2004 3/31 0/15 6.9 % 3.50 [ 0.19, 63.72 ]
Kovach 1974 5/31 10/30 30.6 % 0.48 [ 0.19, 1.25 ]
Maisey 2002 18/102 9/107 36.1 % 2.10 [ 0.99, 4.45 ]
Moertel 1979 6/48 5/46 26.4 % 1.15 [ 0.38, 3.51 ]
Total (95% CI) 212 198 100.0 % 1.18 [ 0.52, 2.68 ]
Total events: 32 (5FU combination), 24 (5FU alone)
Heterogeneity: Tau2 = 0.33; Chi2 = 6.19, df = 3 (P = 0.10); I2 =52%
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 4.4. Comparison 4 Fluoropyrimidine combinations versus fluoropyrimidine alone, Outcome 4
Grade 3/4 anaemia.
Review: Chemotherapy and radiotherapy for advanced pancreatic cancer
Comparison: 4 Fluoropyrimidine combinations versus fluoropyrimidine alone
Outcome: 4 Grade 3/4 anaemia
Study or subgroup 5FU combination 5FU alone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ducreux 2004 0/31 2/15 29.5 % 0.10 [ 0.01, 1.96 ]
Maisey 2002 8/102 9/107 70.5 % 0.93 [ 0.37, 2.32 ]
Total (95% CI) 133 122 100.0 % 0.48 [ 0.06, 3.62 ]
Total events: 8 (5FU combination), 11 (5FU alone)
Heterogeneity: Tau2 = 1.28; Chi2 = 2.02, df = 1 (P = 0.16); I2 =50%
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Not applicable
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Analysis 4.5. Comparison 4 Fluoropyrimidine combinations versus fluoropyrimidine alone, Outcome 5
Grade 3/4 neutropenia.
Review: Chemotherapy and radiotherapy for advanced pancreatic cancer
Comparison: 4 Fluoropyrimidine combinations versus fluoropyrimidine alone
Outcome: 5 Grade 3/4 neutropenia
Study or subgroup 5FU combination 5FU alone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ducreux 2004 4/31 0/15 51.6 % 4.50 [ 0.26, 78.53 ]
Maisey 2002 3/102 0/107 48.4 % 7.34 [ 0.38, 140.36 ]
Total (95% CI) 133 122 100.0 % 5.70 [ 0.73, 44.46 ]
Total events: 7 (5FU combination), 0 (5FU alone)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 1.66 (P = 0.097)
Test for subgroup differences: Not applicable
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Analysis 4.6. Comparison 4 Fluoropyrimidine combinations versus fluoropyrimidine alone, Outcome 6
Grade 3/4 thrombocytopenia.
Review: Chemotherapy and radiotherapy for advanced pancreatic cancer
Comparison: 4 Fluoropyrimidine combinations versus fluoropyrimidine alone
Outcome: 6 Grade 3/4 thrombocytopenia
Study or subgroup 5FU combination 5FU alone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ducreux 2004 1/31 1/15 27.8 % 0.48 [ 0.03, 7.22 ]
Maisey 2002 4/102 2/107 72.2 % 2.10 [ 0.39, 11.21 ]
Total (95% CI) 133 122 100.0 % 1.40 [ 0.34, 5.80 ]
Total events: 5 (5FU combination), 3 (5FU alone)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.82, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 0.46 (P = 0.65)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
5FU alone more toxic Combination more toxic
Analysis 4.7. Comparison 4 Fluoropyrimidine combinations versus fluoropyrimidine alone, Outcome 7
Grade 3/4 fatigue.
Review: Chemotherapy and radiotherapy for advanced pancreatic cancer
Comparison: 4 Fluoropyrimidine combinations versus fluoropyrimidine alone
Outcome: 7 Grade 3/4 fatigue
Study or subgroup 5FU combination 5FU alone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Maisey 2002 26/102 30/107 100.0 % 0.91 [ 0.58, 1.43 ]
Total (95% CI) 102 107 100.0 % 0.91 [ 0.58, 1.43 ]
Total events: 26 (5FU combination), 30 (5FU alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.68)
Test for subgroup differences: Not applicable
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Analysis 4.8. Comparison 4 Fluoropyrimidine combinations versus fluoropyrimidine alone, Outcome 8
Grade 3/4 nausea.
Review: Chemotherapy and radiotherapy for advanced pancreatic cancer
Comparison: 4 Fluoropyrimidine combinations versus fluoropyrimidine alone
Outcome: 8 Grade 3/4 nausea
Study or subgroup 5FU combination 5FU alone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ducreux 2004 4/31 1/15 32.9 % 1.94 [ 0.24, 15.85 ]
Maisey 2002 3/102 4/107 67.1 % 0.79 [ 0.18, 3.43 ]
Total (95% CI) 133 122 100.0 % 1.06 [ 0.32, 3.53 ]
Total events: 7 (5FU combination), 5 (5FU alone)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.47, df = 1 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 0.09 (P = 0.93)
Test for subgroup differences: Not applicable
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Analysis 4.9. Comparison 4 Fluoropyrimidine combinations versus fluoropyrimidine alone, Outcome 9
Grade 3/4 diarrhoea.
Review: Chemotherapy and radiotherapy for advanced pancreatic cancer
Comparison: 4 Fluoropyrimidine combinations versus fluoropyrimidine alone
Outcome: 9 Grade 3/4 diarrhoea
Study or subgroup 5FU combination 5FU alone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ducreux 2004 1/31 1/15 16.7 % 0.48 [ 0.03, 7.22 ]
Maisey 2002 5/102 5/107 83.3 % 1.05 [ 0.31, 3.52 ]
Total (95% CI) 133 122 100.0 % 0.92 [ 0.31, 2.78 ]
Total events: 6 (5FU combination), 6 (5FU alone)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.26, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Not applicable
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A D D I T I O N A L T A B L E S
Table 1. Median survival times and quality of life results of anti-cancer therapy versus best supportive care
Study Anti-cancer therapy details Median survival:anti-
cancer therapy vs best supportive
care (months)
Quality of life
Andren-Sandberg 1983 5FU + CCNU 5 vs 4 No difference in Karnofsky perfor-
mance status (KPS) score
Frey 1981 5FU + CCNU 3.0 vs 3.9 Not addressed
Glimelius 1996 5FU + LV 6.0 vs 2.5 EORTCQLQ-C30 results favoured
the anti-cancer therapy (NB: high
rate of dropouts in the later time
points)
Huguier 2001 5FU + LV + cisplatin 8.6 vs 7.0 Not addressed
Takada 1998 5FU + doxorubicin + MMC 4.9 vs 5.0 Not addressed
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Table 1. Median survival times and quality of life results of anti-cancer therapy versus best supportive care (Continued)
Xinopoulos 2008 Gemcitabine 5.25 vs 5.5 Superior QoL (EORTCQLQ-C30)
in the gemcitabine group during the
1st month (P = 0.028), no differ-
ence from the 2nd to the 4thmonth;
in the 5th and 6th month superior
QoL in the BSC group (P = 0.010
and < 0.001)
5FU: 5-Fluorouracil; CCNU: chloroethylcyclohexylnitrosurea; EORTC QLQ-C30: European Organisation for Research and Treat-
ment of Cancer quality of life questionnaire for cancer patients; LV: leucovorin;MMC: 5FU+doxorubicin + mitomycin C
Table 2. Median survival times and quality of life results of various types of chemotherapy versus gemcitabine
Study Type of other chemotherapy Median survival:other chemother-
apy vs gemcitabine (months)
Quality of life
Burris 1997 5FU 4.4 vs 5.7 Improved clinical benefit 4.8% vs
23.8%. Median time to benefit 7 vs
3 weeks. Duration of benefit 18 vs
13 weeks
Conroy 2011 FOLFIRINOX 11.1 vs 6.8 QLQ-C30: decrease in
Global Health Status and QoL scale
at 3 months
17% vs 31%; at 6 months 31% vs
66%
Median time to definitive deteriora-
tion: not reached vs 5.7 months
Singhal 2014 FOLFIRINOX 10.8 vs 7.4 Definitive degradation of QoL at six
months: 29% vs 59%
Poplin 2013 CO-101 5.2 vs 6.0 Not addressed
Smith 2003 ZD-9331 5.0 vs 3.6 Not addressed
Poplin 2009 Fixed dose rate gemcitabine 1500
mg/m² over 150 min
6.2 vs 4.9 Not addressed
Tempero 2003 Fixed dose rate gemcitabine 1500
mg/m² at 10 mg/m²/min
8.0 vs 5.0 Not addressed
Cheverton 2004 Exatecan (DX-8951f ) 5.0 vs 6.6 Time to worsening of clinical ben-
efit was longer in the gemcitabine
group. Pain (3.7 vs 7.9 months; P
= 0.0493), KPS (3.4 vs 4.6 months;
P = 0.0111) and weight (2.3 vs 3.8
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Table 2. Median survival times and quality of life results of various types of chemotherapy versus gemcitabine (Continued)
months; P =0.0203).QoLmeasured
with QLQ-C3 and QLQ-PAN26
were similar in the 2 groups
5FU: 5-Fluorouracil; FOLFIRINOX: 5-fluorouracil + irinotecan + oxaliplatin; QoL: quality of life; QLQ-C30 and QLQ-PAN26:
general and pancreatic cancer specific QoL questionnaire.
Table 3. Median survival times and quality of life results of gemcitabine combinations versus gemcitabine alone
Study Gemcitabine combination de-
tails
Median survival:gem-
citabine combination vs gemc-
itabine alone (months)
Quality of life
Platinum combinations
Colucci 2002 Gemcitabine + cisplatin 7.5 vs 5.0 Not addressed
Colucci 2010 Gemcitabine + cisplatin 7.2 vs 8.3 The mean difference from base-
line in globalQoL (EORTCC30)
was not significantly different be-
tween the 2 groups: 0.09 (gemc-
itabine/cisplatin) vs 6.20 (gemc-
itabine), P = 0.07
Heinemann 2006 Gemcitabine + cisplatin 7.5 vs 6.0 No difference was detected in the
2 groups with either the Spitzer
index or the pain intensity score
Li 2004 Gemcitabine + cisplatin 5.6 vs 4.6 Clinical benefit (pain control,
performance status, body weight
gain) 29% vs 36% (P > 0.05);
Quality adjusted life months 3.8
vs 5.6 (P < 0.001)
Louvet 2005 Gemcitabine + oxaliplatin 9.0 vs 7.1 Not addressed
Viret 2004 Gemcitabine + cisplatin 8.0 vs 6.7 Q-TWiST results did not differ
significantly between the 2 arms
(EORTC C30)
Wang 2002 Gemcitabine + cisplatin 7.2 vs 9.1 Not addressed
Fluoropyrimidine combinations
Berlin 2002 Gemcitabine + 5FU (weekly) 6.7 vs 5.4 Not addressed
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Table 3. Median survival times and quality of life results of gemcitabine combinations versus gemcitabine alone (Continued)
Cunningham 2009 Gemcitabine + capecitabine 7.1 vs 6.2 89% of people completed QoL
questionnaires (EORTC QLQ-
C30 + ESPAC). No differences
seen at baseline between the 2
groups and no differences across
treatment groups at 3 or 6months
Di Costanzo 2005 Gemcitabine + daily 5FU 7.5 vs 7.75 No differences were seen between
the 2 groups in mean disturbed
days after cycle 1 or 2 or mean of
days a person would like to cancel
treatment in cycle 1 or 2
Herrmann 2007 Gemcitabine + capecitabine 8.4 vs 7.2 CBR seen in 29% of people in
combination arm and 20% of
people in gemcitabine arm. Me-
dian duration of response 9.5 and
6.5 weeks, respectively (P < 0.02)
. No differences in QoL as mea-
sured by LASA
Lee 2017 Gemcitabine + capecitabine 10.3 vs 7.5 Not addressed
Ohkawa 2004 Gemcitabine + UFT Not stated Not addressed
Ozaka 2012 Gemcitabine + S1 13.7 vs 8.0 Not addressed
Riess 2005 Gemcitabine + 5FU (24 hour in-
fusion) + FA
Not stated Not addressed
Scheithauer 2003 Gemcitabine + capecitabine 9.5 vs 8.2 The gemcitabine + capecitabine
arm had an improvement in pain
(35.5 vs 20%),KPS (41.9 vs 27%)
, but not weight (9.7 vs 17%)
Ueno 2013 Gemcitabine + S1 10.1 vs 8.8 The gemcitabine + S1
group showed an improvement in
QALYs 0.525 vs 0.401, P < 0.001
Topoisomerase combinations
Abou-Alfa 2006 Gemcitabine + exatecan 6.2 vs 6.7 Not addressed
Rocha Lima 2004 Gemcitabine + irinotecan 6.3 vs 6.5 FACT-Hep questionnaires were
completed by 80% of people
in irinotecan/gemcitabine group
and 73% of the gemcitabine
group during the first 30 weeks of
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Table 3. Median survival times and quality of life results of gemcitabine combinations versus gemcitabine alone (Continued)
the study. There were no differ-
ences between the 2 groups
Stathopoulos 2006 Gemcitabine + irinotecan 6.4 vs 6.5 Not addressed
Taxane combinations
Von Hoff 2013 Gemcitabine + nab-paclitaxel 8.5 vs 6.7 Not addressed
Other combination chemotherapy including gemcitabine
Petrioli 2015 Gemcitabine + oxaliplatin +
capecitabine (GEMOXEL)
11.9 vs 7.1 The global QoL score was higher
in the combination chemother-
apy group at 2 months (61 vs 56)
and 4 months (72 vs 66)
Reni 2005 Cisplatin/epirubicin/
gemcitabine/5FU (PEFG)
Not stated The EORTC-QLQ Pan 26 ques-
tionnaire was done but the sample
size was insufficient to obtain ad-
equate statistical power to reliably
detect differences between groups
for multiple comparisons. Peo-
ple in PEFG group 20% to 44%
more likely to have improvement
in emotional functioning, overall
quality of life, cognitive measures,
pain, fatigue, indigestion, dysp-
noea, appetite loss and flatulence.
However, people in gemcitabine
group had better scores for sexual
function and body image
Other agents in combination with gemcitabine
Gansauge 2002 Gemcitabine + Ukrain 10.4 vs 5.2 Not addressed
Meng 2012 Gemcitabine + huachansu 5.2 vs 5.3 No significant
differences were seen between the
treatment groups with either the
FACT-G or MDASI assessments
Oettle 2005 Gemcitabine + pemetrexed 6.2 vs 6.3 People in the gemcitabine group
had better financial difficulties
score, better physical functioning
score and better cognitive func-
tioning score. People in the gem-
citabine/pemetrexed group had
better pain scores. Performance
status improvements was seen
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Table 3. Median survival times and quality of life results of gemcitabine combinations versus gemcitabine alone (Continued)
in 11.4% of gemcitabine/peme-
trexed group and 9.4% of gem-
citabine group. Weight gain was
seen in 10.2% of gemcitabine/
pemetrexed group and 5.7% of
gemcitabine group
Ueno 2013 - EPA study Gemcitabine + EPA 8.2 vs 9.7 Not addressed
5FU: fluorouracil; CBR: clinical benefit response; ESPAC: European Study Group for Pancreatic Cancer; EORTC: European Organi-
sation for Research and Treatment of Cancer; FACT-G: Functional Assessment of Cancer Therapy; FA: folinic acid;KPS: Karnofsky
performance status; LASA: linear-analog self-assessment indicators; MDASI: MD Anderson Symptom Inventory; QALY: quality-
adjusted life year;QLQ-C30: quality of life questionnaire for cancer patients;QoL: quality of life;Q-TWiST: quality-adjusted time
without symptoms or toxicity.
Table 4. Median survival times and quality of life results for fluoropyrimidine combinations versus fluoropyrimidine alone
Study Fluoropyrimidine combination
details
Median survival:fluoropyrimidine
combination vs fluoropyrimidine
alone (months)
Quality of life
Ducreux 2004 5FU + oxaliplatin 3.7 vs 3.4 Not addressed
Kovach 1974 5FU + BCNU Not stated Not addressed
Maisey 2002 5FU + MMC 6.5 vs 5.1 EORTC-QLQ C30 showed that at
24 weeks, global QoL was superior
in the combination arm compared to
baseline (P = 0.035), and the pain
score was also improved (P = 0.048).
There was less dyspnoea at 12 weeks
in the combination arm when com-
pared to baseline (P = 0.033)
Moertel 1979 5FU + streptozocin 4.5 vs 5.25 Not addressed
5FU: fluorouracil; BCNU: bis-chloroethylnitrosourea (carmustine); EORTC QLQ-C30: European Organisation for Research and
Treatment of Cancer quality of life questionnaire for cancer patients; MMC: 5FU+doxorubicin + mitomycin C; QoL: quality of
life.
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Table 5. Results of studies addressing unique treatment comparisons
Study Treatment arms/no.
of participants
Survival outcomes Response rates Adverse events Quality of life
Multi-armed studies
Boeck 2008 Capecitabine/
oxaliplatin (n = 61)
versus capecitabine/
gemcitabine (n = 64)
versus modi-
fied gemcitabine/ox-
aliplatin (n = 63)
OS: 8.1 vs 9.0 v 6.9
months
PFS 4.2 vs 5.7 v 3.9
months
PR 13% vs 25% vs
13%
SbD: 36% vs 39% vs
43%
Haematological AEs
more common in
the gemcitabine con-
taining arms
Not studied
Cullinan 1985 5FU (n = 50) versus
5FU/doxorubicin (n
= 44) versus 5FU/
doxorubicin/mito-
mycin C (n = 50)
Median survival of
22 weeks in all treat-
ment groups
30% vs 30% vs 7.7% Haematological AEs
more common in the
5FU and 5FU/dox-
orubicin arm, how-
ever the subgroup
with PC were not re-
ported separately
Not studied
Cullinan 1990 5FU (n = 64) ver-
sus 5FU/cyclophos-
phamide/methotrex-
ate ’Mallinson Regi-
men’ (n = 61) versus
5FU/doxoru-
bicin/cisplatin ’FAP’
(n = 59)
OS: 3.5 vs 4.5 vs 3.5
months respectively
PFS: 2.5 vs 2.5 vs 2.
5 months
7% vs 21% vs 15% More AEs reported
in the combination
arms compared with
5FU alone
Not studied
Kulke 2009 Gemcitabine
(fixed dose rate) (n
= 64) versus infu-
sional gemcitabine +
cisplatin (n = 66) ver-
sus infusional gem-
citabine + docetaxel
(n = 65) versus infu-
sional gemcitabine +
irinotecan (n = 60)
OS: 6.4 vs 6.7 vs
6.4 vs 7.1 months,
respectively. Time to
progression: 3.3 vs
4.5 vs 4.1 vs 4.0
months
14 vs 12.5 vs 12 vs
14%
Neutropenia and fa-
tigue most common
AE and same in all
groups
Not studied
Other studies
Afchain 2009 Gemcitabine/ox-
aliplatin (n = 20) vs
simpli-
fied gemcitabine/ox-
aliplatin (n = 37)
OS: 3.2 vs 7.6
months
PFS: 2.5 vs 4.0
months
PR: 10% vs 27%
SbD: 45% vs 43%
Peripheral neu-
ropathy more com-
mon in the simpli-
fied GemOx arm
Not studied
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Table 5. Results of studies addressing unique treatment comparisons (Continued)
Bukowski 1983 Mito-
mycin C/5FU (MF)
(n = 73) vs Strepto-
zocin/mitomycin C/
5FU (SMF) (n = 72)
OS: 17 vs 18 weeks PR: 8% v 34% More gastrointesti-
nal and renal toxicity
in the SMF arm
Not studied
Corrie 2017 Standard nab-pacli-
taxel and
gemcitabine (n = 75)
vs sequential nab-pa-
clitaxel and gemc-
itabine (n = 71)
OS: 7.9 vs 10.1
months (HR 0.88)
PFS: 4.0 vs 5.8
months (HR 0.66)
PR: 33% vs 50%
SbD: 28% vs 42%
Neutropenia
more common in the
sequential arm
QoL score dropped
by −12.1 points at
24 weeks in the stan-
dard arm vs −2.1 in
the sequential arm
Hirao 2011 Gemcitabine 3-week
schedule (n = 45) vs
gemcitabine 4-week
schedule (n = 45)
OS: 250 vs 206 days
PFS: 114 vs 112 days
17.1% vs 14.2% Thrombocytopenia
more common in the
4-week schedule
Not studied
Kelsen 1991 Strepto-
zocin/mitomycin C/
5FU (SMF) (n =
42) vs cisplatin/ara-
C/caffeine (CAC) (n
= 40)
OS: 10 vs 5 months 10% vs 6% Nausea and vomit-
ingmore common in
CAC arm.
Not studied
Levi 2004 5FU constant infu-
sion vs 5FU constant
infu-
sion/cisplatin versus
5FU chronomodu-
lated infusion
vs 5FU chronomod-
ulated infusion/cis-
platin (no cisplatin n
= 55, with cisplatin n
= 52)
OS: 5.
4 vs 8.3 months (no
cis vs cis)
OS: 6.1 vs
6.7 months (contin-
uous vs chronomod-
ulated)
PFS: 2.1 vs 3.2
months
Not reported Cisplatin increased
rates of haematologi-
cal
AEs. Chronomodu-
lated reg-
imen increased rates
of mucositis
Not studied
Lutz 2005 Gemcitabine + doc-
etaxel (n = 49) vs cis-
platin + docetaxel (n
= 47)
OS: 7.0 vs 7.5
months
PFS: 3.9 vs 2.8
months
19.4% vs 23.5% Febile neu-
tropenia more com-
mon in the cisplatin/
docetaxel arm
Not studied
Moertel 1977 Streptozocin + 5FU
(n = 40) vs strep-
tozocin + cyclophos-
phamide (n = 48)
OS: 13 vs 9 weeks CR: 3 vs 6
PR: 2 vs 0
SbD: 9 vs 9
Haematological AEs
more common in the
cyclophosphamide
arm
Not studied
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Table 5. Results of studies addressing unique treatment comparisons (Continued)
Reni 2012 Capecitabine + cis-
platin + gemcitabine
+ docetaxel (PDXG)
(n = 53)
vs capecitabine + cis-
platin + gemcitabine
+ epirubicin (PEXG)
(n = 52)
OS: 10.7 vs 11
months
PFS: 7.4 vs 7.6
months
CR: 2 vs 4%
PR: 58 vs 33%
Neutropenia
more common in the
PEXG arm
Not studied
Topham 1991 Epirubicin (n = 32)
vs 5FU + epirubicin
+ mitomycin C (n =
30)
1 year survival rates
15.4 vs 23.2%
8% vs 11% AEs were similar in
both arms
Not studied
5FU: fluorouracil; AE: adverse event; CR: complete response; OS: overall survival; PC: pancreatic cancer; PR: partial response; SbD:
stable disease.
A P P E N D I C E S
Appendix 1. Glossary of terms
Adenocarcinoma: cancer arising from glandular tissue
Analgesia: medication used to relieve pain
Anti-neoplastic: stopping or preventing the growth and spread of cancerous cells
Antibody: a protein produced to neutralise another protein. In the case of cancer treatment, these proteins block particular cancer
pathways
Aortic: the large artery that originates in the heart and supplies the body with blood
Biliary: related to the structures that carry bile (a substance which is produced by the liver and responsible for helping the digestion of
fats)
Cobalt source: radioisotope from which radiation is emitted
Coeliac abutment: when tumour touches but does not invade the coeliac vessels, the blood supply around the pancreas
Complete response: when a tumour is no longer seen on imaging in response to treatment
Cytotoxic: chemicals or drugs capable of killing cells
Dyspnoea: difficulty breathing
Epigastric: the top, middle part of the abdomen, the area around the stomach
Flatulence: gas
Insomnia: difficulty sleeping
Jaundice: the yellowing of the skin, whites of of the eyes and mucous membranes due to high levels of bilirubin
Lethal: capable of causing death
Mesenteric vein: one of the two veins responsible for draining the intestines
Neutropenia: low white cell count. Can pre-dispose patients to getting serious infections
Nodal: related to lymph nodes
Palliative: treatment with the intention of improving symptoms, not cure
Partial response: when a tumour shrinks on imaging in response to treatment
Placebo: sham or fake treatment
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Portal occlusion: the blockage of the portal vein, a large vein in the abdomen
Resection: surgical removal
Stable disease: when tumour growth stabilises in response to treatment (does not change in size between scans)
Stent: a small tube used to relieve blockages
Thrombocytopenia: low platelet count. Can pre-dispose patients to serious bleeding
Thromboembolic: blood clots in the calf or lung veins
Toxicities: side effects
Appendix 2. CENTRAL search strategy
1. exp Pancreas/
2. (carcin$ or cancer$ or neoplas$ or tumour$ or tumor$ or growth$ or adenocarcin$ or malig$).mp.
3. 1 and 2
4. Carcinoma, Pancreatic Ductal/
5. Pancreatic Neoplasms/
6. or/3-5
7. Antineoplastic Protocols/
8. chemotherap*.tw.
9. Radiotherapy/
10. chemoradiotherap*.tw.
11. chemo-radiotherap*.tw.
12. radiochemotherap*.tw.
13. radio-chemotherap*.tw.
14. Biological Therapy/
15. Immunotherapy, Adoptive/
16. exp Immunotherapy, Active/
17. cetuximab.tw.
18. erlotinib.tw.
19. bevacuzimab.tw.
20. panitumumab.tw.
21. trastuzumab.tw.
22. Protein-Tyrosine Kinases/ai [Antagonists & Inhibitors]
23. tyrosine kinase inhibitor*.tw.
24. interleukins.tw.
25. exp Interleukins/
26. Cancer Vaccines/
27. Antibodies, Monoclonal/
28. exp Interferons/
29. Molecular Targeted Therapy/
30. or/7-29
31. 6 and 30
160Chemotherapy and radiotherapy for advanced pancreatic cancer (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Appendix 3. MEDLINE search strategy
1. exp Pancreas/
2. (carcin$ or cancer$ or neoplas$ or tumour$ or tumor$ or growth$ or adenocarcin$ or malig$).mp.
3. 1 and 2
4. Carcinoma, Pancreatic Ductal/
5. Pancreatic Neoplasms/
6. or/3-5
7. Antineoplastic Protocols/
8. chemotherap*.tw.
9. Radiotherapy/
10. exp Chemoradiotherapy/
11. chemoradiotherap*.tw.
12. chemo-radiotherap*.tw.
13. radiochemotherap*.tw.
14. radio-chemotherap*.tw.
15. Biological Therapy/
16. Immunotherapy, Adoptive/
17. exp Immunotherapy, Active/
18. cetuximab.tw.
19. erlotinib.tw.
20. bevacuzimab.tw.
21. panitumumab.tw.
22. trastuzumab.tw.
23. Protein-Tyrosine Kinases/ai [Antagonists & Inhibitors]
24. tyrosine kinase inhibitor*.tw.
25. interleukins.tw.
26. exp Interleukins/
27. Cancer Vaccines/
28. *Antibodies, Monoclonal/
29. exp Interferons/
30. Molecular Targeted Therapy/
31. or/7-30
32. 6 and 31
33. randomized controlled trial.pt.
34. controlled clinical trial.pt.
35. randomized.ab.
36. placebo.ab.
37. clinical trials as topic.sh.
38. randomly.ab.
39. trial.ti.
40. or/33-39
41. exp animals/ not humans.sh.
42. 40 not 41
43. 32 and 42
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Appendix 4. EMBASE search strategy
1. exp Pancreas/
2. (carcin$ or cancer$ or neoplas$ or tumour$ or tumor$ or growth$ or adenocarcin$ or malig$).mp.
3. 1 and 2
4. Carcinoma, Pancreatic Ductal/
5. Pancreatic Neoplasms/
6. or/3-5
7. Cancer chemotherapy/
8. Cancer radiotherapy/
9. exp Chemoradiotherapy/
10. chemoradiotherap*.tw.
11. chemo-radiotherap*.tw.
12. radiochemotherap*.tw.
13. radio-chemotherap*.tw.
14. Biological Therapy/
15. exp Immunotherapy, Active/
16. vaccine/ or cancer vaccine/ or tumor cell vaccine/ or tumor vaccine/
17. active immunization/
18. antineoplastic agent/
19. cetuximab/
20. erlotinib/
21. bevacizumab/
22. panitumumab/
23. trastuzumab/
24. protein tyrosine kinase inhibitor/
25. interleukin derivative/
26. cancer vaccine/
27. monoclonal antibody/
28. exp interferon/
29. immunotherapy/ or adoptive immunotherapy/ or cancer immunization/
30. molecularly targeted therapy/
31. or/7-30
32. 6 and 31
33. random:.tw. or placebo:.mp. or double-blind:.tw.
34. 32 and 33
H I S T O R Y
Protocol first published: Issue 6, 2013
Review first published: Issue 3, 2018
Date Event Description
30 October 2008 Amended Converted to new review format.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Biological agents, second line therapies, locally advanced PC
The original protocol included studies addressing biological therapies, studies addressing second-line treatment and people with locally
advanced disease. We felt that due to the large number of comparisons, the review became unmanageable. We therefore decided to split
the review and concentrate on chemotherapy and radiotherapy in the advanced setting. Separate reviews will report on biological and
immunological agents, second-line therapies and studies dealing exclusively with people with non-metastatic, locally advanced disease.
Outcomes
The original protocol did not include adverse events, response rates and quality of life as secondary outcomes. Prior to data extraction,
the review authors added those as secondary outcomes. We deleted disease-specific survival as a secondary outcome.
Measures of treatment effect
The original protocol stated that fixed-effect model meta-analyses would be used to pool results for survival at 6 months and 12 months.
It was never our intention to use 6- and 12-month survival as endpoints in this review. We instead used HRs for overall and progression-
free survival. We employed random-effect models for most analyses given the experimental arms were often very different within each
comparison.
Dealing with multi-armed studies
In such cases where studies reported the event rates for all arms, we divided the control arm accordingly and entered all arms of the
studies into the analysis as appropriate. Where the event rates were not available, if the study had two arms that fell into a subgroup
analysis, then we analysed only these two arms. We described any study that we could not analyse in the above two scenarios in table
form only.
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Number needed to treat (NNT) as a secondary endpoint
We replaced this outcome with GRADE ’Summary of findings’ tables.
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